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Abstract 
 
In inflammatory bowel disease (IBD), both chronic pro-inflammatory pathways and 
failure of anti-inflammatory (healing) mechanisms sustain disease.  The two major 
anti-inflammatory gut cytokines are transforming growth factor (TGF)-β and 
interleukin (IL)-10.  Acetylation of regulatory proteins may play a role in the 
activation of both pathways.  In IBD there is excess production of pro-
inflammatory cytokines such as IL-1β and under-expression of IL-10.  Fibroblasts 
also over-produce matrix metalloproteinases (MMP), mediating tissue destruction.  
Curcumin, a component of the spice turmeric and a known inhibitor of acetylation, 
shows clinical benefit in IBD in early trials.  Objectives:  To assess the anti-
inflammatory effects of curcumin in the gut of children and adults with IBD.  
Methods:  Intestinal mucosal tissue biopsies, mononuclear cells and colonic 
myofibroblasts from children and adults with active IBD were cultured ex vivo with 
curcumin.  p38 MAPK, NF-κB and MMP-3 were measured by immunoblotting.  
IL-1β, interferon (IFN)-γ and IL-10 were measured by enzyme-linked 
immunosorbent assay (ELISA).  Results: We have shown favourable modulation 
of the cytokine profile by curcumin, with enhanced IL-10 expression and decreased 
IL-1β, and we have demonstrated reduced p38 MAPK activation in intestinal 
mucosal tissue.  We have also shown dose-dependent suppression of MMP-3 
expression in colonic myofibroblasts (CMF) with curcumin, by a mechanism which 
appears to be acetylation-dependent.  Conclusion:  Curcumin, a naturally occurring 
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food substance with no known human toxicity, holds promise as a novel therapy in 
IBD. 
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1.0 Introduction 
 
1.1 Inflammatory Bowel Disease 
 
1.1.0 Epidemiology of Inflammatory Bowel Disease in Adults and 
Children 
 
Inflammatory bowel disease (IBD) is a source of considerable morbidity in 
children, adolescents and adults.  It is characterised by chronic inflammation of the 
gastrointestinal tract, which follows a lifelong relapsing and remitting course.  Its 
incidence in children under sixteen in the United Kingdom is 5.2 per 100,000 per 
year [1].  This comprises 3.0 cases of Crohn’s disease (CD), 1.5 cases of ulcerative 
colitis (UC), 0.6 cases of indeterminate colitis and 0.1 cases of orofacial 
granulomatosis (OFG).  In adults the incidence in northern Europe is estimated at 
between 10-20 cases per 100,000 per year, with an approximately equal split 
between CD and UC [2].  The commonest age of onset is in the third decade of life, 
with a peak around the age of 30 years when assessed in 2004 [3].  However the 
incidence of IBD, particularly CD, has been increasing over the past decade, and 
new cases presenting in teenage years seem to account for a significant portion of 
this increase [2].  Although the overall population incidence is rising as well, this 
changing pattern may lower the average age of onset of IBD, particularly CD, 
possibly to be reflected in future epidemiological studies. 
 22 
As well as the changing incidence, and the preponderance of CD over UC in 
childhood, other unexplained differences exist between childhood and adult onset 
IBD.  UC more frequently occurs in a severe phenotype when presenting for the 
first time in childhood compared to adulthood.  A much higher proportion of 
children than adults have disease affecting the entire colon (pancolitis) at the time 
of initial diagnosis [1], and of those presenting with disease only affecting the 
rectum (proctitis), a greater proportion of children than adults go on to develop 
extensive UC [4].  In CD there is an overall preponderance of females; yet of those 
diagnosed in childhood it is commoner amongst males [1, 5].  Finally genetic 
susceptibility appears to be more important in childhood onset IBD [6, 7].  This 
may be logical in a multi-factorial illness, since in childhood there is comparatively 
less time for exposure to environmental factors, therefore genetic influences 
account for a greater part of the aetiology.   
 
The largest disease burden of IBD is in the industrialised world and the prevalence 
is generally higher in more northerly countries.  Until recently IBD was hardly 
recognised in the developing world, although rising numbers of cases in India and 
Asia are now being seen [8] [9] [10].  When families migrate from East to West, 
their children take on a risk at least equal to the local IBD incidence in the first 
generation [11].  These observations suggest that environmental factors related to 
industrialised living are important in the aetiology of IBD.  The study of a dietary 
agent, especially one such as curcumin whose natural levels of consumption are 
much higher in Asia than the UK, therefore holds particularly intriguing relevance. 
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1.1.1 Clinical Features of Inflammatory Bowel Disease 
 
CD can affect any area of the gut from mouth to anus, and may do so in a patchy 
distribution, frequently sparing the rectum.  It is characterised by inflammation 
spanning the entire thickness of the bowel wall (transmural) with a resultant 
tendency to form fistulae (abnormal connections between bowel and other 
structures) and strictures (bowel narrowing).  The classical triad of presenting 
symptoms are diarrhoea, weight loss and abdominal pain, although presentation 
with all three is not universal.  Other frequent clinical features include rectal 
bleeding, anorexia, nausea, anaemia, fever, fatigue and generalised systemic 
malaise.  Systemic upset is commoner in CD than UC.  IBD is accompanied by 
extraintestinal manifestations, at some point in the individual’s lifetime, in at least 
25% of cases, and these occur with slightly higher frequency in CD than UC [12] 
[13].  These include arthritis, erythema nodosum and pyoderma gangrenosum 
(painful inflammatory conditions of the skin), sacroileitis and ankylosing 
spondylitis (back pain and immobility), primary sclerosing cholangitis (bile duct 
disease), uveitis, iridocyclitis, episcleritis (inflammatory eye diseases) and aphthous 
stomatitis (ulceration and inflammation in the mouth) [14].  Predisposing factors to 
CD include family history of the condition [15], residence in an industrialised 
country [8], Caucasian race, Jewish ethnicity [13] and smoking [16]. 
 
UC is limited to the large bowel and characterised by mucosal, rather than 
transmural, inflammation, without fibrosis or fistula formation.  Presentation may 
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be with the classical triad; however the predominant symptom is usually severe 
diarrhoea with high blood and mucus content.  In contrast to CD which is typified 
by skip lesions (patchy areas of disease), inflammation in UC occurs in a 
continuous pattern from distal (rectal) variably through to proximal colon.  A 
similar range of extraintestinal manifestations are seen, which in UC occur with a 
slightly lower overall frequency of around 21% [17], although the incidence 
specifically of primary sclerosing cholangitis is higher (4% compared to 2% in CD) 
[18].  Like CD, UC is also predisposed by family history (although less strongly 
so), industrialised living, Caucasian race and Jewish ethnicity, but conversely 
smoking [16] and prior appendicectomy are protective [19].  
 
 
1.1.2 Diagnosis of Inflammatory Bowel Disease 
 
The diagnosis is suggested by a combination of the above clinical features, together 
with indirect blood test markers of inflammation, the finding of typical mucosal 
changes at colonoscopy (Figure 1.1), and, in the case of small intestinal disease, a 
characteristic irregular appearance of the bowel when outlined on contrast (barium) 
Xray.  The definitive diagnosis is made on histological examination of intestinal 
mucosal biopsies or surgical resection specimens in association with the patient’s 
clinical features.  In CD the inflammation is transmural and characterised in 50% of 
cases by the presence of granulomas (aggregates of macrophage-derived giant 
cells), the histological hallmark of the condition.  In UC the inflammation is limited 
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to the mucosa, with irregularity and shallow ulceration.  There is a chronic 
inflammatory cellular infiltrate in the lamina propria, depletion of goblet (mucus 
producing) cells and distortion of glandular architecture. 
 
 
 
 
 
 
 
 
Figure 1.1 Crohn’s ulcer at colonoscopy 
 
The two less common forms of IBD are indeterminate colitis (sometimes referred 
to as IBD of indefinite type) and orofacial granulomatosis (OFG).  The former is an 
ill-defined entity, sharing some aspects of CD and UC, lacking histological features 
which allow definitive categorisation, and perhaps representing an entirely separate 
type of IBD [20].  OFG is rare and is characterised by swelling, ulceration and 
induration of the mouth, cheeks, gums and buccal surfaces, with a granulomatous 
histology similar to CD.  The relationship between OFG and CD is unclear.  Many 
patients, particularly children, with OFG have endoscopic and/or histological 
features of CD in the gut, and these may be clinically silent in terms of gastro-
intestinal symptoms [21, 22].  OFG can be challenging to treat and may have an 
allergic basis, sometimes responding well to strict dietary exclusions of additives 
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such as cinnamon and benzoates [23].  Conversely, it is not known if there is a 
significant group of patients with CD who have sub-clinical disease changes in the 
mouth, but aphthous ulceration is certainly common in CD, and there is an 
anecdotal perception that this may be the case.  It is possible that OFG and CD 
represent a disease continuum, with more patients on the CD side of the spectrum, 
and a degree of overlap. 
 
 
1.1.3 Management of Inflammatory Bowel Disease 
 
Current treatments for IBD are dietary, pharmacological or surgical.  Newly 
diagnosed or relapsed CD, particularly involving the small bowel, responds well to 
a period of dietary (enteral) therapy, which brings about remission in around 80% 
of patients [24] [25].  This option is used particularly in children and pre-pubertal 
adolescents, in whom avoiding steroids, with their negative effects on growth and 
bone development, is especially important.  The treatment involves six to eight 
weeks of taking a nutritionally complete elemental or polymeric liquid feed, to the 
exclusion of all other solids or liquids except water.  Its mechanism of action 
remains obscure, although theories include reduction of dietary antigen load or 
alteration in gut bacterial flora [26].  This is discussed further in Chapter 1.3.0.  A 
number of anti-inflammatory drugs are currently in use, including 5-aminosalicylic 
acid (5-ASA) preparations such as mesalazine, steroids such as prednisolone (both 
of which may be given orally or rectally) and immunosuppressants such as 
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azathioprine, methotrexate or cyclosporine.  Other drugs used include antibiotics 
such as metronidazole, and in the last decade biological agents have been 
developed, the most commonly used of which is infliximab, a monoclonal antibody 
against human tumour necrosis factor alpha (TNF)-α, which is given as a series of 
intravenous (iv) infusions and is most effective in CD [27].  Colectomy is 
performed in refractory UC which fails to respond to medical therapy or threatens 
life (fulminant colitis).  It is curative but leaves the patient with an ileostomy 
(stoma), which in some cases may be reversible by ileoanal pouch formation at a 
later date.  Surgery is also employed in CD, particularly where disease is localised 
to the ileo-caecal region, in which case right hemi-colectomy can be temporarily or 
occasionally permanently effective.  None of these treatments (except colectomy 
for UC) are curative and many are associated with significant side effects. 
 
IBD, particularly UC, carries a long term risk of cancer.  Overall prevalence of 
colorectal cancer in all individuals with UC is estimated at around 3.7% [28].  The 
risk increases in relation to extent of colonic involvement and disease duration, and 
as such may apply equally to Crohn’s colitis [29].  Thus the probability of 
developing cancer is cumulative over a life time of colonic inflammation, a fact of 
clear relevance to people diagnosed in childhood.  In the first decade after diagnosis 
of UC the risk is estimated at 2% and this rises to 18% by the third decade [28].  
This necessitates regular surveillance colonoscopies and some individuals opt for 
prophylactic colectomy.  There is evidence that long term use of 5-ASA 
medications reduces the life time cancer risk [30]. 
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1.2 Aetiology of Inflammatory Bowel Disease 
 
1.2.0 Genetics of Inflammatory Bowel Disease 
 
The cause of IBD is unknown but is likely to be complex and multi-factorial, with 
interplay between genetic predisposition, defective mucosal immune regulation and 
trigger factors in the luminal and/or external environment.  10-15% of cases of IBD 
in adults occur with a positive family history.  75% of these are concordant for 
disease type, and in the remaining 25% UC and CD occur in one family [31].  This 
suggests that some susceptibility genes are common to both CD and UC, whilst 
others are specific to one form.  Compared to adults with IBD, children with IBD 
more commonly have a positive family history [6], and this history is more often 
concordant for disease type [32].  CD has a higher genetic penetrance, with a 
monozygotic twin concordance rate of 42-58%, compared to UC with 6-17%.   
 
The first IBD susceptibility gene to be discovered was the c-terminal caspase 
recruitment domain 15 (CARD15) gene on chromosome 16 [33] [34].  Originally 
called nucleotide-binding oligomerisation domain containing 2 (NOD2), it encodes 
an intracellular receptor, which, on ligation by bacterial cell wall muramyl 
dipeptide (MDP) [35] causes release of nuclear factor (NF)-κB and transcription of 
inflammatory cytokines.  It is found in macrophages, dendritic cells, intestinal 
epithelial cells and Paneth cells.  The commonest mutations of CARD15 involve 
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the leucine-rich repeat (LRR) region which encodes the protein’s bacterial (MDP) 
recognition site and cause increased NF-κB production [36].  Although this is the 
most significant genetic association known in CD to date, evidently heterogeneous 
mechanisms operate, as evidenced by the relatively low incidence of the mutation 
in CD patients (27-39%) and significant incidence in the normal population (14-
16%).  In the paediatric CD population the CARD15 mutation occurs with greater 
frequency than in the adult CD population [37], further consistent with the 
observation that genetic factors are very important in childhood onset IBD.  In UC 
CARD15 does not appear to be implicated in aetiology; mutation occurs with an 
incidence of 12-14%.   
 
Subsequently other IBD susceptibility genes have been discovered, such as those 
encoding two organic cation transporters, OCT1 and OCT2, on chromosome 5q31 
[38].  Mutation in one of the two transporters (for example transversion in the 
SLC22A5 promoter) occurs in 53% of individuals with CD, compared to 23% of 
normal controls.  These variants appear to interact with variants in CARD15 to 
increase susceptibility to CD, although similarly they do not play a role in the 
pathogenesis of UC.  Several genome-wide association studies have been 
performed in IBD; a powerful tool which, by examining a large number of single 
nucleotide polymorphisms (SNP’s) from many individuals, can measure the 
relative contributions of different genes to common diseases.  A series of IBD 
susceptibility regions are now recognised throughout the genome at 12 different 
loci (Table 1.1).  These susceptibility genes encode a number of products including 
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those involved in both the innate and adaptive immune systems.  Genes involved in 
the innate immune system such as the autophagy related 16-like protein 
(ATG16L)1, the immunity-related GTPase family (IRG) M and CARD15 are 
specific to CD, whereas those involved in the interleukin (IL)-23 pathway, such as 
the IL-23 receptor (IL23R), IL12B (which encodes the p40 subunit common to both 
IL-12 and IL-23) and STAT3 are implicated in both CD and UC [39].  The role of 
innate and adaptive immunity, including the IL-23 pathway, in the 
immunopathology of IBD is further addressed in Chapter 1.2.1. 
 
Chromosome Gene Also associated with 
UC? 
1p31.1 IL23R  Yes 
2q37.1 ATG16L1  No 
3p21 Macrophage stimulating (MST)1 Yes 
5p13 Prostaglandin receptor EP4 No 
5q31 Solute carrier family 22 member 5 
(SLC22A5) 
Unclear 
5q33.1 IRGM No 
5q33 IL12B (IL-12β (p40)) Yes 
10q21 Zinc-finger protein 365 Unclear 
10q24 NK2 transcription factor related locus 3 Yes 
16q12 CARD15 No 
17q21 Signal transducer and activator of Yes 
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transcription (STAT) 3 
18p11 Protein tyrosine phosphatase non-receptor 
type 2 
Unclear 
12q12 LRRK2 Unclear 
6p21.33 BTNL2 Yes 
7q22 MUC3A Yes 
7q21.1 ABCB1 Unclear 
7q32 IRF5 Yes 
9q32 TNFSF15 Unclear 
1q32.1 IL-10 Yes 
20q13 TNFRSF6B Yes 
21q22 PSMG1 Yes 
 
Table 1.1 Genetic susceptibility loci in inflammatory bowel disease   
 
 
1.2.1 Pro-inflammatory Responses to Bacterial Flora in 
Inflammatory Bowel Disease 
 
Uniquely the gut mucosal immune system is faced with the challenge of constant 
exposure to a heavy load of bacterial, nutritional and other potentially pro-
inflammatory luminal antigens.  By necessity for nutrient absorption, this surface 
contact is intimate and extensive.  The mucosa must simultaneously achieve 
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efficient extraction of nutrition and water, exclusion of bacteria and toxins, defence 
against potentially invasive organisms and, crucially, tolerance of non-pathogenic 
bacterial flora.  The mucosal immune system constantly samples, processes and 
reacts to luminal bacterial antigens, sending pro- or anti-inflammatory signals and 
promoting the differentiation of naïve T cells into effector or regulatory T cells 
[40].   
 
In CD there is aberrant immune reactivity to normally non-pathogenic (commensal) 
bacteria.  In general these immune responses can be divided into innate and 
adaptive.  Cells of the innate immune system include natural killer cells, mast cells, 
macrophages, neutrophils and dendritic cells; which together mount a non-specific, 
generic host defence against potential pathogens.  The adaptive immune system 
conversely is characterised by memory.  It is highly specialised and directed against 
specific pathogens which are recognised by T and B lymphocytes.  The 
susceptibility genes for CD encode proteins which contribute to both pathways 
(Chapter 1.2.0 and Table 1.1).   
 
There are two important bacterial recognition receptors in the mucosa which 
comprise part of the innate immune system; intracellular CARD15 receptors and 
membrane bound toll-like receptors (TLR’s), of which ten have been identified to 
date [41].  TLR’s are expressed on epithelial cells, dendritic cells, macrophages and 
other immune cells and recognise pathogen-associated molecular patterns 
(PAMP’s), a group of ligands common to many luminal microbes.   Evidence from 
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animal studies suggests that TLR4 is required for the development of T helper cell 
type 1 (Th1)-mediated colitis [42].  In normal gut, there is low level TLR 
expression and an environment in which inflammation is well controlled, with high 
levels of the anti-inflammatory cytokine IL-10, and low levels of pro-inflammatory 
mediators [43].  In IBD there is high expression of TLR2 and TLR4 and dendritic 
cells have an activated phenotype, sampling luminal bacteria and mediating pro-
inflammatory consequences.  The CARD15 receptor is extremely sensitive to 
muramyl dipeptide (MDP), a bacterial product ubiquitously present in Gram 
positive and negative bacteria [44].  Upon ligation by MDP, CARD15 leads to the 
activation of inflammatory signalling pathways including NF-κB and MAPK [35] 
[45]. 
 
The discovery of an association between CD and mutations in CARD15 [33] [34] 
supports the observation that in CD there is inappropriate innate immune reactivity 
to normally non-pathogenic bacteria.  However the precise relationship between 
CARD15 and the immunopathology of CD is incompletely understood and 
investigation of this relationship has yielded some inconsistencies.  For example 
MDP stimulation of primary human mononuclear cells possessing CARD15 
mutations leads paradoxically to decreased NF-κB activation, in contrast to the 
increased NF-κB activation seen with in vivo disease [46].  To further evidence the 
complexity of the relationship, CARD15 deficient mice do not develop intestinal 
inflammation [45], and the presence of a CARD15 genetic variant alone is 
insufficient to cause disease (see Chapter 1.2.0).   
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Also strengthening support for aberrant innate immunity in CD is the discovery of 
genetic mutations encoding proteins involved in autophagy; ATG16L1 [47] and 
IRGM [48] (Chapter 1.2.0 and Table 1.1).  Autophagy is a process by which 
intracellular pathogens are destroyed and antigens presented, regulating T cell 
responses.  The precise mechanistic relationship by which these mutations lead to 
increased susceptibility to CD is not as yet understood.  However the discovery that 
these mutations are relevant to CD and not UC imply that a defect in intracellular 
processing of bacteria is important specifically to the pathogenesis of CD. 
 
In most people with CD there is no specifically identified genetic mutation and the 
reason for the generalised aberrant immune responsiveness to bacterial flora is 
unknown.  This in turn leads to an adaptive (specific) immune response.  According 
to the classical dogma, in CD this takes the form of a Th1 (cell-mediated) response 
[49] [50], with IL-2 and interferon gamma (IFN-γ) activating macrophages and 
driving the release of IL-1, IL-6 and TNF-α.  In UC the cytokine profile is said 
more closely to resemble a Th2 (humoral) type response, with activation of natural 
killer (NK) cells, production of IL-4, IL-5 and IL-13 and antibody-mediated 
immunity [51] [52].  In reality, overlap between the two conditions complicates this 
simplified view of their respective immunopathologies.   
 
More recently, other cytokines have been recognised as important in IBD.  IL-17 is 
a potent pro-inflammatory cytokine which is elevated in the serum and colonic 
mucosa of individuals with IBD, particularly CD, in apparent correlation with 
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disease activity [380].  IL-17 is produced by a subset of CD4+ T cells called Th17 
cells under stimulation by IL-23.  Th17 cells express the IL-23 receptor at high 
levels [53].  Blocking IL-17 attenuates intestinal inflammation in animal models 
[381].  Both IL-23 and the structurally related IL-12 appear to drive T cell subsets 
towards Th1 responses, and blockade of both ameliorates colitis in animal models 
[382].  Anti-IL-12 antibodies have shown promise in the treatment of CD in 
humans [383].  Furthermore, as described in Chapter 1.2.0 and shown in Table 1.1, 
mutations in genes which encode products in the IL-23 pathway are associated with 
both CD and UC [39, 54], as well as with other chronic inflammatory diseases such 
as psoriasis (skin disease) [55] and ankylosing spondylitis (inflammatory disease of 
the spine) [56].  The IL-23 receptor comprises two subunits; IL-23R and IL-12Rβ1.  
Multiple different SNP’s in the IL-23R region have been identified in association 
with IBD [39] and mutations of genes in the IL-23 pathway are some of the 
strongest genome-wide associations identified in IBD [57]. 
 
A later consequence of activation of these inflammatory cascades is recruitment of 
further leukocytes from the circulation into the gut wall.  This occurs by two 
different mechanisms.  Firstly the upregulation of cellular adhesion molecules such 
as mucosal addressin cell adhesion molecule 1 (MadCAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1), which, when expressed on mucosal vascular 
endothelial surfaces, interact with circulating leukocytes possessing cell surface 
markers α4β7 and α4β1 [384].  By this means, activated leukocytes adhere and are 
recruited into the inflamed gut.  Secondly, chemokine (C-C motif) ligand (CCL) 25, 
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a chemokine expressed by intestinal epithelial cells, is chemotactic to lymphocytes 
expressing chemokine (C-C motif) receptor (CCR) 9 [385].  Both of these 
mechanisms provide potential new therapeutic targets to prevent leukocyte 
recruitment into inflamed gut, and are currently under study.  Natalizumab, an anti-
α4 integrin, has now been licensed for CD in the United States [58] and 
Vedolizumab, an anti-α4β7 integrin, is currently undergoing phase III trials in CD 
and UC [ClinicalTrials.gov number NCT00783692].  CCX282-B, an anti-CCR9 is 
presently in phase II trials in CD [ClinicalTrials.gov number NCT00306215]. 
 
 
1.2.2 p38 Mitogen Activated Protein Kinase 
 
The bacterial components and pro-inflammatory cytokines described above activate 
inflammatory signalling cascades including NF-κB and mitogen-activated protein 
kinases (MAPK).  The MAPK’s are a family of enzymes which, when activated by 
signals from the external environment, initiate phosphorylation cascades, 
culminating in cellular events such as transcription, differentiation and apoptosis.  
They are central to the coordination of inflammatory, cell death, growth and other 
responses and are highly conserved, suggesting critical functions for survival.  By 
their most basic classification they fall into three different families; extracellular 
signal-related kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 MAPK.  
Within the MAPK family, the stress-activated protein kinases are a sub-group 
which are activated by stimuli that cause cell stress, including lymphocyte 
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receptors, TLR’s, cytokine receptors and physical or chemical alterations in the 
cellular environment.  Whilst ERK pathways are largely activated by growth 
factors, JNK and p38 MAPK comprise the stress-activated group of kinases (figure 
1.2). 
 
 
 
Figure 1.2 The c-Jun N-terminal kinase and p38 mitogen-activated protein kinase 
signalling pathways [59] 
 
The p38 group is further sub-classified into p38α, β, δ and γ.  Each isoform is 
encoded by a distinct gene, although there is high amino acid homology between 
the isoforms, with  more than 60% overall homology and over 90% within the 
kinase domains of the enzyme [60].  The isoforms are expressed in a tissue-
selective manner, with p38α and β the most ubiquitously expressed and p38α the 
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major form involved in the inflammatory response [61].  p38 MAPK was originally 
discovered in 1994, and this was only after its inhibitor SB2035820, which was 
identified in the course of a search for compounds inhibitory to TNF-α [62].  p38 
MAPK, as well as regulating the production of inflammatory enzymes such as 
COX2 [63], plays a central role in regulating the expression of a number of key 
inflammatory cytokines including TNF-α, IL-1, IL-8 and interferon (IFN)-γ [64] 
[65].   
 
The MAPK cascade is activated by a large number of different types of receptor, 
including cytokine receptors, TLR’s and receptors sensitive to environmental 
stressors.  The precise mechanisms of activation are incompletely understood.  p38 
MAPK becomes activated on phosphorylation by MAPK kinase (MKK) 3 and 6.  
This process is tightly regulated and dynamic, involving a balance between 
phosphorylation by upstream MKKs and dephosphorylation by MKK phosphatases 
[66].  Downstream, various MAPK substrates have been identified, including 
several different transcription factors.  Final inflammatory and other cellular 
consequences of MAPK activation are probably mediated through multiple 
different mechanisms [67], and again these have not been fully elucidated. 
 
The MAPK’s and molecules in their signalling pathways therefore present 
interesting therapeutic targets in inflammatory disease.  p38 MAPK is the most 
markedly elevated of the MAPK’s in IBD [68] but an early trial of its 
pharmacological inhibition in CD has so far been disappointing [69].  This might be 
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because the very wide field of p38 MAPK-regulated cellular activities makes it too 
imprecise as a therapeutic target in IBD.  Alternatively, this trial used an oral 
formulation and lack of clinical efficacy could also have been due to drug delivery 
issues.  For the reasons outlined above, p38 MAPK is a highly relevant pathway in 
the study of inflammation in IBD. 
 
 
1.2.3 Nuclear Factor-κB 
 
The nuclear transcription factor (NF)-κB proteins are a family of five members 
which exist in dimers: p65 (relA), c-Rel, RelB, p50 and p52 (Figure 1.3).  The first 
three members possess the ability to activate gene transcription directly; the latter 
two requiring dimerisation with the former for activation [70].  Like the MAPK 
family, NF-κB path ways p lay a cen tral and ubiquitous role in relaying various 
inflammatory stimuli into transcriptional events.  Under normal non-inflamed 
circumstances NF-κB dimers are held inactive in the cytoplasm by small inhibitory 
proteins IκB, of which three isoforms exist; α, β and ε [71].  There are two separate 
pathways by which NF-κB dimers may be activated and released from cytoplasmic 
hold into the nucleus; the classic and alternative pathways [72].  Classical (or 
canonical) activation occurs with a wide range of external and host-derived stimuli 
including bacterial lipopolysaccharide (LPS), viruses, TNF-α and IL-1.  These 
trigger signalling cascades leading to activation of the IκB kinase (IKK)/NF-κB 
essential modulator (NEMO) complex.  IKK/NEMO catalyses the phosphorylation 
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and proteasomic degradation of IκB, releasing NF-κB for nuclear localisation and 
transcriptional activity [73].  Gene targets of NF-κB include some of the same 
products which themselves activate NF-κB, such as TNF-α and IL-1.  Thus a feed-
forward loop is set up and undergoes self-amplification.   
 
More recently alternative (or non-canonical) NF-κB activation pathways have been 
elucidated, which do not involve agonist stimulation but post-translational 
processing and cleavage of the p52 precursor, p100, to produce p52/RelB dimmers 
which move into the nucleus [74].  This is dependent on IKK-α homodimers, and 
occurs in response to B cell activating factor (BAFF), CD40 ligand (CD40L) and 
lymphotoxin β receptor (LTβR).  These pathways are as yet less clearly delineated.  
It is thought that the alternative pathway plays an important role in the maintenance 
of secondary lymphoid organs.  By either route of activation, the gene targets of 
NF-κB may be divided functionally into inflammatory, cell-cycle regulating and 
anti-apoptotic genes.  Thus NF-κB sits at a crossroads between inflammation and 
apoptosis.  NF-κB also targets genes which encode auto-inhibitory feedback loop 
proteins to negatively regulate its own activation [75]. 
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Figure 1.3 (a) Classical and (b) alternative NF-κB activation pathways  [Bonizzi G, 
Karin M. Trends in immunology 2004;25:280-8] 
 
NF-κB (particularly the p65 subunit) plays an important role in IBD, as evidenced 
by its increased expression and activation in inflamed gut tissues, which appear to 
correlate with disease severity [76], and by the finding that its abrogation is a 
highly effective treatment for experimental colitis of different types [77].  These 
data come from macrophages and monocytes of the mucosa and lamina propria, 
where the pro-inflammatory role of NF-κB is well established.  However more 
recent animal work suggests that NF-κB may function as a master regulator of 
immune responses, with different, perhaps protective, effects in other cell types in 
IBD.  For example conditional ablation of NEMO in mouse intestinal epithelial 
cells (which prevents NF-κB activation) causes spontaneous colitis and sensitises 
epithelial cells to TNF-α-induced apoptosis [78].  This suggests that NF-κB 
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improves epithelial integrity and barrier function, and thus in the epithelium has a 
homeostatic role guarding against immune dysregulation and the development of 
inflammation.  Others have shown pro-inflammatory consequences of NF-κB 
activation in the epithelium, where IL-6 activates NF-κB in CaCo2 cells, leading to 
the induction of ICAM-1 which is known to further recruit immune cells into the 
inflamed gut [79].  Thus normal NF-κB functioning is crucial for intestinal 
homeostasis, but its functions are complex and include both pro-inflammatory and 
stabilising effects.   
 
 
1.2.4 Anti-inflammatory Mechanisms 
 
Much work to date has concentrated on proinflammatory pathways such as those 
described above, which are excessively active in the gut wall in IBD.  The intestine 
of normal individuals, despite its intimate contact with a lumen teeming with 
potential inflammatory antigens, does not suffer pathological inflammation.  
Likewise, in individuals with IBD, spontaneous remission and periods of sustained 
quiescence occasionally occur in the absence of pharmacological treatment [80] 
[81].  These observations suggest that natural anti-inflammatory, healing 
mechanisms operate [82] and provide a new avenue for research and potential new 
lines of therapy.  The immune system exerts negative control over inflammation at 
a number of different levels, including anergy (lack of immune reactivity in a 
lymphocyte), apoptosis of active lymphocytes (programmed cell death) and through 
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the actions of regulatory T cells, the most important group of which are understood 
to be the CD4+ regulatory T cells.  This population can suppress immune responses 
and are important for maintenance of tolerance, both to self antigens and to normal 
bacterial gut flora.  By inference this group of cells does not function sufficiently in 
IBD to suppress inflammation but no specific defect has as yet been identified.  
There is evidence that defective T cell apoptosis plays a role in maintaining 
inflammation in CD [83]. 
 
There are two major cytokines which inhibit inflammation; transforming growth 
factor beta (TGF-β) [84] and IL-10 [85], and the current work builds on the recently 
growing understanding of the ways in which they are abnormally regulated in IBD. 
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1.2.5 Transforming Growth Factor-β 
 
 
Figure 1.4 Mechanism of signal transduction mediated by transforming growth factor 
β [Blobe GC, Schiemann WP, Lodish HF. The New England journal of medicine 
2000;342:1350-8] 
 
TGF-β was originally characterised in 1983 [87].  Nearly all cell types produce it 
and have receptors for it.  There are three subtypes; TGF-β1 which is produced by 
endothelial, haematopoietic, connective tissue and importantly regulatory T cells 
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[82]; TGF-β2, produced by epithelial and neuronal cells and TGF-β3, produced by 
mesenchymal cells.  TGF-β is highly conserved in mammals, suggesting critical 
functions for survival [86].  In support of this, TGF-β1 knock-out mice die of 
severe early multi-organ inflammation [88].  There is evidence to suggest that TGF-
β1 produced by regulatory T cells prevents intestinal inflammation [89].  TGF-β1 is 
consistently associated with significant improvement in colitis in animal studies, 
both in trinitrobenzene sulfonic acid (TNBS)-induced colitis; a model of CD, and in 
oxazolone-induced disease; a model of UC.   
 
Extracellular TGF-β binds either directly to a type II TGF-β transmembrane 
receptor (RII), or to a type III TGF-β receptor (RIII) which presents it to a RII.  
This leads to the binding of a type I TGF-β receptor (RI), and with the formation of 
this complex there is phosphorylation of RI (red sphere in Figure 1.4).  This in turn 
activates the RI protein kinase, and this initiates an intracellular signal by 
phosphorylation of Smad proteins 2 and 3.  The Smads are a family of polypeptides 
in the TGF-β signalling cascade.  The name is an amalgam from their structural 
homology to the Drosophila MAD protein (mothers against decapentaplegic; so 
named because its mutation in the Drosophila mother insect causes its repression in 
the embryo) and the C. elegans protein SMA.  Smad 3 deficient mice have 
impaired T cell and mucosal immunity [90].  After TGF-β binding, phosphorylated 
Smads 2 and 3 complex with Smad 4 and move into the nucleus where target 
effects are exerted.  Once in the nucleus the Smad complex interacts with other 
transcription factors (in grey in Figure 1.4) in a cell-specific manner to mediate 
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ultimate TGF-β cellular effects.  Inhibitory Smads 6 and 7 lack the region normally 
phosphorylated by RI for TGF-β signal transduction and thus interfere with normal 
TGF-β signalling by blocking the phosphorylation of Smad 2 or 3 by RI.  This is 
examined in detail in Chapter 1.2.8. 
 
The ultimate biological effects of TGF-β are complex, varied and depend on tissue 
type.  Its immunosuppressive effects include promotion of leukocyte differentiation 
and inhibition of leukocyte proliferation, macrophage activation and dendritic cell 
maturation [91].  It inhibits growth, promotes apoptosis and causes deposition of 
extracellular matrix.  Through this latter effect it can thus be involved in the 
development of tissue fibrosis; paradoxically contributing to the potential clinical 
problem of stricture formation in CD.  It stimulates IL-10 production and inhibits 
NF-κB activation in some cell types. 
 
 
1.2.6 Interleukin-10 
 
IL-10 was originally described in 1989 as cytokine synthesis inhibitory factor [92].  
It is released by T helper cells following antigen-specific and polyclonal activation, 
by B cells and by monocytes in response to TNF-α, IFN-γ and bacterial LPS [85].  
It is synthesised late after a stimulus in comparison to other cytokines [93] and its 
key role is to inhibit the production of proinflammatory cytokines including TNF-α, 
IL-1, IL-2, IL-6, IL-12 and IFN-γ [94].  It also downregulates major 
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histocompatibility complex type II (MHC II) molecules thus inhibiting antigen 
presentation [95] and induces the production of various cytokine inhibitors such as 
IL-1 receptor antagonist [96] [97].  It directly inhibits differentiation and 
proliferation of T cell clones [98] and has a probable role in the generation and 
activation of regulatory CD4+ T cells [99] [100] [101].  It inhibits matrix 
metalloproteinase (MMP) activity thus limiting tissue damage [102].  The IL-10 
knock out mouse is one of the few animal models in IBD with inflammation 
affecting the small intestine as well as the colon [103] [104].  This is mediated by 
CD4+ T helper cells and is entirely dependent on exposure to luminal bacteria, with 
an exaggerated TNF-α response to endotoxin.  Thus IL-10 is important in 
maintaining tolerance to intestinal flora. 
 
Recent work indicates that TGF-β and IL-10 pathways are interdependent.  IL-10-
deficient mice lack TGF-β signalling, with consequent failure to inhibit 
inflammatory responses of the gut epithelium to commensal bacteria [105].  
Evidence is accumulating to suggest that both TGF-β and IL-10 are downregulated 
by acetylation of certain regulatory proteins, and this will now be described in more 
detail. 
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1.2.7 Acetylation 
 
 
 
Figure 1.5 Acetylation 
 
Acetylation is a chemical modification of a protein in which an acetyl group binds 
to the terminal lysine residue of the protein (Figure 1.5).  This alters the protein’s 
shape, charge and biological fate in the cell.  Traditionally the study of acetylation 
has centred on acetylation of histones.  Histones form a key component of 
chromatin, the scaffold in which deoxyribonucleic acid (DNA) is packaged into the 
nucleosome.  When histones undergo acetylation, this changes their conformation 
and electrical charge, loosens their interactions with DNA and thus opens out the 
nucleosome, exposing DNA for gene transcription [106] [107].  The short chain 
fatty acid (SCFA) butyrate is a product of bacterial fermentation in the intestine and 
an inhibitor of the enzyme histone deacetylase (HDAC), thus it acts to increase the 
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acetylation status of the cell.  Butyrate and its actions are discussed in greater detail 
in Chapter 7.4.3.  As expected due to its acetylation of histones, butyrate 
upregulates gene expression [108] [109] [110] [111].  However, as will be 
introduced below, further work has shown that other (non-histone) proteins within 
the cell are also subject to acetylation and that this initiates separate events which 
affect gene expression. 
 
 
1.2.8 Smad 7 
 
As described in Chapter 1.2.5 an inhibitory Smad, Smad 7, is known to block TGF-
β signalling [112].  Smad 7 interacts with the activated TGF-β receptor and 
prevents the docking of Smads 2 and 3 [113], which under normal circumstances 
would be phosphorylated on activation, starting a TGF-β cellular signalling cascade 
(Figure 1.4).  In normal individuals Smad 7 is transcribed and transported out of the 
nucleus in complex with Smad ubiquitin regulatory factor (Smurf) 1 or 2 [114].  
Smurf and Arkadia, which are ubiquitin ligases, in combination with the ubiquitin-
binding Jun activation domain-binding protein (JAB) 1, quickly induce 
ubiquitination of Smad 7 at specific lysine residues.  Ubiquitination is a covalent 
modification of a protein and an important regulatory mechanism by which cellular 
proteins are degraded, trafficked and quality controlled.  Thus ubiquitination causes 
the Smad 7 to be degraded by proteasomes and removed from biological activity 
within the cell.   
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When Smad 7 is kept highly acetylated as it is in IBD, the acetylation of lysine 
residues on Smad 7 prevents its ubiquitiniation and thus potentiates its activity in 
the cell (Figure 1.6).  In IBD, despite the abundant presence of TGF-β,  there is a 
failure of TGF-β-mediated anti-inflammatory effects, including failed negative 
regulation of both NF-κB and proinflammatory cytokine production [115] [116].  In 
IBD there is reduced phosphorylation of Smad 3 and increased amounts of Smad 7 
(levels of which are controlled by its acetylation status as described above).   
 
Exogenously administered TGF-β, in cells from normal individuals, prevents TNF-
α-induced NF-κB activation, but in IBD exogenous TGF-β has no effect [117].  
This data is somewhat discrepant with the earlier description of TGF-β-associated 
improvement in animal models of colitis.  A possible explanation is that very high 
levels of TGF-β effectively bypass the Smad 7 block, a theory supported by the 
observation that human CD lamina propria mononuclear cells (LPMC), whilst 
unresponsive to low dose TGF-β, do exhibit a partial response to high doses, in 
which signalling is restored to a certain extent [115].  Specific inhibition of Smad 7 
in cells and tissues from patients with IBD restores Smad 3 phosphorylation and 
TGF-β-mediated suppression of proinflammatory cytokine production [117].  In 
recent animal studies, oral administration of Smad 7 antisense oligonucleotide 
restored TGF-β signalling and improved experimentally induced colitis by clinical 
and histological parameters, in both TNBS- and oxazolone-induced disease [118].  
This may potentially yield a promising new line of therapy in IBD.   
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Figure 1.6 Fate of Smad 7 in normal and inflamed gut 
 
 
The mechanisms underlying Smad 7 upregulation in IBD are not yet clear.  Smad 7 
manifestly undergoes post-transcriptional stabilisation in inflamed tissues, but the 
fundamental molecular explanation for why this is so remains obscure.  Why the 
acetylation status in IBD is higher is not known.  It has been proposed that TGF-
β/Smad 3 signalling induces Smad 7 in a negative feedback loop.  Against this 
theory is the observation that phosphorylated Smad 3 levels  are reduced when 
Smad 7 is high [118].  It has been shown that Smad 7 is inducible by IFN-γ in 
monocytes (via STAT1) [119] or by TNF-α in fibroblasts (via NF-κB) [120].  
However, as causative pathways these are made less likely by the observation that 
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blocking IFN-γ, STAT1, TNF-α and NF-κB in inflamed LPMC’s leaves Smad 7 
expression unchanged [115]. 
 
 
1.2.9 Acetyl Transferase p300 
 
Acetyl transferase enzymes are classified into families based on their structural 
similarities.  These include the GNAT family (Gcn5-related N-acetyl transferase), 
in which one example is PCAF (p300/CBP-associated factor), the MYST family 
(so named because it includes MOZ, YBF2/SAS3 and TIP60 groups) and the 
p300/cAMP response element binding protein (p300/CBP) family.  In the 
experiments described in Chapter 1.2.8 it was demonstrated that the acetylation of 
Smad 7 was associated with an increase in p300 acetyl transferase.  p300 acetyl 
transferase is a global transcriptional co-activator and, through its potent histone 
acetyl transferase activity, plays a role in a wide variety of gene transcription 
events.  As previously mentioned, other non-histone proteins in the cell are subject 
to acetylation, and p300 also catalyses these events.  An important such non-histone 
example is the tumour suppressor gene p53, ‘the guardian of the genome’, whose 
capacity to activate transcription and therefore DNA repair is altered by p300 status 
[121] [122], and indeed mutations in p300 have been found in several different 
types of cancer specimen, particularly in gut cancers [123].  Blocking p300 inhibits 
Smad 7 acetylation, enhances its ubiquitination and leads to reduced amounts of 
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Smad 7 in the cell [117], reflecting the situation seen in normal cells in contrast to 
that in IBD. 
 
 
1.2.10 Transcription Factor Sp3 
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Figure 1.7 Transcription factor Sp3 
 
Sp3 is a negative transcription factor which, on binding to the promoter region of 
insulin-like growth factor binding protein 3 (IGFBP-3), causes its expression to be 
downregulated [124].  This may occur by preventing the binding of Sp1, a positive 
transcription factor, from binding to the promoter.  IGF binding proteins hold 
insulin-like growth factors (IGF) inactive in the circulation, limiting their 
bioavailability [125] and are thought to reduce T cell proliferation by preventing 
access of IGF’s to receptors expressed by activated T cells [126], thus effecting an 
anti-inflammatory action.  In addition, IGF binding proteins have themselves been 
shown to exert direct anti-proliferative effects in the gut [127].  When Sp3 is 
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acetylated, it binds more avidly to the IGFBP-3 promoter, further downregulating 
its expression, and this effect is dependent on the acetylation activity of p300 [128] 
(Figure 1.7).  IL-10 shares the same Sp3/Sp1 binding sequence in its promoter as 
IGFBP-3 [129] and indeed the anti-inflammatory role of IL-10 is more clearly 
documented than that of IGFBP-3.  This work will investigate the hypothesis that 
expression of IL-10 can be altered by manipulation of the acetylation status of Sp3. 
 
 
1.3 Environmental Factors in Inflammatory Bowel 
Disease 
 
1.3.0 Diet and Inflammatory Bowel Disease 
 
As discussed above, the aetiology of IBD is complex and multi-factorial.  As well 
as the genetic influences and disorders of immune regulation already addressed, 
environmental factors, including diet and other changes in the luminal environment, 
are of clear relevance.  There is a robust geographic gradient in incidence of IBD 
from south to north, and individuals who move from a country of low incidence to 
one of high incidence take on the risk of the new country within the first generation 
born there [11].  This strongly suggests that environmental factors such as diet and 
other features of modern living are important causative influences.  (See Chapter 
1.1.0 for more on the epidemiological issues in IBD.)  The rising global incidence 
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of IBD, especially CD, in both Western and developing countries, coincides with 
increasing hygiene and industrialisation, and a move away from traditional local 
cooking methods and ingredients, towards more ‘fast food’ and globalisation of the 
diet.  Such considerations are particularly relevant to the study of a dietary agent 
such as curcumin, which is found in high natural concentrations in the food of 
India, China and other parts of Asia; regions where the incidence of IBD is low; in 
contrast to Europe and the United States, where dietary curcumin ingestion is low 
and IBD incidence much higher. 
 
Which particular facet of Westernisation of lifestyle is to blame, if indeed it is 
responsible for the increasing incidence of IBD, remains a matter for debate.  A 
recent review of seven case-control studies of patterns of food consumption in IBD 
concluded that certain dietary components were associated with greater odds ratios 
of having IBD (Table 1.2) [130].  Foods associated with both CD and UC broadly 
coincided, and included meat, fish, fats, sweets and ‘fast food’.  The finding that 
fish has no protective effect for IBD is consistent with a recent Cochrane review 
which concluded that supplementation of the diet with ω-3 polyunsaturated fatty 
acids (fish oil), although safe, was ineffective at maintaining remission in CD 
[131].  With perhaps the exception of fish, this list of foods is generally typical of a 
modern Western diet, whilst fresh fruit and grain-based foods like rice and bread, 
typical components of more traditional diets, were associated with reduced odds 
ratios of IBD [130].  The capacity for confounding variables in epidemiological 
studies of diet and disease is high, and cause or effect difficult to infer.  However 
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the case-control design of the studies included here was rigorous and the findings 
do suggest that elements in the luminal environment are relevant to the disease 
process in IBD. 
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Table 1.2  Odds ratios and relative risks of foods against the occurrence of Crohn’s 
disease and ulcerative colitis [130] 
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Elemental or polymeric nutrition is highly effective in bringing about remission in 
small bowel CD [24] [25].  The mechanism of action remains unknown.  An early 
theory stated that the reduced antigen load somehow triggered resolution of 
inflammation, however subsequent trials clearly showed that polymeric formulas 
were equally as effective at inducing remission as elemental formulas [132].  An 
alternative theory proposes that alteration in bacterial flora is the important 
mechanism of action [26].  In either case, the efficacy of enteral nutrition therapy 
further demonstrates that a change in the luminal contents alters the inflammatory 
process in the gut in CD.   
 
Surgical diversion of the faecal stream has been used as a treatment for Crohn’s 
colitis for several decades [133].  Although this approach may be effective in the 
short term, outcomes are inconsistent and long term remission rates generally 
disappointing [134].  Conversely, diversion colitis occurs in the distal defunctioned 
rectal stump in about one third of patients who undergo ileostomy for any 
indication.  This suggests that elements lacking in the normal faecal stream 
predispose to inflammation in the colon.  There is evidence that this missing factor 
is short chain fatty acids (SCFA), and administration of a SCFA solution into the 
distal colon remnant can induce resolution of the diversion colitis [135].  Faecal 
diversion as a treatment for IBD versus faecal diversion as a cause of colitis, are 
clearly somewhat in contradiction with each other.  Yet both observations further 
support the understanding that dietary factors modulate inflammatory processes in 
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the colon, and that the influences of luminal nutrients upon colonic inflammation 
and homeostasis are complex and presently far from fully understood. 
 
 
1.3.1 Bacteria and Inflammatory Bowel Disease 
 
As well as antigens of dietary origin, the bacterial population in the lumen also 
presents a multitude of potential antigenic stimuli to the host and is crucially 
involved in intestinal inflammatory responses in health and disease.  As presented 
in Chapters 1.2.0 and 1.2.1, many of the known IBD susceptibility genes encode 
proteins involved in the innate and adaptive immune systems which alter the way 
the host processes signals from commensal gut bacteria.  Furthermore strong 
evidence exists that IBD requires the presence of (normally harmless) bacteria in 
order to develop, and that individuals with IBD mount an inappropriate immune 
reactivity to their gut microflora (see Chapter 1.2.1). 
 
The human gut microbiota has been evolving to its environment, and the human gut 
evolving to its microbiota, over millennia.  New appreciation of the important 
interplay between the gut microbiota and human health and disease, as well as new 
molecular technologies for the study of microbiotic composition, architecture and 
function, have led to the launch of the Human Microbiome Project by the National 
Institutes of Health [136].  The healthy human gastrointestinal tract is colonised by 
up to 1000 different bacterial species, the vast majority of which have yet to be 
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cultured [137].  The concentration of bacteria increases greatly from proximal to 
distal small bowel, and the greatest concentrations are found in the colon.  This 
coincides with the observation that the commonest sites for IBD are the colon and 
terminal ileum (distal small bowel).   
 
Does the harbouring of such a large microbial biomass within the mammalian host 
impart mutual biological advantage?  The advantage to bacteria of a 
homeostatically regulated environment is clear, but the symbiotic nature of the 
relationship may not be immediately apparent.  Normal mice raised in germ-free 
conditions consume more food and yet have 40% less body fat than those raised in 
a normal environment, and conventionalisation of germ-free mice by transfer of 
normal microbiota completely reverses this [138].  This suggests that the 
microbiota greatly improves the efficiency of host nutrient handling; an enormous 
survival advantage during mammalian evolution.  Aside from nutritional 
advantages, colonisation with commensal bacteria appears to confer immunological 
advantage on the host as well, playing a vital role in host defence by stimulating 
normal tolerogenic immune responses and competing with potential pathogenic 
species [139].  Normal mice raised in a germ-free environment fail to develop IgA-
secreting plasma cells; a key element in the specific adaptive immune response of 
the intestinal mucosa to luminal bacteria [140]. 
 
Changing global patterns of human diet, with increased consumption of animal fats 
and refined sugars, appear to have an impact on the bacterial populations of the gut.  
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Differences in microflora are seen between individuals living in urban compared to 
rural areas of Japan, where rural lifestyles are associated with traditional Japanese 
diets and urban with more Westernised food influences [141].  Microbiotic 
composition also differs in health and disease, including IBD.  Analysis of bacterial 
flora from inflamed and healthy gut reveals differences in species composition; 
specifically reduced species diversity in IBD [142].  Individuals with IBD have 
more bacteria directly attached to the colonic mucosa than do healthy controls 
[143].  This increases in proportion to disease severity, but is seen equally in 
inflamed and non-inflamed areas of gut.  In patients with IBD and high 
concentrations of bacteria, the investigators also found characteristic bacterial 
inclusions in enterocytes near the lamina propria; cells which are not in contact 
with the faecal stream.  These findings suggest that the changes in microflora seen 
in IBD are not merely secondary to inflammation but indicate an altered host 
response and different host-bacterial ‘cross-talk’. 
 
Mice ordinarily used as models of IBD either fail to develop, or develop greatly 
attenuated, intestinal inflammation when raised in germ-free conditions [144] 
[103].  This crucially implicates bacteria in the pathogenesis of IBD.  Meta-analysis 
of ten randomised controlled trials concluded that antibiotics as an adjunct therapy 
are of clear benefit at inducing remission in UC [145].  Meta-analysis of six 
randomised controlled trials of antibiotic therapy in active CD suggested improved 
clinical outcomes, particularly if the therapy included ciprofloxacin [146].  These 
data are consistent with the observation that IBD is characterised by aberrant 
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bacterial processing by the host, and that manipulation of the bacterial composition 
can alter the inflammatory process.   
 
Perhaps as a natural extrapolation of these observations, there has been an interest 
in the use of probiotics in IBD.  Probiotics are living viable microorganisms which 
when ingested have demonstrable positive health benefits.  One of the issues that 
has made the study of probiotics more complex is the existence of a large number 
of different candidate organisms, and the trialling of various different species and 
combinations clinically.  The most widely studied species are Lactobacillus, 
Bifidobacterium and Saccharomyses.  To date the only evidence with sufficient 
strength to support clinical use is for probiotics in pouchitis.  Pouchitis is 
inflammation of unknown cause occurring relatively commonly in the ileo-anal 
reconstructed pouch which substitutes the rectum following colectomy for UC.  In 
two separate randomised controlled trials including a total of 76 patients, probiotics 
showed significant benefit over placebo at maintaining antibiotic-induced remission 
in pouchitis [147] [148].  Both trials used VSL#3, a combination probiotic 
containing four strains of Lactobacillus, three strains of Bifidobacterium and 
Streptococcus salivarius thermophilus.  The evidence also supports the use of 
VSL#3 in post-operative prophylaxis of pouchitis, in which a randomised 
controlled trial showed significant benefit of treatment over placebo after one year 
[149].  Conversely there is no evidence for efficacy of probiotics in the treatment of 
acute pouchitis, either of Lactobacillus rhamnosus GG against placebo [150], or of 
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an open-label combination of Lactobacillus acidophilus and Bifidobacterium lactis 
[151].  There is no convincing evidence that probiotics are useful in CD or UC. 
 
 
1.4 Curcumin 
 
1.4.0 Background: Human Uses of Curcumin 
 
For thousands of years humans have used plants for therapeutics.  Recent years 
have seen the development of highly targeted biological treatments and synthetic 
therapies, some with serious side effects.  At the same time there is renewed public 
interest in complementary therapies, naturally occurring treatments with minimal 
toxicity, and diets related to health and disease.   
 
 
Figure 1.8 Turmeric plant (Curcuma longa) with flowers and root 
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Curcumin is a constituent of the spice turmeric, one of the principle ingredients in 
curry powder.  Turmeric is prepared from the root of the Curcuma longa plant 
(Figure 1.8), a member of the ginger family.  It is native to India and Southeast 
Asia, where fresh turmeric root is widely used in a similar way to ginger; in the 
West turmeric is much more commonly available as a dried powder.  It has been 
used to treat a broad range of common ailments in Indian Ayurvedic medicine for at 
least 4000 years, as well as in Chinese, Arabic and other traditional medicines.  
Curcumin is in modern use worldwide as a cooking spice, flavouring agent and 
colorant.  Dishes traditionally made with turmeric include dahls and most other 
curries, as well as pickles, relishes and chutneys.  It is widely used to colour 
mustards, mayonnaises and margarines and has been designated as international 
food additive E100.  Because of its resemblance to saffron, curcumin is sometimes 
referred to as ‘Indian saffron’ and used as a (much less expensive) substitute. 
 
 
1.4.1 Chemistry of Curcumin 
 
 
Figure 1.9 Molecular structure of curcumin 
 
The active ingredient of curcumin is diferuloylmethane, a hydrophobic polyphenol 
with a characteristic yellow colour.  In chemical terms it is a bis-α, β-unsaturated β-
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diketone, a linear diarylheptanoid compound, where two oxy-substituted aryl 
moieties are linked together through a seven carbon chain (Figure 1.9).   
 
 
1.4.2 Dose and Safety of Curcumin 
 
The safety, tolerability and non-toxicity of curcumin at high doses are well 
established.  Oral doses up to 12g per day are well tolerated in humans [152], 
although dosing regimes above 8g may be difficult to achieve due to the bulky 
nature of this quantity of compound [153].  However drug delivery is a problem and 
the bioavailability of oral curcumin is low [154, 155] due to a combination of 
efficient first pass metabolism, poor gastrointestinal absorption, rapid elimination 
and poor aqueous solubility.  Elimination is largely via hepatic glucuronidation and 
sulfation.  Metabolites lack pharmacological activity [156], and are excreted 
through stool.  Serum concentrations peak one to two hours after oral administration 
and are undetectable by 12 hours [153].  Some investigators report that serum 
curcumin is undetectable below oral doses of about 4g [152, 153], however others 
have detected curcumin not only in serum, but also urine, at much lower doses 
[157].  Some studies also demonstrate the presence of curcumin in colorectal tissue 
at oral doses of 3.6g [158], so the gut may represent a promising local clinical target 
for curcumin. 
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The apparent discrepancies in pharmacodynamics observed between different 
dosing regimes may relate to the differing formulations used.  Curcumin constitutes 
about 5% of turmeric root [159] [160]; the remainder is made up of carbohydrates, 
proteins and essential oils.  There are three natural analogues of curcumin 
(curcuminoids) which vary in methoxy substitution on the aromatic ring.  Curcumin 
is the most abundant (77%), followed by demethoxycurcumin (17%), then 
bisdemethoxycurcumin (3%) [161].  Preparations used for human consumption are 
either naturally produced from purified turmeric extract, which contains varying 
proportions of the different curcuminoids, or are synthetically produced, containing 
only pure chemically synthesised curcumin.  The bioactivity of these different 
analogues varies according to the cell type and function analysed, disease system 
and organism.  There is no consensus as to the most effective preparation for 
human use.  Strategies have also been employed to improve bioavailability based 
on changes in drug formulation, such as the use of nanoparticles to reduce particle 
size delivery, and micelles to counter hydrophobicity.  Recently it has been 
reported that heat treatment improves the water solubility of curcumin [162]. 
 
In human trials only minor side effects of curcumin, namely diarrhoea [157], have 
been reported, and it is considered safe and well-tolerated.  As a caveat however, 
these trials have usually examined short term outcomes.  There is some evidence 
that long term, high dose curcumin administration in rodents can be tumorigenic 
[163] [164].  It has also been shown that curcumin’s predominant activity switches 
from anti-oxidant to pro-oxidant with increasing concentration [165], which may 
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provide an explanation for its seemingly opposing biological effects in vivo.  These 
apparent contradictory roles of curcumin, as both anti-cancer, and pro-carcinogenic 
agent, are as yet unexplained, and epitomise the complexity and paradoxical nature 
of the compound.  Nevertheless there is good evidence from India, at a population 
level, of the safety of lifelong curcumin ingestion up to about 100mg/day [166], and 
it is classified ‘Generally Recognised As Safe’ by the United States Food and Drug 
Administration. 
 
 
1.4.3 In Vitro Studies of Curcumin 
 
A wide variety of cellular properties of curcumin have been demonstrated, 
including anti-oxidant, anti-inflammatory, anti-proliferative, pro-apoptotic, anti-
bacterial and anti-cancer activities (Table 1.3 and Figure 1.10).   
 
Biological 
Activity 
Molecular 
Mechanism 
Cell line 
(human unless otherwise stated) 
Anti-
inflammatory 
↓NF-κB Myeloid leukaemia[167] [168], B non-Hodgkin’s 
lymphoma (NHL)[169] [170], embryonic kidney 
(HEK)[167], mouse macrophage[171] 
↓COX2 Intestinal microvascular endothelial[172], colonic 
epithelial[173], microglial[174], mouse macrophage[171] 
↓IL-1β, IL-6, IL-8  Oesophageal epithelial[175], head and neck 
cancer[176], mouse macrophage[171] 
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↓TNF-α Mouse macrophage[171] 
↓ICAM-1 Epithelial/umbilical vein endothelial (HUEVC) 
hybridoma[177] 
↓p300 
acetyltransferase  
Tracheal smooth muscle[178], cervical cancer[179], 
HEK[179], lymphoblastic T lymphoma[179], Burkitt’s 
lymphoma[180] 
↑PPAR-γ Colon cancer[181], rat hepatic stellate[182] 
Anti-oxidant ↓Nitric oxide synthase 
(NOS)  
Mouse macrophage[171] 
↑Glutathione Lymphocytes[183] 
↑Haem oxygenase 
(HO)-1 
Epithelial/HUEVC hybridoma[177], porcine renal 
epithelial[184] 
↑Superoxide dismutase 
(SOD)  
Lymphocytes[183] 
↑Reactive oxygen 
species (ROS) 
Promyelocytic leukaemia (PML)[185] 
Pro-apoptotic ↓Bcl-2 B NHL[170], colon cancer[186] [187] 
↓survivin Colon cancer[187] 
↓Akt T leukaemia[188] 
↓c-myc B NHL[170] 
↓Ornithine 
decarboxylase (ODC)  
PML[185] 
↑Bax  Colon cancer[186] [187] 
↑caspases  PML[185], colon cancer[186] [187] 
↕JNK  T lymphocyte↓[189], breast cancer↓[189], HEK↓[189], 
colon cancer↑[190] 
Anti-cancer ↓cyclin D1 Colon cancer[181] 
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↓MMP  HUEVC[191], melanoma[191], fibrosarcoma[191, 192], 
breast cancer[191], blood mononuclear[193], intestinal 
epithelial[194] 
↓Epidermal growth 
factor (EGF)  
Hepatocellular carcinoma (HCC)[195] 
↓STAT Multiple myeloma[196], Hodgkin’s lymphoma[197] 
↓Hypoxia-inducible 
factor (HIF)-1α 
HCC[195] 
↓Protein kinase C 
(PKC)  
Mouse embryonic fibroblast[198] 
↓Early growth 
response factor (egr)-1 
B NHL[170], HUEVC[199], lung fibroblast[199] 
↓Activator protein 
(AP)-1 
HEK[174], microglial[174] 
↕p38 MAPK Intestinal microvascular endothelial↓[172], 
neutrophils↑[200] 
↕p53 B NHL↓[170], colon cancer↑[186]↓[201], thymocytes↓[202], 
myeloid leukaemia↓[202], breast cancer↑[203] 
 
Table 1.3 Molecular targets of curcumin in cell line studies 
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Figure 1.10 Cellular activities of curcumin and molecular mechanisms of action 
 
 
1.4.4 Transcription Factors: in vitro Actions of Curcumin 
 
Nuclear Factor (NF)-κB 
General information on the role of NF-κB in inflammation and IBD is presented in 
Chapter 1.2.3 and NF-κB signalling pathways are depicted in Figure 1.3.  NF-κB is 
one of the key transcription factors responsive to curcumin.  In human myeloid 
ML-1a cells, curcumin suppresses NF-κB activation induced by TNF-α, phorbol 
ester and hydrogen peroxide [168].  The mechanism appears to be via reduced IκBα 
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phosphorylation and degradation [167], suggesting that curcumin acts at a step 
above IκB kinase (IKK) in the NF-κB activation pathway.  Overall, inhibition of 
NF-κB signalling by curcumin is a consistent finding in a number of studies.  For 
example in four different human mantle cell lymphoma lines (an aggressive non-
Hodgkins B cell lymphoma), curcumin down-regulated NF-κB, inhibited IKK and 
reduced IκBα phosphorylation, leading to cell cycle arrest, apoptosis and 
suppression of proliferation [169].   
 
Signal Transducer and Activator of Transcription (STAT) 3 
STAT3 is a transcriptional activator with a ubiquitous role in tumourigenesis.  It is 
involved in dysregulation of cell growth, invasion, angiogenesis and metastasis 
[204].  Curcumin inhibits STAT3 activation in human multiple myeloma cells 
[196], and in five different human Hodgkin and Reed-Sternberg lymphoma cell 
lines [197]. 
 
Peroxisome Proliferator-Activated Receptor (PPAR)-γ 
PPAR-γ is a nuclear receptor and transcription factor involved in cell cycle control, 
proliferation and differentiation, exerting anti-inflammatory, anti-cancer and 
insulin-sensitising actions.  It is activated by prostaglandin products of the 
eicosanoid cascade [205] [206], and possibly by dietary components such as 
linolenic and linoleic acid, although the role of these is controversial.  Its activity in 
Moser cells (a human colon cancer cell line) is enhanced by curcumin, 
consequently interrupting the cell cycle through reduced expression of cyclin D1 
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[181].  The same group also show induction and activation of PPAR-γ by curcumin 
in rat hepatic stellate cells, a liver cell type responsible for fibrosis in liver injury 
which contributes to chronic liver damage and cirrhosis.  PPAR-γ inhibited the 
proliferation of stellate cells, and curcumin greatly enhanced this effect [182].  
 
 
1.4.5 Mitogen-Activated Protein Kinase Signalling Pathways: in 
vitro Actions of Curcumin 
 
The MAPK cascade is activated by a large number of different types of receptor, 
including cytokine, growth and toll-like receptors, and receptors sensitive to 
environmental stressors.  General background on MAPK signalling is presented in 
Chapter 1.2.2 and Figure 1.2.  The precise mechanisms of activation are 
incompletely understood [207].  Curcumin modulates MAPK signalling in several 
different in vitro models, although the data are somewhat contradictory.  Under 
some circumstances, curcumin inhibits MAPK activation, as in a recent study in 
primary human intestinal microvascular endothelial cells, where curcumin inhibited 
p38 MAPK activation in response to vascular endothelial growth factor, as well as 
COX-2 and prostaglandin E(2) production [172].  These anti-angiogenic properties 
of curcumin are of potential clinical benefit in gut inflammation and cancer.  
Further evidence that curcumin inhibits MAPK pathways includes its inhibition of 
JNK in Jurkat T cells (a human T cell line) [189].   
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Other investigators paradoxically show activation of MAPK by curcumin, for 
example of JNK in HCT116 cells, a human colon cancer cell line [190] and of p38 
MAPK in primary human neutrophils [200].  Thus curcumin can activate MAPK 
signalling, with the biological consequence of apoptosis; and can also inhibit 
MAPK signalling, where the consequences are anti-inflammatory and anti-
angiogenic.  Whilst the mechanism for its opposing actions is unexplained, in both 
cases its ultimate effects are anti-neoplastic and anti-inflammatory.  Where MAPK 
activation is seen, it is possible that this is due to bacterial contaminants such as 
LPS rather than a true effect of curcumin.  It is likely that the primary molecular 
targets lie elsewhere, and the MAPK signals which are observed experimentally 
represent intermediary pathways by which the biological effects of curcumin are 
mediated. 
 
 
1.4.6 Tumour Suppressor Gene p53: in vitro Actions of Curcumin 
 
Mutation of the tumour suppressor gene p53 plays an important role in the 
evolution of many different human cancers.  Once again, the role of curcumin is 
complex.  In an early study of the effects of curcumin on BKS-2 and WEHI-231 
cells (both immature B cell lymphoma mouse cell lines) proliferation was inhibited 
[170].  Interestingly, and with obvious potential clinical benefit in cancer 
chemotherapy, this inhibitory effect was much less marked on normal B cells.  The 
investigators demonstrated (unexpected) inhibition of expression of p53 by 
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curcumin, as well as inhibition of various other genes involved in growth, 
proliferation and transcriptional activation, including early growth response factor 
(egr)-1, the proto-oncogene c-myc and the transmembrane anti-apoptotic bcl-XL.  
The finding of reduced p53 activity was confirmed in RKO cells (a colon cancer 
cell line) where curcumin impairs the post-translational folding of p53 required for 
its function [201], and in myeloid leukemic cells where it induces p53 degradation 
[202].  
 
Conversely, other experiments show induction of p53 by curcumin, for example in 
human epithelial breast cancer, prostate cancer and B cell lymphoma cell lines 
[203], and in HT-29 cells (a human colon adenocarcinoma cell line) [186].  In the 
former work, once again the authors show differential sensitivity of cancer cells 
compared to healthy cells to curcumin.  Whilst some investigators have shown anti-
proliferative effects despite inhibition of the tumour suppressor p53 [170], 
established precedents exist where an agent which is cancer-preventative in one 
system, can be carcinogenic in another, for example tamoxifen (therapeutic in 
breast; pro-neoplastic in uterus) [208]. 
 
 
1.4.7 Angiogenesis: in vitro Actions of Curcumin 
 
There is strong evidence that curcumin is anti-angiogenic.  Angiogenesis (the 
growth of new blood vessels) is required for the development of both inflammation 
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and cancer, where it is crucial for the survival of tumours beyond a certain size.  It 
is also integral to the generation of diabetic eye disease, which is characterised by 
growth of abnormal vessels across the retina, a major cause of blindness 
worldwide.  In an early study in both primary bovine and immortalised mouse 
endothelial cells, curcumin inhibited endothelial cell proliferation [209].  Curcumin 
inhibits the angiogenic differentiation of human umbilical vein endothelial cells 
(HUVECs) [210] [195].  Also in HUVECs, curcumin binds to and irreversibly 
inhibits aminopeptidase N [191], a membrane-bound matrix metalloproteinase 
(MMP) which increases tumour invasiveness and is involved in retinal neo-
vascularisation and tumour angiogenesis [211].  Finally curcumin decreases 
hypoxia-inducible-factor (HIF)-1α, an angiogenic transcriptional activator, in 
human hepatocellular carcinoma cells [195].  In this work curcumin also inhibited 
the transcriptional action of HIF-1α, downregulating expression of vascular 
endothelial growth factor (VEGF), a potent hypoxia-induced angiogenic factor.   
 
 
1.4.8 Inflammatory Cytokines: in vitro Actions of Curcumin 
 
Several studies demonstrate the suppression of downstream pro-inflammatory and 
pro-neoplastic mediators by curcumin.  Recent examples include reduced 
expression of IL-6 and IL-8 in response to acid exposure in a human oesophageal 
epithelial cell line [175] and reduced spontaneous expression of IL-6 and IL-8 in 
four different head and neck squamous carcinoma cell lines [176].  Several of the 
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authors suggest that these observations may be secondary to the suppression by 
curcumin of intermediary signalling pathways such as NF-κB, and some 
investigators provide evidence to this effect [176]. 
 
 
1.4.9 Cyclo-oxygenase 2: in vitro Actions of Curcumin 
 
Cyclo-oxygenase (COX) 2 is an inducible form of prostaglandin H synthase.  It 
mediates inflammation through production of prostaglandins and plays an 
important role in colon cancer.  Over-expression of COX2 in colonic epithelium 
appears to promote tumour development [212] and non-steroidal anti-inflammatory 
drugs, which inhibit COX2, reduce the risk of colon cancer [213].  Curcumin 
inhibits COX2 production in a primary human intestinal microvascular endothelial 
cell line [172] and inhibits COX2 induction in human colonic epithelial cells [173].  
In this latter work the authors note that the COX2 gene promoter contains two NF-
κB binding sites and show evidence to suggest that the effect of curcumin on COX2 
is due to inhibition of the NF-κB signalling pathway. 
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1.4.10 Matrix Metalloproteinases: in vitro Actions of 
Curcumin 
 
In health, fibroblasts produce low levels of matrix metalloproteinases (MMP) that 
remain largely in latent form and mediate physiological extracellular matrix 
turnover.  In IBD, MMP’s are over-expressed and become activated in cascades 
causing unchecked tissue destruction, fibrosis and further increasing immune cell 
activation and homing [214].  MMP’s also play a key role in tumour progression, 
since matrix dissolution is an important step in the conversion of a pre-malignant 
cell into a frankly malignant one, as well as in tumour growth, invasion, metastasis 
and angiogenesis [215].  There are over 20 different types of MMP, which are sub-
classified according to the primary stromal substrate upon which they act.  
Curcumin down-regulates MMP production in various cell types.  In human 
fibrosarcoma cells it decreases invasion, migration and production of MMP-2 and 
MMP-9 [192], and in human and rabbit peripheral blood mononuclear cells it 
reduces MMP-9 [193].  Recently it was shown to reduce MMP-9 in human 
intestinal epithelial cells [194].  
 
 
1.4.11  p300 Acetyl Transferase: in vitro Actions of Curcumin 
 
Lastly, curcumin is a known inhibitor of acetylation, acting on the enzyme p300 
acetyl transferase [178] [179].  Acetylation modifies proteins when an acetyl group 
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binds to a lysine residue, altering the protein’s shape, charge and biological fate in 
the cell.  Traditionally the study of acetylation has examined how the acetylation of 
histones changes their conformation, loosens their interactions with 
deoxyribonucleic acid (DNA) and thus opens out the nucleosome, exposing DNA 
for gene transcription [106] [107].  However, recent work shows that other (non-
histone) regulatory proteins within the cell are also subject to acetylation, initiating 
separate cellular events which regulate for example transforming growth factor 
(TGF)-β signalling [117] and insulin-like growth factor binding protein (IGFBP)-3 
expression [124] [128] (Chapters 1.2.7 – 1.2.10).  Such events are important in 
inflammation and cellular proliferation.  Another important such non-histone 
example is the tumour suppressor gene p53, whose capacity to activate 
transcription and therefore DNA repair is altered by p300 status [121] [122], and 
indeed mutations in p300 have been found in several different types of cancer 
specimen, particularly in gut cancers [123]. 
 
p300 acetyl transferase, as a potent catalyst of acetylation, plays a role in a wide 
variety of gene transcription and other cellular events. Several effects of curcumin 
resulting from its p300 inhibitor activity are documented, including inhibition of 
inflammatory responses in human tracheal smooth muscle cells [178], suppression 
of human immunodeficiency viral (HIV) proliferation [179] and inhibition of 
proliferation of Raji cells (a non Hodgkin B cell lymphoma line) [180]. 
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1.4.12  Curcumin in Animal Models: Inflammatory Bowel 
Disease 
 
Whilst curcumin has shown benefit in a number of different models of 
inflammatory disease, particular interest has focused on its use in the gut.  IBD is a 
source of considerable morbidity, and its incidence is increasing worldwide.  
Currently available treatments such as steroids, 5-aminosalicylic acids and 
immunomodulators do not offer cure, but CD responds well to polymeric or 
elemental feed, which brings about remission in 80% of paediatric patients [24] 
[25].  IBD is less common in developing countries than in the industrialised world 
[216], and individuals emigrating from East to West take on the Western disease 
risk [11, 216].  This holds further relevance to the importance of diet in 
inflammatory bowel disease, and there is keen interest to develop nutritional 
therapies. 
 
Several studies in various rodent disease models provide strong pre-clinical 
evidence for the benefit of curcumin [217] [218] [219] [220].  For example in 
multidrug resistance gene deficient mice, which spontaneously develop colitis, the 
addition of curcumin to their diet significantly reduced intestinal inflammation 
[219].  Other investigators used 2,4 dinitrochlorobenzene colitis in rats, and showed 
a dose-dependent improvement in disease activity parameters with dietary 
curcumin, of equal potency to sulfasalazine treatment [220].  Curcumin treatment 
was associated with a reduction in colonic NF-κB, inducible nitric oxide synthase 
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(iNOS) and various measures of oxidative stress, for example myeloperoxidase and 
lipid peroxidation. 
 
The efficacy of curcumin in IBD may differ according to inflammatory 
circumstances and dose.  For example trinitrobenzene sulfonic acid (TNBS) colitis 
in NKT-deficient SJL/J mice exhibits a classic T helper cell (Th)1-type response, 
whilst BALB/c mice with TNBS colitis exhibit a mixed Th1/Th2 profile [221].  
Curcumin caused improvement in all disease activity parameters only in the 
BALB/c mice.  In simple terms Th1-type inflammation relates more closely to CD 
and Th2 to UC, although in real terms the situation is probably more complex with 
a degree of overlap.  The reason for the differential efficacy of curcumin in these 
two models is unclear.  The IL-10 knock out mouse develops spontaneous Th1-type 
inflammation in large and small bowel which is dependent on gut bacteria, making 
it a good model of CD.  The protective effect of curcumin in this model (by colon 
morphology and colonic interferon (IFN)-γ and IL-12/23p40 mRNA) was modest 
[222].   
 
This finding bears interesting relevance to the work proposed in this thesis.  The 
effect of curcumin on the IL-10 knockout mouse may have been minimal because 
one of the mechanisms for the efficacy of curcumin in IBD is through enhanced IL-
10 expression, and in this model curcumin was unable to increase IL-10 expression 
as the gene had been deleted.  These investigators also found that any small 
protective effect of curcumin in this model occurred paradoxically only at the 
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lowest dietary concentration of 0.1% and was not observed at higher concentration 
[222].  In vivo NF-κB activation in the gut was unaffected by curcumin at any 
concentration, but curcumin acted synergistically with IL-10 on epithelial cells to 
decrease NF-κB activity.  These data raise once again the suggestion that curcumin 
can have paradoxically opposing effects at different concentrations, and when 
clinical studies take place, a wide range of dosages is warranted. 
 
 
1.4.13  Curcumin in Animal Models: Cancer 
 
Chemoprevention 
The molecular targets of curcumin include many pathways and processes involved 
in the generation and propagation of cancer.  The observation that many common 
cancers (including colon, breast, prostate and lung) are commoner in the Western 
world than in countries such as India where there is high natural dietary curcumin 
consumption [166], whilst not indicative of cause and effect, is intriguing.  
Curcumin has been investigated as both chemotherapeutic and chemopreventive 
agent in many different animal (largely rodent) models of carcinogenesis.  Its 
chemopreventive efficacy for colon cancer is particularly well established [223] 
[224].  Other gastrointestinal cancers against which curcumin has shown protective 
effects include oesophageal [225], stomach [226], liver [227] and oral [228]; all in 
rodent models.  Curcumin also shows chemopreventive properties in rodent models 
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of various extra-intestinal cancers, including breast [229], lung [230], kidney [231], 
bladder [232], blood [229] and skin [233] (Table 1.4). 
 
 
Cancer Animal Model Reference 
Gastrointestinal System: 
Colon 
  
Mouse [223, 224, 234, 235] 
Rat [236, 237, 238, 239, 240, 241, 242, 
243, 244, 245] 
Small intestine Mouse [234] 
Stomach 
 
Mouse [246, 247, 248] 
Rat [226] 
Oesophagus Rat [225] 
Liver Rat [227] 
Pancreas Mouse [249] 
Mouth 
 
Rat [250] 
Hamster [228, 251] 
Breast Mouse [229, 252] 
Rat [238, 253, 254, 255, 256, 257] 
Lung Mouse [230] 
Skin Mouse [233, 246, 248, 258, 259, 260, 261, 
262, 263, 264] 
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Blood Cancers: 
Leukaemia 
  
Mouse [229, 265] 
Multiple myeloma Mouse [266] 
Urinary Tract: 
Kidney 
  
Mouse [231, 267] 
Bladder Mouse [232] 
Brain Mouse [268] 
Prostate Mouse [269] 
 
Table 1.4 Animal models in which curcumin has chemopreventive efficacy 
 
 
Chemotherapy 
Curcumin inhibits tumour growth and metastasis, and has chemosensitising and 
radiosensitising properties.  One of the earliest examples of the ability of curcumin 
to inhibit tumour growth is that of lymphoma cells in a mouse ascites model, when 
it was administered intra-peritoneally at 50mg/kg [270].  Curcumin also has anti-
tumour efficacy against human melanoma cell xenografts if given intra-peritoneally 
[271].  Also in xenograft models, sub-cutaneous delivery of curcumin suppresses 
growth of head and neck squamous carcinoma cells [272], and when given orally it 
inhibits proliferation and angiogenesis, and induces apoptosis in prostate cancer 
cells [273].   
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Curcumin also suppresses proliferation and angiogenesis and enhances apoptosis in 
pancreatic cancer, both when given orally in combination with gemcitabine in an 
orthotopic model [274], and in a xenograft model when given intravenously in a 
liposomal formulation [275].  The same group have also used an intravenous 
liposomal curcumin preparation in luminal gastrointestinal cancers, where it has 
chemosensitising properties against colorectal cancer in a mouse xenograft model 
[276].  In this work tumour growth and angiogenesis were inhibited and apoptosis 
enhanced in combination with oxaliplatin.  In an orthotopic implantation model of 
hepatocellular carcinoma, curcumin also prevented intrahepatic metastasis [277].   
 
Finally, in recent work, oral curcumin has shown efficacy in preventing breast 
cancer metastasis to lung in orthotopic models, both as chemosensitiser in 
conjunction with paclitaxel [278] and in the prevention of its haematogenous spread 
in immunodeficient mice [279].  Curcumin given intraperitoneally in combination 
with docetaxel inhibits tumour growth and angiogenesis in an orthotopic nude 
mouse model of ovarian cancer [280]. 
 
 
1.4.14  Curcumin in Human Trials 
 
In clinical trials, curcumin improves rheumatoid arthritis [281] [282], lowers serum 
cholesterol [283], treats psoriasis [284], enhances early post-transplant renal graft 
function [285], improves post-operative inflammation [286], reduces inflammation 
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in chronic anterior uveitis [287, 288] and orbital inflammatory pseudo-tumours 
[287, 288] and improves endothelial function in type 2 diabetes mellitus [289].  In 
specific relation to the gut, curcumin reduces symptoms in irritable bowel 
syndrome [290], improves outcomes in tropical pancreatitis [291] (a type of chronic 
pancreatitis involving the main pancreatic duct, occurring usually in young people 
and mainly in tropical countries such as southern India), normalises gall bladder 
and biliary motility [292, 293, 294], promotes resolution of gastric ulceration [295] 
and reduces polyp number and size in familial adenomatous polyposis coli [296] 
(Figure 1.11). 
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Figure 1.11 Clinical effects of curcumin: Results from human trials (with references) 
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Clinical Trials of Curcumin in Inflammatory Bowel Disease 
Curcumin is also showing early promise as a treatment for CD and UC.  In a small 
open-label study of five consecutive patients with CD and five with ulcerative 
proctitis performed in 2005 by a group in New York, improvements in clinical and 
laboratory parameters with reduction in need for concomitant medications were 
observed in nine out of ten cases [297].  The patients with ulcerative proctitis were 
all on concurrent 5-ASA preparations and one was also taking prednisolone and 
azathioprine.  They received 550mg oral curcumin twice daily for one month, 
followed by the same dose three times daily for a further month; a relatively small 
dose compared to that trialled by other investigators (Chapter 1.4.2).  
Measurements included standard symptom questionnaires, serological markers of 
inflammation and sigmoidoscopy with histology, both at baseline and two months, 
after the treatment period had ended, as well as symptom diaries throughout the 
treatment period.  All five patients showed global improvement and four out of five 
reduced their 5-ASA medications.  The patient who was on steroids stopped these 
by the end of the trial period.  The patients with CD had ileitis, colitis or ileocolitis, 
and all but one were taking concomitant steroid medications.  They were treated 
with 360mg curcumin orally three times per day for the first month, followed by 
1440mg four times daily for a further two months.  The patients with CD were 
assessed in the same way as those with ulcerative colitis, except for endoscopic 
evaluation, which was not done.  Four out of five patients successfully completed 
the trial; one dropped out because of lack of treatment effect.  Of the four who 
completed CD activity index questionnaires, their scores fell in four out of four, 
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with percentage change -13% to -44%.  The serological marker for inflammation, 
erythrocyte sedimentation rate, also fell in all four patients, with percentage change 
-17% to -71%.  No side effects were reported.   
 
Further encouraging results came from Japan in 2006, where a larger  eight centre 
randomised double blind controlled trial of 89 patients with quiescent UC was 
carried out, in which 45 patients were randomised to receive curcumin at a dose of 
1g twice daily alongside 5-ASA treatment; and 44 patients to receive placebo and 
5-ASA [298].  Any patient receiving an immunomodulator was excluded.  The 
treatment period was six months, and this was followed by a further six month 
period of ongoing 5-ASA treatment only.  Disease severity was measured by both 
clinical activity index and endoscopic index at baseline, at the end of the six month 
trial period and six months after that.  In addition the clinical activity index was 
measured every two months throughout the duration of the trial.  Seven patients 
violated the protocol; two in the curcumin group and five in the placebo group.  
Disease relapse rates were evaluated on an intention to treat basis.  In the curcumin 
treated group, 2/43 patients relapsed (4.6%), compared to 8/39 (20.5%) in the 
placebo group.  This difference was significant at p=0.04.  The investigators also 
showed significant clinical and endoscopic improvements in the curcumin treated 
group.  The clinical activity index worsened in the placebo group from 1.0 to 2.2 
(p=0.0003), whilst in the curcumin group it improved from 1.3 to 1.0 (p=0.04).  
There was no change in endoscopic appearances in the placebo group, but there 
was significant evidence of endoscopic healing in the curcumin group, with 
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endoscopic index improving from 1.3 to 0.8 (p=0.0001).  During the further six 
month follow up period, there was no difference in number of patients relapsing in 
either study arm.  Seven patients experienced mild transient side effects including 
bloating, nausea and diarrhoea, although attribution to curcumin is uncertain, 
particularly since the patients were also taking 5-ASA drugs.  None of these 
patients discontinued the treatment.  One patient experienced transient hypertension 
and curcumin was discontinued in this individual. 
 
It is particularly encouraging to note that on ClinicalTrials.gov of the United States 
National Institutes of Health, a phase 1 trial of curcumin therapy in paediatric UC 
was recently registered at Seattle Children’s Hospital (identifier NCT00889161).  
This will be a single centre open label dose titration study to determine the 
tolerability and safety of oral curcumin in children with UC.  The investigators plan 
to recruit 20 children aged 8-18 with mild or quiescent UC, for an initial nine week 
study period, after which appropriate dose will be determined to proceed to double 
blinded placebo controlled trial.  The dose will start at 500mg twice daily for three 
weeks, will escalate to 1g twice daily for a further three weeks and will finish at 2g 
twice daily for the final three weeks.  The study plans to complete in May 2010. 
 
These studies so far involve relatively small patient numbers, but the results 
certainly indicate that larger trials of rigorous design are warranted for curcumin 
therapy in IBD.  It is particularly encouraging that curcumin is now being trialled in 
children with IBD for the first time.  Its non-toxicity and normal presence in the 
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diet make it ideally suited to the strict ethical constraints surrounding recruitment of 
children into pharmaceutical trials.  Many drugs are necessarily used outside their 
commercial licences in children because of the lack of clinical trial evidence 
supporting their paediatric use.  The burden of IBD in childhood is increasing and 
with the lifetime risk of intestinal inflammation and cancer that this carries, a 
greater choice of long term maintenance anti-inflammatory medications with low 
side effect profiles is required. 
 
Clinical Trials of Curcumin in Cancer 
Lastly there is building clinical evidence that curcumin can prevent and treat cancer 
in humans.  Results from a trial of 25 patients with various different pre-malignant 
or high risk lesions, suggested that oral curcumin may have chemopreventive 
effects in progression of these lesions [153].  Whilst two of the 25 patients 
progressed to frank cancer, seven regressed; a remarkably high proportion 
considering the high grade nature of the lesions (bladder cancer, oral leukoplakia, 
gastric intestinal metaplasia, cervical intraepithelial metaplasia and Bowen’s 
disease).  In another uncontrolled study of 15 patients with advanced colorectal 
cancer refractory to standard treatments, the lymphocytic biomarker glutathione S 
transferase showed a 59% reduction in activity with low dose (440mg daily) oral 
curcuma extract, and five patients maintained radiologically stable disease over the 
2-4 month study period [299].  Once again there is a suggestion here that curcumin 
exhibits paradoxical efficacy at low versus high dose, since this effect was not 
observed at higher doses.  In an interesting, but also uncontrolled, study of 62 
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patients with oral cancerous lesions, topical curcumin application reduced 
symptoms in the majority (70%) and caused tumour shrinkage in 10% [300].  Of 21 
patients with advanced, normally rapidly fatal, pancreatic cancer treated with high 
dose oral curcumin, encouragingly four showed disease stability or regression 
[301].  The cancer preventive properties of curcumin would be a clearly attractive 
side effect if it comes into clinical use in IBD, since colitis carries a long term risk 
of bowel cancer. 
 
Future Clinical Trials of Curcumin 
These preliminary data hold promise, and interest in curcumin as a therapeutic 
agent continues to grow.  There are several clinical trials currently ongoing, some 
involving larger numbers of patients and with a more rigorous randomised 
controlled design.  A search on ClinicalTrials.gov currently reveals 31 human trials 
using curcumin, of which 14 are investigating its chemopreventive or 
chemotherapeutic potential in cancer or pre-malignant conditions.  As in the data 
already reviewed, there is a preponderance of gut cancers; six are in colorectal 
cancer, two in familial adenomatous polyposis coli, one in ulcerative colitis and 
three in pancreatic cancer.  A novel area of interest is in Alzheimer’s disease and 
cognitive impairment.   The first clinical trial failed to show benefit, but this may 
have been due to an unexpected lack of cognitive decline in the placebo group 
[302].  Three current ongoing trials of curcumin are further assessing its efficacy in 
age-related cognitive impairment.  Interest also continues in systemic inflammatory 
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conditions and there are two ongoing trials of curcumin in arthritis and one in 
psoriasis. 
 
 
1.4.15 Curcumin: Summary and Relevance to the Current Work 
 
Since ancient times, curcumin has been used in a wide range of inflammatory, 
neoplastic and other conditions.  In recent years the molecular basis for its efficacy 
has been extensively investigated.  Many cellular and molecular targets have been 
identified and many questions still remain.  In complex multi-factorial illnesses 
such as systemic inflammatory diseases and cancer, an agent that acts at a number 
of different cellular levels offers perhaps a better chance of effective prophylaxis or 
treatment.  Its non-toxicity and good tolerability in humans, in combination with 
strong promising results from cell line, animal and early human clinical studies, 
support the ongoing research and development of curcumin as a preventive and 
disease modifying agent. 
 
The current work will explore the effects of this biologically complex compound in 
inflamed human gut.  We will examine the effects of curcumin on both TGF-β and 
IL-10 pathways, as well as on the expression of pro-inflammatory cytokines IL-1β 
and IFN-γ.  We will study in vitro models of IBD, using cell and tissue culture 
systems derived directly from patients with active IBD.  These will include colonic 
lamina propria mononuclear cells (LPMC’s) and colonic mucosal biopsies.  We 
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will also examine the actions of curcumin on key gut mucosal stromal effector cells 
in IBD, colonic myofibroblasts (CMF), also isolated from patients with active IBD.  
We will measure the effects of curcumin on matrix metalloproteinase (MMP) 
expression by CMF.  We will explore potential mechanisms behind these actions, 
including p38 MAPK signalling, NF-κB activation, and acetylation status. 
 
 
1.5 Anacardic Acid 
 
 
Figure 1.12 Molecular structure of anacardic acid 
 
Anacardic acid (AA) is the only other known naturally occurring inhibitor of acetyl 
transferase p300 [303].  It is a component of cashew nut shell liquid and thus, if 
found to offer therapeutic potential, has the advantage of human non-toxicity.  
Chemically it is salicylic acid substituted with an alkyl chain which can vary 
slightly in composition (Figure 1.12).  The alkyl chain may contain 15 or 17 carbon 
atoms and may be saturated or unsaturated.  Naturally occurring anacardic acid 
contains a mixture of these closely related molecules, in varying proportion 
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depending on the subspecies of the plant.  It is antibacterial, against both 
methicillin-resistant Streptococcus aureus (MRSA) [304] and Streptococcus 
mutans,  the primary causative organism for human tooth decay [305].  In 
Ayurvedic and Aboriginal traditional medicine it is used to treat a wide range of 
ailments, including the chewing of its bark or leaves for gum and tooth ache.  It is a 
potent non-specific inhibitor of p300, and also inhibits PCAF, a member of one of 
the other families of acetyl transferases as mentioned above.  Inhibition of p300 is 
the only known molecular mechanism of action of anacardic acid, and this is the 
only known shared property of curcumin and anacardic acid. 
 
 
1.6 Hypotheses and Objectives 
 
We have discussed how IBD confers lifelong morbidity on its sufferers, and that 
the disease is becoming more common especially amongst young people.  There is 
no cure and many available treatments have undesirable side effects.  The disease is 
complex with a multi-factorial aetiology including genetic susceptibility, immune 
dysregulation and environmental factors.  In IBD normal anti-inflammatory 
mechanisms fail.  Protein acetylation is important in the regulation of these 
pathways, with excessive acetylation status leading to failure of normal anti-
inflammatory signalling.  The dietary compound curcumin is an inhibitor of 
acetylation, is non-toxic even at high dose and has anti-inflammatory properties.   
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We hypothesised that curcumin would have direct anti-inflammatory effects in the 
gut mucosa in IBD.  To study this, we obtained mucosal tissue biopsies and lamina 
propria mononuclear cells from children and adults with active IBD and treated 
them in vitro with curcumin.  We measured cytokine output and assessed p38 
MAPK and NF-κB activation.   
 
We hypothesised that the anti-inflammatory effects of curcumin in IBD are at least 
in part due to its activity as an inhibitor of acetylation.  To examine this, we aimed 
to study the effect of curcumin on pathways known or suspected to be controlled by 
acetylation status.  We hypothesised that curcumin, as an inhibitor of acetylation, 
can release TGF-β signalling from Smad 7 suppression, release IL-10 transcription 
from Sp3 suppression, and thus restore anti-inflammatory pathways in IBD.  We 
measured in vitro Smad 7 levels in intestinal mucosal cells and tissues from patients 
with active IBD, cultured with curcumin.  We measured in vitro IL-10 production 
by intestinal mucosal cells and tissues from patients with active IBD, in response to 
curcumin, and compared this with production of other cytokines. 
 
We hypothesised that curcumin would decrease MMP-3 production, a key 
contributor to tissue destruction in IBD, and that this effect was at least in part 
acetylation-dependent.  We measured in vitro MMP-3 production by colonic 
myofibroblasts (CMF) from patients with active IBD, cultured with curcumin.  We 
examined candidate intermediary signalling pathways p38 MAPK and NF-κB to 
assess whether activation of these pathways was responsible for changes in MMP-3 
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production by CMF.  We compared MMP-3 responses to curcumin with those to 
anacardic acid, another naturally occurring inhibitor of acetylation.  This is the only 
known biological property of anacardic acid and the only shared property of the 
two compounds.  We measured in vitro MMP-3 production by CMF in response to 
trichostatin A, a pro-acetylating agent. 
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2.0 Materials and Methods 
 
2.1 Human Cell and Tissue Culture 
 
2.1.0 CaCo2 Cells 
 
CaCo2 cells (a human colon cancer epithelial cell line) (ECACC, Salisbury, UK) 
were cultured for 24 hours in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with non-essential amino acids (both Invitrogen, Paisley, UK), 
penicillin/streptomycin and Hepes buffer (both Sigma, Gillingham, UK), stimulated 
with bacterial lipoprotein (BLP) (EMC, Tubingen, Germany) at 20µg/ml or 
unstimulated.  In other experiments CaCo2 cells were cultured in the presence or 
absence of butyrate (Sigma) for 24 hours, and then stimulated with IL-1β (Firstlink, 
Brierley Hill, UK) to a concentration of 1ng/ml for a further 24 hours. 
 
All experiments were performed on exclusively human cells and tissues, as relevant 
to the study of inflammatory bowel disease and its potential treatment in humans.  
CaCo2 cells have been used extensively to model intestinal epithelial function in 
vitro for over 20 years.  The parental cell line was originally obtained from a 
human colon adenocarcinoma.  Caco2 cells are immortalised and differentiate 
spontaneously in long term culture to form a monolayer.  They have some 
characteristics of mature small intestinal enterocytes including apical microvilli and 
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intercellular tight junctions.  They also express small intestinal hydrolases including 
sucrase-isomaltase and lactase.  These enzymes are expressed transiently in the 
human foetal colon but are not found in the adult colon.  Thus enterocytic and 
colonocytic characteristics co-exist in CaCo2 cells.  Characteristics of CaCo2 cells 
including function, metabolism and rate of differentiation change with number of 
passages, including expression of enterocyte differentiation markers such as the 
glucose transporter (GLUT)-5 which increases with passage number [306].  The 
parental CaCo2 cells which generated the current CaCo2 population were 
intrinsically heterogeneous, and this may explain the reason for changing 
characteristics of the cells with rising passage, since different sub-populations are 
selected [307].  We addressed this potentially confounding factor by performing all 
experiments on CaCo2 cells between passages 20 and 29. 
 
Other factors which influence the behaviour of CaCo2 cells relate to culture 
conditions, including seeding density, time of culture, composition and age of the 
medium and frequency of medium change.  Since all of these variables can affect 
cell replication, senescence and differentiation, we kept these factors as strictly 
standardised as possible to achieve robust reproducibility of results. 
 
The use of this cell type allowed our familiarisation with basic human cell culture 
techniques including maintenance, passaging, counting, stimulation and storage.  
We were able to achieve reproducibility of results using a cell line of relative 
uniformity and ready availability before progressing to the use of precious and 
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delicate material from patients, containing cell and tissue types of greater 
heterogeneity. 
 
 
2.1.1 Peripheral Blood Mononuclear Cells 
 
Blood samples from healthy volunteers with consent were collected onto lithium-
heparin, diluted in equal volume phosphate buffered saline (PBS) (Invitrogen), 
layered onto Ficoll (GE Healthcare, Little Chalfont, UK) and centrifuged.  The 
mononuclear cell layer was withdrawn, washed in PBS, centrifuged and the cell 
pellet re-suspended, counted and their viability checked by trypan blue exclusion.  
Cells were stimulated with lipopolysaccharide (LPS) 1µg/ml and cultured for 24 
hours in the presence of graded doses of curcumin (Sigma) or anacardic acid 
(Merck, Nottingham, UK). 
 
We planned to study lamina propria mononuclear cells (LPMC), but because we 
were reliant on unpredictable clinical factors for supply, we considered PBMC’s a 
valuable related cell type upon which to perform experiments.  They share many 
functional and behavioural characteristics with intestinal mononuclear cells, but 
have the advantage of ready availability and are easy to collect from healthy 
volunteers.  PBMC’s are a mixture of circulating lymphocytes and monocytes.  
Their precise composition and characteristics, as well as a comparative discussion 
between PBMC’s and LPMC’s can be found in Table 2.1 and Chapter 2.1.3.   
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There is inconsistent data in the literature as to whether PBMC’s from normal 
individuals behave differently to those from individuals with IBD.  Several 
investigators note wide inter-individual variability in cytokine production [308].  Ex 
vivo TNF-α production by PBMC’s from patients with CD or UC was no different 
to that from healthy controls in one study [308], was increased in CD and UC in 
another [309], and was only increased in UC upon pokeweed mitogen stimulation 
in a third study [310].  The production of other pro-inflammatory cytokines by 
PBMC’s in IBD including IL-1β, IL-6 and IFN-γ,  is eq ually inconsistent in 
different studies.  The only investigation to our knowledge of ex vivo IL-10 
production by PBMC’s in IBD shows no difference between PBMC’s derived from 
healthy controls or patients with CD or UC [311].  In the present work, we studied 
PBMC’s partly in order to refine cell separation, purification and handling 
techniques as well as to optimise culture conditions before applying these to 
LPMC’s obtained from precious patient samples. 
 
 
2.1.2 Intestinal Mucosal Biopsies 
 
Colonic mucosal biopsies were obtained from children and adolescents with CD or 
UC undergoing ileo-colonoscopy at the Royal London Hospital.  Ethics approval 
for the study was granted from East London and The City Health Authority 
Research Ethics Committee (approval numbers P/97/330; Professor Ian Sanderson 
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and Dr Nick Croft, and P/01/023; Professor Tom MacDonald).  Consent was 
obtained and biopsies collected personally by us.  In this way we ensured quality, 
uniformity and optimal treatment of samples from the outset.  Biopsies were taken 
from areas showing clear macroscopic disease changes, and histopathological 
diagnosis and inflammation subsequently confirmed.  Biopsies were collected into 
ice cold Roswell Park Memorial Institute (RPMI) medium 1640 + Glutamax 
(Invitrogen) supplemented with foetal bovine serum (Sigma), 
penicillin/streptomycin and gentamicin.  Biopsies were immediately placed into 
wells in a 12 well plate and cultured overnight in 500μl HL-1 medium (Lonza, 
Wokingham, UK) supplemented with L-glutamine (Invitrogen), 
penicillin/streptomycin and gentamicin, with graded doses of curcumin.  All efforts 
were made to orientate each biopsy so that the mucosal side faced up and interior 
side down, to mimic the in vivo situation, where luminal contents interact with the 
apical side of the epithelium.  The plate size and medium volume was carefully 
calculated so that the mucosal side was partially exposed to air, as it would be in 
vivo (Figure 2.1).  By culturing the biopsies in this way we also ensured longer 
tissue survival times, as we found that excessively submerged biopsies underwent 
more rapid disintegration.   
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submerged in medium
Single well of 12 well plate
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Figure 2.1 Orientation of intestinal mucosal biopsy in culture 
 
As we wished to study the potential of a therapeutic agent to reduce inflammation 
in IBD, we chose to study tissue taken directly from areas of actively inflamed 
colonic mucosa in children with clinically and histologically confirmed active IBD.  
These were used immediately and unaltered in ex vivo culture.  In this way we 
obtained a disease model which was very near to the true disease situation in vivo.  
Every experiment was carried out alongside a negative control.  This negative 
control was a similar inflamed biopsy from the same individual placed in medium 
containing vehicle Dimethyl sulfoxide (DMSO) (Sigma) only, at the same 
concentration required to carry the curcumin.  In this way we were able to discount 
any confounding effects of the DMSO, however minimal.  Because clinically we do 
not wish to use curcumin in children who have no disease, our studies were carried 
out upon diseased tissue only.  We did not study biopsies from non-diseased areas 
of gut or from healthy controls for this reason. 
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An advantage of this model is its proximity to the in vivo disease state.  Equally the 
complexity of in vivo disease is reflected in this model, and can render the results 
difficult to interpret.  A biopsy contains most or all of the cell types found in the 
intestinal mucosa, in differing and variable proportions.  Thus some biopsies may 
contain by chance a high proportion of lymphoid tissue or immune cells, whilst 
others contain more fibrous tissue.  Such differing collections of cells may be 
expected to respond to the same culture conditions in a non-uniform way, and this 
will result in a wide inter-experiment variability.  These issues are encountered 
more commonly when working with biopsy cultures compared to cell lines.  What 
is gained in terms of close resemblance to in vivo disease may be lost in an inability 
to isolate specific pathways and responses, as can be possible with a more 
reductionist model.  To counteract the inter-individual variation and heterogeneity 
of biopsy work, we repeated all experiments using samples from multiple 
individuals with active IBD and included all results in the analysis.  In this way 
trends could be observed, and their significance quantified statistically. 
 
 
2.1.3 Intestinal Lamina Propria Mononuclear Cells 
 
Intestinal resection specimens were obtained from children and adults undergoing 
surgery for CD or UC at the Royal London Hospital or the Homerton Hospital, 
which also forms part of Barts and The London School of Medicine and Denstistry.  
Once again ethics approval for the study was granted from East London and The 
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City Health Authority Research Ethics Committee (approval numbers P/97/330 and 
P/01/023).  Patient consent was obtained and tissue collected from the operating 
theatre personally by us.  In this way we ensured maximal freshness and optimal 
treatment of the gut tissue from patient to laboratory bench.  Tissue was collected 
onto ice cold complete RPMI medium as above.  The mucosal layer was removed, 
washed in Hanks balanced salt solution (HBSS) (Sigma) and incubated in ethylene 
diamine tetra-acetic acid (EDTA) (Sigma) to remove mucus and epithelial cells.  
This was followed by incubation in collagenase (Sigma), a proteolytic enzyme 
which breaks down intercellular connective tissues.  The resultant suspension was 
then passed through a cell strainer, washed in complete RPMI and centrifuged.  The 
pellet was re-suspended in complete RPMI and further purified by Ficoll density 
gradient separation.   
 
Finally the cells were washed once again, centrifuged and re-suspended in complete 
RPMI.  Any debris was allowed to settle standing on ice, then cells were counted 
and their viability checked by trypan blue exclusion.  This is done by suspending a 
sample of cells 1:10 in sterile filtered trypan blue solution and immediately 
examining them under the microscope in a haemocytometer.  Those cells which are 
alive and healthy are seen to be white or yellow as their cell membranes have 
successfully excluded the trypan blue solution.  These are the cells which are 
counted.  Cells were cultured for 24 hours in the presence of curcumin in graded 
doses, alongside DMSO vehicle control.  For cytokine experiments cells were 
seeded at 4 x 105 cells per well for every experiment; for Smad 7 and p38 MAPK 
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experiments (requiring a greater quantity of protein for immunoblotting) cells were 
seeded at 4 x 106 cells per well. 
 
The LPMC isolation method described above is adapted only minimally from its 
original description by a group in Harvard in 1977 [312].  This marked an 
important step forward in the study of gut mucosal immune processes, which prior 
to that had relied on PBMC’s for research questions.  With no guarantee that 
circulating mononuclear cells exhibit similar responses in health and disease to 
tissue-fixed lymphoid cells, results from such work may not truly reflect gut 
mucosal immunological events.  For this reason we chose to concentrate our study 
upon LPMC’s rather than PBMC’s.  The treatment processes used to isolate 
LPMC’s, if similarly applied to PBMC’s, cause no change in morphology or 
viability [312].  The cells obtained are 97% mononuclear and 3% 
polymorphonuclear (mainly eosinophils), with no contaminating epithelial, muscle, 
fibrous or other cell types.   
 
The original investigators also compared the properties of PBMC’s to LPMC’s 
(Table 2.1).  The differences point to a generalised increased activity of intestinal 
compared to circulating leukocytes; larger in size, more irregular in shape, with 
nucleoli and basophilic stippling suggesting active immunoglobulin synthesis.  
They also showed greater mobility, plate adherence and phagocytic activity, fewer 
null cells, more activated cells and greater intercellular associations; a likely 
reflection of antigen processing.  The investigators also compared membrane 
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antibody distribution by class, and found a greatly increased proportion of cells 
positive for IgA and IgE, and fewer IgM-positive cells in intestinal versus 
circulating populations, suggesting that intestinal B-lymphocyte cells have 
undergone maturation.  As expected the commonest immunoglobulin class found 
was IgA, whose vital role in intestinal secretory immunity is well documented. 
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Table 2.1 Properties of Intestinal Mucosal and Circulating Lymphoid Cells [312] 
 
Our choice to use leukocytes isolated directly from areas of active inflammation in 
patients with IBD was again because we wished to examine the effects of curcumin 
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upon the active disease state in IBD.  These cells possess an intrinsic degree of 
activation, and unlike PBMC’s produce cytokines spontaneously.  This means that 
we can culture them with curcumin and observe effects directly without the need 
for extrinsic stimulation, keeping our cell model system near to the in vivo 
situation.  We wished to produce results which could as far as possible be 
extrapolated to understand the in vivo actions of curcumin in the human gut. 
 
Although we attempted to isolate LPMC’s from intestinal mucosal biopsies, we 
found that the cell yields from these were consistently too low to be usable for our 
experiments (less than 1x105 cells were typically yielded from 4 biopsies).  Thus 
the requirement for actively inflamed surgically resected IBD tissue naturally 
limited our progress due to its relatively low availability.  However we were 
consistently able to isolate over 5x106 cells from a 1-2cm2 piece of tissue, which 
was sufficient to carry out our experiments. 
 
 
2.1.4 Colonic Myofibroblasts 
 
Colonic resection specimens were obtained from children and adults undergoing 
surgery for CD or UC at the Royal London Hospital or the Homerton Hospital.  
Once again ethics approval for the study was granted from East London and The 
City Health Authority Research Ethics Committee (approval numbers P/97/330 and 
P/01/023).  Tissue was collected and mucosal cells isolated as described above.  At 
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the final stage after washing, cells were re-suspended in DMEM supplemented as 
before.  The adherent colonic myofibroblasts (CMF) were grown in successive 
passages until sufficient numbers resulted for experimentation (usually to passage 
4).  Cells were then plated into wells and when confluent, harvested for 24 hours in 
serum-free DMEM, then stimulated with TNF-α (R&D Systems, Abingdon, UK) 
and cultured in the presence of curcumin or anacardic acid in graded doses for 
either 30 minutes or 24 hours, or with trichostatin A (Sigma) for 24 hours.  All 
experiments were performed alongside vehicle (DMSO) as a negative control. 
 
There are two types of myofibroblasts in the intestine, the sub-epithelial fibroblasts 
which we isolate for this work (and refer to as CMF), and the deeper interstitial 
cells of Cajal which are located in the submucosa and muscularis propria in close 
association with the smooth muscle layers.  The interstitial cells of Cajal are 
involved in coordination of gut motility.  These fibroblasts were not included in our 
studies, as the initial step in our isolation technique entailed dissection and retention 
of the mucosa; all deeper tissues were discarded.  CMF are activated and proliferate 
in response to various growth factors, and are able to do so in vitro.  They play an 
important role in embryological evolution of the gut and are key cells in tissue 
injury, promoting wound healing through epithelial restitution and proliferation.  
They form a mucosal barrier to sodium diffusion, which may account for the ability 
of the gut to absorb water against an osmotic gradient [313].  Finally they are a key 
effector cell type in IBD, secreting matrix metalloproteinases in excess, which are 
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responsible for much of the tissue damage and fibrosis.  The roles of CMF and 
MMP in IBD are described in more detail in Chapters 1.4.10 and 7.1. 
 
As well as being a highly relevant cell type for study in IBD, CMF have a practical 
advantage over LPMC in experimental use.  Because they can be grown in culture, 
sufficient numbers of CMF may be obtained from much smaller resected gut 
specimens than those required to provide LPMC.  Therefore clinical supply was a 
much less restrictive issue.  Again this is a primary cell type obtained exclusively 
from actively inflamed mucosa.  Successive in vitro passages are required, although 
the number of these was minimised in order to retain as far as possible the primary 
phenotype, characteristics and behaviour of the cells.  Nonetheless these cells do 
require stimulation in order to produce MMP-3, and whilst another choice of 
cytokine could equally have been made, we successfully achieved this with TNF-α.  
All cell handling and culture techniques were carefully standardised across 
experiments, for example cell seeding density and time period between seeding and 
harvesting.  In this way we aimed to minimise potential confounding variable 
factors which could affect cell behaviour, for example senescence, proximity of 
cells to their neighbours, time between medium changes, and many other facets of 
cell handling technique. 
 
As a possible alternative cell type for study we considered an immortalised 
intestinal myofibroblast cell line such as CCD-18.  This would have had the 
advantage of ready availability and perhaps greater uniformity between individual 
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samples.  However throughout all of our ex vivo experiments we aimed to focus on 
disease models as little removed from the in vivo disease state as possible, in order 
to maximise clinical relevance.  Use of an immortalised cell line would have 
constituted a significant step away from this principle.  In the case of intestinal 
epithelial cells we were obliged to use the CaCo2 cell line, since no primary 
isolatable alternative exists.  However in the case of myofibroblasts, we were able 
to reject this option in favour of primary CMF. 
 
 
2.2 Enzyme-Linked Immunosorbent Assay for 
Cytokines 
 
Supernatants from cell or tissue cultures were subjected to enzyme-linked 
immunosorbent assay (ELISA) for IL-1β, IFN-γ (both R&D Systems) or IL-10 
(Immunotools, Friesoythe, Germany).  Each sample was tested in duplicate against 
the appropriate standard and optical densities measured by Microplate reader 
(Biorad, Hemel Hempstead, UK).  Results were analysed and presented using 
Microsoft Excel and Prism software. 
 
ELISA is an immunological technique used to detect and quantify the amount of 
antigen in a sample.  The type of ELISA used here is a sandwich ELISA, where the 
antigen (cytokine) to be measured is sandwiched between two layers of antibodies 
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(Figure 2.2).  Therefore this type of ELISA requires the measured protein to be 
multivalent; it must have at least two antigenic sites capable of binding to antibody.  
Thus it is useful for the detection of proteins and polysaccharides, and it can 
quantitate these even at low concentrations.  It is also highly specific, and can be 
used even when the test substance is in solution with other contaminating proteins.  
Therefore it has found many applications ranging from diagnostics (for example 
measurement of serum HIV antibody concentration, or urine β-human chorionic 
gonadotrophin (HCG) in home pregnancy tests), toxicology (screening body fluids 
for drugs) and the food industry for seeking traces of potential allergens such as 
milk, nuts and eggs. 
 
 
Figure 2.2  Sandwich enzyme-linked immunosorbent assay.  Diagram from Abcam 
http://www.abcam.com/index.html?pageconfig=resource&rid=12064 
 
A capture antibody is first applied to the plate in known concentration.  After this 
has coated the plate and bound to it, excess is washed off and non-specific antibody 
binding sites are blocked with a high concentration protein solution; here we used 
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bovine serum albumin (BSA).  After washing again the test solutions are applied in 
equal volume and in each sample in duplicate.  A standard is also applied in serial 
dilutions at known concentrations.  The excess is again washed off and a detection 
antibody solution applied in known concentration.  Once this has bound to the 
antigen the excess is again removed and an enzyme-linked secondary antibody 
applied in known concentration; here this was streptavidin-horse radish peroxidase 
(HRP).  Streptavidin is derived from Streptomyces avidinii and reacts specifically 
with biotin (in the detection antibody).  Finally a substrate is applied which is 
converted by the HRP into a colour signal.  This process is illustrated 
diagrammatically in Figure 2.2.  The density of colour is thus proportional to the 
concentration of cytokine in the plate, and this is measured by a plate reader which 
converts the optical absorbance of the plate at a specified wavelength into a 
number.  This number is then translated into a cytokine concentration by 
comparison against the known standard curve obtained in the same ELISA 
experiment. 
 
The ELISA technique was well suited to our requirements for the reasons outlined 
above.  The important steps to ensure accuracy and reproducibility in this technique 
are careful preparation of all reagents at known concentrations, ensuring solutions 
are always used at room temperature, and washing and drying plates thoroughly 
between each step of the procedure.  We achieved consistent results with very low 
variability between duplicates, of less than 5% in the great majority of experiments.  
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Where we occasionally obtained significantly wider variation between duplicates 
these experiments were repeated. 
 
 
2.3 Immunoblotting 
 
2.3.0 Western Blot for Smad 7 and p38 Mitogen-Activated 
Protein Kinase 
 
Cells or tissues were snap frozen and subjected to physical disruption and protein 
lysis with ice cold RIPA lysis buffer containing protease and phosphatase 
inhibitors, to prevent the digestion of the sample by its own enzymes.  Protein 
estimation was performed using bicinchonic acid (BCA)/copper sulphate assay 
against bovine serum albumin (BSA) standard (all Sigma).  Protein samples were 
resolved on 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS/PAGE), transferred onto nitrocellulose membrane and probed overnight with 
primary antibody against Smad 7 (molecular weight 47 kDa) (Imgenex, San Diego, 
CA), β-actin loading control (molecular weight 42 kDa) (Abcam, Cambridge, UK); 
phosphorylated p38 MAPK (molecular weight 43 kDa) (R&D Systems) or non-
phosphorylated p38 MAPK loading control (Cell Signalling Technology, Danvers, 
MA).  Membranes were then re-probed with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit secondary antibody (both Dako, Ely, UK) and 
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chemiluminescent substrate applied for photographic visualisation.  Membranes 
were then stripped and re-probed as appropriate. 
 
In order to quantify the signal as far as possible, the photographically developed 
films were scanned into electronic format.  Using Adobe Photoshop software, the 
intensity of each band was measured under uniform conditions, giving a numerical 
result which in arbitrary units directly reflected the signal intensity, and thus the 
corresponding amount of protein.  The loading control signals were similarly 
converted into arbitrary units of intensity, and a final result was obtained by 
dividing the test substance signal by its loading control, to obtain the final 
standardised densitometry figure. 
 
The term immunoblotting refers to the transfer of biological samples from a gel to a 
membrane for their subsequent detection on the membrane, using an antibody.  The 
procedure was originally described in 1979 [314] and since that time has had a 
wide impact in molecular biology, facilitating protein analysis in multiple settings.  
It is highly specific to its target protein, which it is able to detect in a complex 
mixture of other biological substances.  However it provides only semi-quantitative 
data.   
 
The cells are first treated with detergents, salts and buffers in order to lyse the cell 
membranes and solubilise the proteins.  The protein mixture is then separated using 
gel electrophoresis.  It is important to measure the protein concentrations accurately 
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and to load equal amounts of each sample onto the gel for meaningful comparison 
between samples.  Each sample is combined with loading buffer containing 
reducing agents which removes secondary and tertiary protein bonds to maintain 
the polypeptides in a denatured state.  The proteins, coated in negatively charged 
SDS, move through the gel towards the positive electrode.  The acrylamide in the 
gel creates a mesh and the percentage of acrylamide in the gel can be adapted to the 
approximate size of the proteins being separated.  Proteins migrate at different 
speeds according to their charge and size.  In this case we wished to identify 
proteins with molecular weights in the range of 42- 47 kDa; in the middle range and 
therefore a 10% gel was used.  A ladder containing a mixture of coloured proteins 
of differing molecular weights is run in one lane alongside the samples, to monitor 
migration of the samples and mark molecular weight positions. 
 
The proteins are then transferred (blotted) onto a nitrocellulose membrane.  The 
membrane avidly binds proteins of all types, therefore non-specific antibody 
binding sites must then be blocked using a protein solution (we used non-fat dry 
milk in detergent solution).  The membrane is probed by applying the primary 
antibody, followed by a secondary antibody directed against the primary.  In this 
case the primary antibody was derived from rabbit, therefore the secondary 
antibody was a goat anti-rabbit antibody.  The secondary antibody is linked to the 
enzyme HRP.  At the final stage, a chemiluminescent substrate is applied which 
reacts with the HRP to produce a visual signal.  This can be captured on film when 
developed photographically.  The intensity of the signal correlates with the 
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abundance of the antigen on the membrane and in this way the protein can be 
measured in a semi-quantitative fashion.  In order to ensure differences in signal 
intensity are truly due to biological differences in protein production, equal loading 
must be ascertained.  In the case of NF-κB th is was by co-measurement of the 
ubiquitous cytoplasmic protein, β-actin.  Against phosphorylated p38 MAPK, the 
appropriate load control was the total form of p38 MAPK. 
 
We chose this technique for the measurement of p38 MAPK and Smad 7 because 
we wished to detect the production and activation of these proteins (rather than for 
example messenger (m)RNA), since changes in their production could equally be 
due to post-translational events.  For the reasons described above Western blotting 
is a well-suited technique for the detection of such proteins, and semi-quantitative 
results were sufficient for our purposes.  It is a technique which requires careful 
optimisation since it contains multiple critical steps, each of which must be carried 
out at the correct concentration, temperature and pH, for the correct duration and 
under the correct conditions, in order to produce a result.  If the final signal is not 
obtained, or is inadequate, troubleshooting must be systematic and comprehensive, 
and can be challenging since it may need to take into account every contributory 
step.  During the course of optimising these experiments, we gained experience in 
correlating specific sub-optimal results with likely problems and causes, ultimately 
to obtain clean and reliable signals. 
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2.3.1 Western Blot for Matrix Metalloproteinase-3 
 
Equal volumes of supernatant (15μl) were resolved on 10% SDS/PAGE, transferred 
onto nitrocellulose membrane and probed overnight with primary antibody against 
MMP-3 (molecular weight 54 kDa) (The Binding Site, Birmingham, UK).  
Membranes were then re-probed with HRP-conjugated rabbit anti-sheep secondary 
antibody (Dako) and chemiluminescent substrate applied for photographic 
visualisation.  
 
MMP-3 was the only protein in this work which was detected in the supernatant, 
rather than in cell lysates.  Because each well was seeded with equal numbers of 
confluent cells, and contained an identical volume of medium, by loading identical 
volumes (15μl) of supernatant into each lane of the gel, we ensured equal loading 
of sample and thus valid comparison between lanes.  Thus a load control signal was 
not indicated in these experiments unlike in all of the other Western blots in this 
work. 
 
 
2.3.2 Western Blot for NF-κB and IκBα 
 
Cells or tissues were fractionated using a commercial fractionation kit (Biovision, 
Mountain View, CA).  Cells or tissues were disrupted, centrifuged and vortexed on 
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ice with cytosol extraction buffer containing protease inhibitors.  This was 
centrifuged at four degrees centigrade and the supernatant (cytosolic extract) 
removed and stored on ice.  The resulting nuclear pellet was re-suspended in ice-
cold nuclear extraction buffer and after repeated intermittent vortexing was 
centrifuged.  The resulting supernatant (nuclear extract) was removed and stored on 
ice.  Protein estimation was performed using BCA/copper sulphate assay against 
BSA standard.  Nuclear fractions were resolved on 10% SDS/PAGE, transferred 
onto nitrocellulose membrane and probed overnight with primary antibody against 
NF-κB p65 subunit (molecular weight 65 kDa) (Santa Cruz Biotechnology) or 
histone H1 loading control (molecular weight 32 kDa) (AbD Serotec, Oxford, UK).  
Cytosolic fractions were similarly resolved on 10% SDS/PAGE, transferred onto 
nitrocellulose membrane and probed overnight with primary antibody against 
phosphorylated IκBα (molecular weight 35 kDa) or non-phosphorylated IκBα 
loading control (both Santa Cruz Biotechnology).  Membranes were then re-probed 
with HRP-conjugated goat anti-rabbit or anti-mouse secondary antibody as 
appropriate (Dako) and chemiluminescent substrate applied for photographic 
visualisation.  Membranes were stripped and re-probed as required.  
 
We used a very similar principle for the detection of proteins within the NF-κB 
pathway.  The p65 subunit (when activated) is a nuclear protein, and therefore to 
detect it we separated the nuclear from the cytoplasmic cellular fractions.  With p65 
we used histone H1, a ubiquitous nuclear protein, as an appropriate nuclear loading 
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control.  The load control for phosphorylated IκB was total IκB, both of which are 
cytosolic proteins. 
 
2.3.3 Western Blot for p300 Acetyl Transferase 
 
Cells or tissues were snap frozen and subjected to physical disruption and protein 
lysis with ice cold RIPA lysis buffer containing protease and phosphatase 
inhibitors.  Protein estimation was performed using BCA/copper sulphate assay 
against BSA standard.  Protein samples were resolved on 6% SDS/PAGE, 
transferred onto nitrocellulose membrane and probed overnight with primary 
antibody against p300 (Santa Cruz Biotechnology).  Membranes were then re-
probed with HRP-conjugated goat anti-rabbit secondary antibody and 
chemiluminescent substrate applied for photographic visualisation.   
 
p300 acetyl transferase is, as its name suggests, a protein of relatively large 
molecular weight at 300 kDa.  In order to optimise its electrophoretic separation we 
reduced the concentration of acrylamide in the gel to 6%, creating a wider mesh.  
We also increased the running time of the electrophoresis, to maximise separation 
of the largest (and therefore slowest moving) proteins.  We encountered challenges 
optimising the p300 signal.  After making the above adjustments and altering the 
chemiluminescent and photographic signal sensitivities, we ultimately obtained a 
signal for p300 only after greatly increasing the amount of protein loaded on the 
 120 
gel.  (A faint signal was obtained on loading 200μg per lane; compared to the 30μg 
per lane required for all other Western blot antibodies we used.)  The requirement 
for this quantity of protein meant that this technique was unsuitable for use in our 
experiments, since growing, maintaining and culturing such high numbers of 
fibroblasts would be unfeasible, particularly as we wished to maintain 
standardisation of experimental conditions and low passage numbers. 
 
 
2.4 Immunofluorescent staining for NF-κB 
 
At the end of the experiments as described above, CMF were fixed in 4% 
paraformaldehyde, permeabilised with 0.1% Triton, washed then blocked in 10% 
donkey serum (Sigma). The cells were next incubated with a rabbit polyclonal 
antibody against NF-κB p65 subunit (Santa Cruz), washed again and then incubated 
with a secondary donkey anti-rabbit antibody conjugated to Alexa488 (Invitrogen). 
Nuclei were counter-stained with 4,6-diamidino-2-phenylindole (DAPI) (Molecular 
Probes, Invitrogen) and slides mounted with ProLong antifade reagent (Invitrogen) 
and observed under a Leica DM5000 epi-fluorescence microscope with an attached 
digital camera using x63 magnification.  We performed these experiments under 
the kind supervision of Dr Olivier Marches, whose generous help we appreciate 
greatly. 
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Since our results examining the role of NF-κB in mediating the effects of curcumin 
in both biopsies and CMF were negative by Western blot, we wished to verify these 
results using an alternative method.  Immunofluorescence is another antibody-
based detection method, this time using antibodies linked to fluorescent dyes.  The 
principle is related to immunoblotting in that a primary anti-p65 rabbit antibody is 
recognised by a secondary donkey anti-rabbit antibody.  However the secondary 
antibody is dye-coupled.  Unlike Western blotting this technique allows 
visualisation of the precise location of the antigen within different cellular or 
histological compartments.  This is particularly useful for measurement of elements 
in the NF-κB activation pathway, since nuclear translocation is a key event in 
activation.  The position of the nuclei is visualised by DAPI counter-stain.  In this 
way the relative position of the p65 NF-κB subunit can be assessed.  In the 
quiescent state p65 is seen largely in the cytoplasmic compartment, where it is held 
inactive in complex with IκB; when activated it is seen more abundantly in the 
nucleus.  By staining the nuclear proteins and the p65 subunit with opposing 
colours, their positions can be pinpointed and any changes noted. 
 
The advantage of this technique is its specificity, and the opportunity to observe 
molecular events, albeit indirectly, on a sub-cellular level.  A disadvantage can be 
the qualitative nature of the observations.  This can be minimised by repeating 
experiments for example in triplicate, ensuring that the entire microscopic field is 
examined in every slide, and a random selection of cells photographed.   
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2.5 Statistics 
 
Each patient donated four inflamed biopsies, which were cultured in four separate 
wells with curcumin concentrations ranging from 0-30μM.  LPMC experiments 
were performed under similar conditions.  No clear dose-response relationship was 
observed against the curcumin doses tested (5-30μM).  Therefore the question arose 
as to which dose to select for the purposes of statistical analysis.  We elected to 
express our results as two straightforward numbers for each patient; negative 
internal control and curcumin-treated.  Curcumin response was given as a single 
figure for each individual patient, which was calculated as the average response of 
that patient to curcumin across all three concentrations tested.  In the absence of a 
dose-response relationship this was chosen as the most representative way to 
express our data.   
 
In retrospect it would have been equally valid simply to culture three biopsies from 
each individual in a single concentration of curcumin, for example 20μM.  At the 
outset however we wished to test more than one dose, expecting a dose response.  
Concentrations over about 50μM were associated with decreased cell viability so 
we elected to avoid these.  In previously published work concentrations in the range 
2-50μM are largely studied.  If other concentrations had been tested in the current 
work, it may have been useful to test a much lower dose, for example 0.1μM.  This 
would have broadened our dosing range and might have brought surprising results, 
as there are some reports of curcumin’s paradoxical efficacy at low dose.   
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The inter-individual variability was generally wide and Gaussian distribution could 
not be assumed.  Therefore data were analysed as non-parametric paired differences 
using the Wilcoxon signed rank test, 95% confidence intervals applied and two-
tailed p values calculated.  The Wilcoxon test was chosen because (a) it was unsafe 
to assume that our data were normally distributed, and (b) we wished to test a 
statistical hypothesis concerning a series of related pairs of measurements.  It is a 
good alternative to the paired Student’s t-test when normal distribution cannot be 
assumed.  Our null hypothesis stated that any difference between our pairs of 
results (control versus curcumin) was no greater than would be expected to arise by 
chance alone.   
 
The choice of 95% confidence intervals is in part based on accepted statistical 
convention.  Confidence intervals give an estimate of the amount of error involved 
in the data.  They are based on the value of the statistic, the standard error of the 
measurements, and the desired width of the confidence interval.  As we are seeking 
a difference between a set of two pairs (A and B), we are asking the question, does 
the 95% confidence interval for median A include median B?  If so, then the 
medians are not statistically different from each other.  If not, then the medians are 
different from each other, at p=0.05.  p is the probability of the result arising if the 
null hypothesis is true (ie by chance alone).  Conventionally data is often regarded 
as significant if the p value is less than 0.05 (that is, a 5% probability that the 
difference arose by chance alone), and this is the p value that we have taken as 
significant.  The application of two-tailed p values is more stringent, as it tests 
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whether deviation in either direction from the null hypothesis can be ascribed to 
chance alone.   
 
Power calculations were not performed prior to the experiments.  This was because 
we were planning novel experiments, in which it was not possible to estimate the 
size of any effect of curcumin.  Furthermore the relevance of power calculations to 
clinical or epidemiological studies, in which recruitment numbers are critical to 
study design at the outset, is not applicable in the same way to basic experimental 
science. 
 
Data were analysed and presented using Prism statistical and graphical software. 
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3.0 Effect of Curcumin on Smad 7 Levels in 
Intestinal Mucosal Tissue and Mononuclear 
Cells 
 
3.1 Smad 7 Western Blot Optimisation 
 
As described in Chapter 2.3.0, a Western blot entails multiple steps, the conditions 
for each of which must be optimised in order to obtain a good signal.  One of the 
key choices early in the experimental protocol is the quantity of protein loaded on 
the gel.  Our choice between 50, 75 and 100μg was based on the practice of 
experienced investigators working in Rome who were previous collaborators of our 
department and experts in Smad 7 immunoblotting [117].  After repeating this 
experiment in duplicate, we established that for an optimal Smad 7 signal, the 
quantity of protein load per lane was 75µg (Figure 3.1).  This was therefore the 
amount of protein we loaded onto the gel in all future Smad 7 experiments.  In this 
way we obtained consistent and reliable protein bands, which were sufficiently 
prominent to read clearly, and not excessively dense so as to obscure differences in 
signal strength. 
 
The purpose of normalising the Smad 7 signal against a housekeeping protein (in 
this case β-actin) is to correct for any differences in sample loading and for factors 
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such as transfer efficiency when blotting the protein bands from gel to membrane.  
Thus the housekeeping gene acts as an internal standard and is chosen for its 
ubiquitous, stable and constitutive expression in every tissue.  Others which are 
commonly used include glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-
tubulin and phospholipase A (PLA)2.  Actins occur in three main isoforms; α, β 
and γ.  They are the most abundant proteins in eukaryotic cells, playing key roles in 
cell motility and cytoskeletal maintenance.  They are expressed constitutively; β- 
and γ-actin being found in practically all cells; α-actin being confined to smooth 
muscle cells [315].  Recent evidence suggests that under some circumstances β-
actin, and other housekeeping genes in common use, are subject to more variation 
than was previously thought, and this therefore may call into question the validity 
of their use as internal controls.  Such variation may occur in response to for 
example drug treatments, disease states, cell cycle phase, differentiation, age and 
sex of the individual and source of tissue [315, 316].  It seems however that such 
variability may affect RNA-based studies (polymerase chain reaction (PCR)) more 
than protein-based (Western blot), perhaps due to the higher sensitivity of PCR, and 
the amplification involved in this technique. 
 
In specific relation to Smad 7, the loading control used by investigators who have 
previously published is consistently β-actin.  There is no published comparison of 
housekeeping proteins in this precise context, therefore unambiguous identification 
of a ‘gold standard’ protein is not possible.  However there is some work on choice 
of housekeeping genes for PCR in the gut [317].  These investigators mainly 
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focused on normal differentiating enterocytes versus gut adenocarcinomas.  They 
examined the expression of a number of classical and novel candidate 
housekeeping genes in enterocytes at varying stages in differentiation and in 
adenocarcinoma cells.  They analysed their respective standard deviations by a 
variety of statistical methods and concluded that β-2-microglobulin was the most 
robust normalising gene overall, although β-actin was an acceptable alternative.  
The investigators commented that due to non-uniformity of expression in different 
cell types, it was not possible to select an overall gold standard. 
 
For the reasons outlined above, we chose β-actin as our loading control for Smad 7 
protein.  Because protein blotting is a less sensitive and less quantitative tool than 
PCR, and since the existing evidence from PCR work suggests that β-actin 
performs acceptably well as a loading control, we accepted this choice in our 
immunoblots.  We found that our β-actin signals were clear, consistent and of 
similar intensity throughout all experiments in intestinal tissues and LPMC’s, 
reinforcing the validity of this choice. 
 
 
 
Figure 3.1 W estern blot for Smad 7 with β-actin loading control showing optimal 
protein load 75µg 
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3.2 Curcumin Does Not Reduce Smad 7 in Intestinal 
Mucosal Tissue or Mononuclear Cells 
 
We hypothesised that curcumin, as an inhibitor of acetylation, can release TGF-β 
signalling from Smad 7 suppression, and thus restore this anti-inflammatory 
pathway in IBD.  We measured in vitro Smad 7 levels in intestinal mucosal tissue 
biopsies and LPMC’s from patients with active IBD, cultured ex vivo with 
curcumin.  Precise methods are detailed in Chapters 2.1.2, 2.1.3 and 2.3.0.  Our 
choice of curcumin concentrations was largely influenced by concentrations used 
by other investigators who have previously published in the field.  The doses used 
in cell culture work largely range from 2-50μM.  We found that cell viability (as 
assessed by trypan blue exclusion) dropped below 80% at concentrations above 
about 50μM and therefore to avoid the risk of contaminating our results in this way, 
we only tested concentrations below this.   
 
Such in vitro concentrations are probably considerably higher than blood or tissue 
concentrations that can be achieved in vivo through oral dosing in humans, due to 
drug delivery and bioavailability issues as described in Chapter 1.4.2.  In one study 
3.6g of oral curcumin achieved plasma levels of 11.1nmol/L one hour post dose in 
humans [157]; a concentration a factor of 1000 lower than those we have used in 
vitro.  Other investigators found peak human plasma levels of 0.41-1.75μM one 
hour after oral dosing of 4-8g of curcumin [153]; these are only a factor of 10 lower 
than the concentrations we have used.  Due to the wide variability in 
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pharmacokinetic data from different studies it is difficult to ascertain for certain the 
relationship between in vitro and in vivo curcumin dosing.  In retrospect we would 
have liked to study some much lower curcumin concentrations in our in vitro work, 
since these would probably hold relevance to the human clinical situation and there 
is some evidence from in vitro and animal work that curcumin can have paradoxical 
high efficacy at low doses. 
 
We found that Smad 7 levels did not alter in any consistent pattern with the 
addition of curcumin in ex vivo intestinal mucosal tissue or mononuclear cell 
cultures (figure 3.2).  All patient details and individual results can be found in the 
Appendix. 
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Figure 3.2 Curcumin causes no consistent change in Smad 7 in inflamed intestinal 
mucosal tissue or mononuclear cells.  (A) Western blot from single representative experiment 
showing Smad 7 with β-actin loading control in CD biopsies with varying concentrations of 
curcumin.  (B) Smad 7/β-actin densitometry as percentage change from baseline (vehicle 
control) with varying concentrations of curcumin.  Each point represents a single experiment.  
Data from 8 individuals [5CD + 3UC]. 
 
 
As discussed in detail in Chapters 1.2.5 and 1.2.8, Smad 7 is a negative regulator of 
TGF-β signalling, an important anti-inflammatory pathway.  This is the first time to 
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our knowledge that the response of Smad 7 to curcumin has been investigated in 
any animal or cell type.  Although we know Smad 7 levels are increased by 
acetylation, that curcumin is an inhibitor of acetyl transferase p300, and that 
curcumin does indeed show positive clinical benefit in animal and human IBD 
studies, we found no consistent response of Smad 7 to curcumin in our ex vivo 
experimental models, either in biopsies or mononuclear cells, and this data is 
presented together in figure 3.2.  This could be due to the lower anti-acetylating 
potency of curcumin compared to other inhibitory strategies previously employed 
experimentally, namely short interfering ribonucleic acid (siRNA) against p300 
[117].  Alternatively, it may be that curcumin exerts some of its clinical effects in 
IBD through mechanisms unrelated to acetylation, or through acetylation of other 
non-Smad elements.   
 
Thus our hypothesis that curcumin restores TGF-β signalling by reducing Smad 7 
acetylation, is rejected.  However it is possible that acetylation of different proteins 
is dependent on different acetylation pathways.  Whilst Smad 7 is not affected by 
curcumin, other proteins relevant to inflammation in IBD may be regulated by 
acetylation-dependent mechanisms and these may be susceptible to manipulation 
by curcumin. 
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4.0 Effects of Curcumin on Cytokine Expression 
in ex vivo Intestinal Mucosal Tissue 
 
4.1 Curcumin Increases Interleukin-10 Production in 
Intestinal Mucosal Tissue 
 
We hypothesised that curcumin, as an inhibitor of acetylation, can release IL-10 
transcription from Sp3 suppression, and thus restore anti-inflammatory pathways in 
IBD.  We measured in vitro IL-10 production by intestinal mucosal tissue biopsies 
from children and adolescents with active IBD, in response to curcumin, and 
compared this with production of other cytokines. 
 
With curcumin there was an overall increase in IL-10 production by inflamed 
intestinal tissue from children with active IBD (Figure 4.1A).  No clear dose-
response relationship was evident over the curcumin dosing range tested (5-20μM).  
Therefore for the purposes of statistical analysis, these data were expressed as a 
single mean response to curcumin across all doses (5-20μM) for each patient 
(Figure 4.1B and Table 4.1).  This rationale is explained in more detail in chapter 
2.5.  Thus Figure 4.1B displays the same data as figure 4.1A, only expressed as a 
matched pair of results for each individual patient; negative (vehicle) control and 
curcumin.  Curcumin caused a median rise of +265% (+283pg/ml) in IL-10 
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expression in ex vivo intestinal mucosal tissue culture from patients with active IBD 
(Figure 4.1B), and this increase was significant (p=0.0015) (table 4.1).   
 
When analysed by separate disease groups, CD biopsies showed a 92% increase in 
IL-10 expression with curcumin, which was significant (p=0.016) (Figure 4.2A), 
and UC samples a large 498% increase, which did not however reach statistical 
significance (p=0.13) (Figure 4.2B).  All patient details and individual results can 
be found in the Appendix. 
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Figure 4.1 Curcumin enhances interleukin-10 production in inflamed intestinal 
mucosal tissue.  (A) IL-10 production by intestinal mucosal biopsies as percentage change 
from baseline (vehicle control) with varying concentrations of curcumin.  Each point 
represents a single experiment.  Data from 12 individuals (8 CD + 4 UC).  (B) The same data 
expressed as mean IL-10 response by each patient to all curcumin concentrations 5-20µM. 
p = 0.0015 
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 Median IL-10 (pg/ml) Inter-quartile range p value 
Vehicle control 273 41-617 0.0015 
Curcumin 536 253-804 
 
Table 4.1 Statistics describing figure 4.1B.  Wilcoxon matched pairs test shows significant 
difference between the two groups. 
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Figure 4.2 Interleukin-10 responses of inflamed intestinal mucosal tissue to curcumin 
by disease group.  (A) CD: median difference +276pg/ml (+65%) (p=0.0078).  (B) UC: median 
difference +163pg/ml (+498%) (p=0.13). 
 
 
Published data demonstrate that curcumin increases IL-10 production in various 
cell types, including human T cells [318] and in the colonic mucosa in animal 
studies of experimentally induced colitis [319].  To our knowledge this is the first 
p = 0.0078 
p = 0.13 
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study of curcumin in human ex vivo intestinal mucosal tissue. We show a marked, 
consistent and significant overall increase in IL-10 expression of 265% with 
curcumin.  This increase in IL-10 was observed in both CD and UC groups, 
however it only attained statistical significance in CD, and overall in both disease 
groups.  As expected, generally higher levels of cytokine expression were observed 
in CD than UC, both spontaneously and after culture with curcumin.  Consistent 
with known epidemiological patterns (Chapter 1.1.0), there were lower numbers of 
children with UC available from whom to obtain biopsies.  This, coupled with the 
lower levels of cytokine expression in UC, explains why in the UC group, response 
to curcumin did not achieve statistical significance.  Nonetheless a convincing trend 
towards increased IL-10 expression with curcumin was observed in UC. 
 
We observed a wide variability in IL-10 expression, both between individuals, 
between different biopsies from the same individual and between differing 
concentrations of curcumin.  To explain this we consider the random composition 
of biopsies, the nature of ex vivo disease models and the heterogeneous and 
sometimes patchy disease phenotype in IBD.  Despite measures to standardise, 
including taking a single biopsy only at each pass of the forceps, taking samples 
from a small disease area, and uniformity of handling and culture, four biopsies 
taken from one individual will inevitably be of variable composition in terms of 
cellularity and size.  For example a biopsy which contains by chance a high 
proportion of immune cells can be expected to produce large amounts of cytokines, 
whilst one which contains a high proportion of fibrous tissue may produce less.  To 
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minimise the confounding effect of these factors, we examined a relatively high 
sample size of 12 individuals with active IBD, and simplified our data analysis by 
presenting it as a matched pair of results for each patient.  In this way we were able 
to quantify the overall direction of effect of curcumin upon heterogeneous samples, 
and to measure its statistical significance.   
 
This rise in IL-10 is consistent with our hypothesis (discussed in greater detail in 
Chapter 1.2.10 and depicted in Figure 1.7) that curcumin inhibits acetylation of 
Sp3, reducing its binding to the IL-10 promoter and releasing suppression of IL-10 
gene transcription.  To further strengthen support for our hypothesis, we wished to 
investigate whether the actions of curcumin on IL-10 expression were specific to 
IL-10 and different to any effects on other cytokines.  We therefore next examined 
the expression of key pro-inflammatory cytokines in the same experimental system. 
 
 
4.2 Curcumin Decreases Interleukin-1β Production in 
Intestinal Mucosal Tissue 
 
We wished to show that the effect of curcumin to enhance IL-10 production was 
specific to that cytokine and not shared by its effects on other, pro-inflammatory 
cytokines.  Here we show that the overall IL-1β response to curcumin is to decrease 
production.  Once again, a dose-response relationship was not clearly observed 
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(Figure 4.3A).  Therefore for statistical analysis these data were treated exactly as 
before, and expressed as a single matched pair of results for each patient; control 
versus curcumin.  Curcumin response was given as the individual’s mean response 
across all curcumin doses tested (5-20μM) (Figure 4.3B and Table 4.2).   
 
Curcumin caused a median reduction of -17% (-79pg/ml) in IL-1β expression in ex 
vivo tissue cultures from children and adolescents with active IBD, and this 
reduction was significant (p=0.0098) (Table 4.2).  When analysed by separate 
disease groups, CD samples showed a 13% decrease in IL-1β expression with 
curcumin, which was significant (p=0.031) (Figure 4.4A), and UC samples a 15% 
decrease, which did not reach statistical significance (p=0.25) (Figure 4.4B).  
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Figure 4.3 Curcumin reduces interleukin (IL)-1β production in inflamed intestinal 
mucosal tissue.  (A) IL-1β production by intestinal tissue as percentage change from baseline 
(vehicle control) with varying concentrations of curcumin.  Each point represents a single 
experiment.  Data from 10 individuals (6CD + 4UC).  (B) The same data expressed as mean 
IL-1β response by each patient to all curcumin concentrations 5-20µM. 
p = 0.0098 
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 Median IL-1β (pg/ml) Inter-quartile range p value 
Vehicle control 463 210-913 0.0098 
Curcumin 384 201-789 
 
Table 4.2 Statistics describing figure 4.2B.  Wilcoxon matched pairs test shows significant 
difference between the two groups. 
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Figure 4.4 Interleukin-1β responses to curcumin by disease group.  (A) CD: median 
difference -59pg/ml (-13%) (p=0.031).  (B) UC: median difference -68pg/ml (-15%) (p=0.25). 
 
 
Our results show for the first time the suppression by curcumin of IL-1β expression 
in ex vivo human intestinal mucosal tissue culture from patients with active IBD.  
This reached statistical significance in the case of CD samples and in overall data 
from both disease types.  Furthermore, although not statistically significant, in UC 
p = 0.031 
p = 0.25 
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samples a trend towards decreased IL-1β with curcumin was also seen.  This 
reduction in IL-1β, although relatively modest at -17% overall, holds likely 
biological and future clinical importance in the treatment of IBD.  Importantly the 
effect of curcumin on IL-1β is to decrease its production; in contrast to its 
enhancing effect upon IL-10.  This indicates that IL-10 is subject to a particular 
action by curcumin, which directly opposes its effect on pro-inflammatory 
cytokines such as IL-1β.  As with our IL-10 data, we observed a wide inter-
individual variability in IL-1β production, and the reasons for this have previously 
been discussed (Chapter 4.1).  To counteract this we once again included samples 
from a relatively large number of individuals in our analysis.  For reference, the 
raw individual patient data can be found in the Appendix. 
 
IL-1β is one of the most central and important effectors of the inflammatory 
response.  It is produced by monocytes, macrophages, dendritic cells and other 
immune cells in response to all types of inflammatory stimuli and mediates a wide 
range of pro-inflammatory consequences.  It is transcribed in the form of its 35kDa 
precursor, pro-IL-1β, cleaved to its 17kDa active form by caspase-1 (also known as 
interleukin converting enzyme (ICE)), then secreted, the precise mechanisms by 
which are incompletely understood [320].  It exerts its effects by binding to the IL-
1 receptor IL-1RI [321], leading to recruitment of myeloid differentiation marker 
Myd88 [322], Toll interacting protein Tollip [323] and IL-1 receptor associated 
kinase IRAK [324].  This launches an activation cascade starting with 
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phosphorylation of IRAK [325], and leading ultimately to the activation of NF-κB.  
It is characteristically raised in the serum and tissues of patients with IBD.   
 
Curcumin is known to suppress IL-1β production in numerous different cell types 
[326] [327] [328], including in the intestinal mucosa in models of colitis [319].  
Various putative mechanisms have been proposed, including inhibition of NF-κB 
and MAPK [329] and prevention of recruitment of IRAK to IL-1RI [330].  Once 
again it seems likely that curcumin has a complex mode of action, possibly 
involving more than one mechanism.  Whilst our hypothesis for the mechanism of 
action of curcumin upon IL-10 is via the acetylation-sensitive transcription factor 
Sp3, the question remains as to the mechanism(s) of action of curcumin on IL-1β.  
Putative candidate mechanisms include inhibition of elements in the receptor and 
signalling cascades, inhibition of cleavage of its inactive precursor, and inhibition 
at, or prior to, the transcriptional level, for example through NF-κB or MAPK 
signalling.  These latter possibilities in particular are further to be explored in this 
work. 
 
 
 
 
 
 
 145 
4.3 Interferon-γ Production in Intestinal Mucosal Tissue 
is Not Significantly Affected by Curcumin 
 
Although in the majority of individuals (9/13) we observed that IFN-γ expression 
decreased with curcumin (Figure 4.5A), overall no significant change in IFN-γ 
expression was identified in response to curcumin in ex vivo intestinal mucosal 
tissue (Figure 4.5B).  Similarly when examined by separate disease groups, changes 
did not reach statistical significance in either CD or UC (Figure 4.6).  We conclude 
that curcumin does not significantly affect IFN-γ in intestinal mucosal tissue from 
children with active IBD.  Once again and for the reasons discussed above 
variability was wide.  All patient details and individual results can be found in the 
Appendix. 
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Figure 4.5 Curcumin causes no significant change in interferon (IFN)-γ production in 
inflamed intestinal mucosal tissue.  (A) IFN-γ production by intestinal tissue as percentage 
change from baseline (vehicle control) with varying concentrations of curcumin.  Each point 
represents a single experiment.  Data from 13 individuals (8 CD + 5 UC).  (B) The same data 
expressed as mean IFN-γ response by each patient to all curcumin concentrations 5-20µM.  
p = NS 
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Figure 4.6 Interferon-γ responses to curcumin by disease group.  (A) CD: Median 
difference +187pg/ml (+22%) (p=0.74).  (B) UC: Median difference -232pg/ml (-45%) (p=0.19). 
 
 
Ours is the first investigation, to our knowledge, of the effect of curcumin on IFN-γ 
expression in human ex vivo intestinal mucosal tissue.  We observed that 
spontaneous IFN-γ production by intestinal mucosal biopsies was higher in CD 
p = 0.74 
p = 0.19 
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than UC.  This is an expected finding for a cytokine of Th1 type such as IFN-γ and 
is consistent with the findings of other groups [331].  We found no statistically 
significant overall or disease-specific change in IFN-γ levels with curcumin.  
Nonetheless a key aspect of our findings is that the responses to curcumin of both 
pro-inflammatory cytokines IFN-γ and IL-1β did not mirror that of IL-10.   
 
IFN-γ is a pro-inflammatory cytokine produced in response to a wide range of host 
invaders including viruses, bacteria, parasites and cancer cells.  It is a member of 
the type II group of interferons and binds to the type II IFN transmembrane 
receptor.  This leads to activation of Janus family Kinases Jak 1 and Jak 2 and 
phosphorylation of STAT1, homodimers of which then translocate to the nucleus 
and initiate transcriptional events.  By a separate pathway IFN-γ also activates p42 
MAPK.  Its downstream effects are wide ranging and include activation of 
lymphocytes, macrophages and other immune cells, and upregulation of expression 
of MHC II on antigen presenting cells (APC) [332].  Serum and tissue levels of 
IFN-γ are raised in IBD.  Like IL-1β, IFN-γ is classically considered a cytokine of 
Th1 type, although the concept of CD as a Th1 disease and UC as Th2 is evidently 
an over-simplification, and our data corresponds with other published studies in 
which IL-1β and IFN-γ are observed to be raised in UC as well as CD [333].  IFN-γ 
is a novel target for biological therapies in IBD; a humanised monoclonal antibody 
fontolizumab is currently showing promise in early phase human trials [334] [335]. 
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There is some published evidence that curcumin decreases IFN-γ production in T 
cells in vitro  [327] [336].  Various potential mechanistic explanations are given for 
this effect, including suppression of IL-12 [327] and inhibition of NF-κB [336], but 
these are largely speculative.  From a separate angle, in brain microglial cells, 
studies show suppression of IFN-γ signalling by curcumin, via inhibition of the 
Jak/STAT1 pathway.  It seems likely that the effects of curcumin differ according 
to cell type, and occur through complex and possibly multiple mechanisms.  
 
To summarise our cytokine findings in the inflamed intestinal mucosa, we observed 
significantly enhanced IL-10 production, significantly decreased IL-1β and 
unaltered IFN-γ expression, in ex vivo culture with curcumin.  Although they do not 
provide conclusive proof, these findings are consistent with our original hypothesis 
that a specific, acetylation-sensitive element exists in the IL-10 promoter region, 
leading to enhanced IL-10 production in response to curcumin (Chapter 1.2.10 and 
Figure 1.7); an effect which is separate from the action of curcumin upon other 
cytokines.  Furthermore they show favourable modulation of the cytokine profile in 
the human intestinal mucosa in response to curcumin, an observation which holds 
clear potential therapeutic relevance for curcumin in IBD.  The mechanism(s) of 
action of curcumin upon cytokine production remains unknown, but candidate 
mechanisms include intermediary signalling cascades such as NF-κB and p38 
MAPK.  As previously mentioned, some investigators provide evidence suggesting 
that these pathways are involved in the modulation of IL-1β and IFN-γ by curcumin 
[329, 336].  We will proceed to investigate these possibilities in the current work. 
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5.0 Cytokine Production by Mononuclear Cells  
 
5.1 There is a Trend Towards Decreased Interleukin-1β 
and Interferon-γ in Lamina Propria Mononuclear 
Cells With Curcumin  
 
From our work on cytokine expression in intestinal mucosal biopsies with curcumin 
(Chapter 4.0), we concluded that there was a modest but significant decrease in IL-
1β and a non-significant trend towards decreased IFN-γ production.  Importantly we 
found that neither of these pro-inflammatory cytokines mirrored the enhanced 
production of IL-10 which we observed with curcumin.  The wide inter-sample 
variability which we observed in these tissue experiments was ascribed to the use of 
biopsy culture as a model of disease, containing heterogeneous mixtures of cell 
types.  Thus we wished to refine our study to a single cell type from the inflamed 
gut mucosa.  A natural choice was LPMC’s, since mononuclear cells are activated 
in IBD and are a major source of cytokine production. 
 
During the time period in which we were collecting surgical resection specimens 
for cytokine analysis, we encountered a prolonged shortage of clinical supply due 
to reduced numbers of patients undergoing surgery for active inflammation in IBD.  
The data we were able to collect strongly suggest that curcumin causes decreased 
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production of both IL-1β and IFN-γ (Figure 5.1).  Furthermore they appear to point 
to a more consistent and less variable response, with every one of the six individual 
patients showing a reduction in pro-inflammatory cytokine production with 
curcumin.  Unfortunately patient numbers were insufficient to reach statistical 
significance.  All patient details and individual results can be found in the 
Appendix. 
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Figure 5.1  Curcumin may reduce interleukin (IL)-1β and interferon (IFN)-γ 
production in lamina propria mononuclear cells (LPMC) from patients with active IBD.  (A) 
IL-1β production by LPMC’s cultured ex vivo with curcumin.  Each point represents a single 
experiment.  Data from 2 individuals (1CD + 1UC).  (B) IFN-γ production by LPMC’s 
cultured with curcumin.  Data from 4 individuals (3CD + 1UC). 
A 
B 
p = NS 
p = NS 
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The data shown complement our intestinal mucosal biopsy findings, and provide 
evidence that the most part of cytokine production measured in tissue culture comes 
from mononuclear cells.  LPMC’s are described in more detail in Chapter 2.1.3.  
They are gut mucosal lymphocytes and monocytes, comprising a large proportion 
of T cells and macrophages and have a generally activated phenotype.  Therefore 
they are an excellent model of disease and do not require in vitro stimulation.  
Cytokine production by LPMC’s from actively diseased tissue is spontaneous, and 
as we show here amenable to inhibition by curcumin.  We would have liked to 
obtain LPMC’s from a greater number of individuals to further examine these 
effects, including upon IL-10 production, but unfortunately this was not possible so 
we considered alternative strategies.  Firstly we studied readily available peripheral 
blood mononuclear cells, and later we will isolate another gut mucosal cell type of 
key relevance to IBD, myofibroblasts. 
 
 
5.2 Interleukin-10 Production by Peripheral Blood 
Mononuclear Cells Increases with 
Lipopolysaccharide 
 
Ideally we would study IL-10 production in gut mononuclear cells, but because of 
clinical supply interruption, we instead elected to examine IL-10 production in 
PBMC’s from healthy donors.  There are some differences in composition, 
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phenotype, morphology and immunology between PBMC’s and LPMC’s, which 
are largely attributed to the increased reactivity of mononuclear cells in the gut 
compared to peripheral blood (Chapter 2.1.3) [312].  For these reasons, healthy 
PBMC’s differ from LPMC’s taken from inflamed gut in that PBMC’s require 
stimulation in order to induce significant cytokine production.  Nonetheless these 
two groups of leukocytes behave similarly in vitro and share many similarities; 
both immunologically active cells comprising predominantly T lymphocytes, with 
lesser proportions of B cells and natural killer cells, as well as monocytes which 
may differentiate into macrophages or dendritic cells.   
 
Spontaneous IL-10 production by normal PBMC’s was generally low, but a wide 
variation between individual donors was seen.  Stimulation with LPS caused a 
dose-dependent increase in IL-10 production (Figure 5.2). 
 
 
Figure 5.2 Interleukin-10 production by peripheral blood mononuclear cells after 24 
hours of culture with varying concentrations of lipopolysaccharide.  Error bars represent 
standard errors of the mean.  
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We confirm successful activation of PBMC’s with LPS in a dose-dependent fashion 
(Figure 5.2).  LPS is a structural component of the outer membrane of Gram 
negative bacteria.  Structural motifs expressed by bacteria, viruses and fungi, 
known as pathogen-associated molecular patterns (PAMP’s), stimulate the host 
innate immune system via toll-like receptors (TLR’s).  The main PAMP of LPS is 
lipid A; also known as endotoxin [337].  Lipid A is the hydrophobic domain of 
LPS, and it is flanked by two hydrophilic components, a core oligosaccharide and a 
distal polysaccharide, or O antigen.  LPS is largely sensed by TLR4 [338] and the 
transfer of LPS onto TLR4 is mediated by interaction with several other proteins 
including LPS binding protein (LPB) and the co-receptor cluster of differentiation 
(CD)14 [339].  Upon TLR4 ligation by LPS, TLR4 recruits downstream adapter 
proteins and its subsequent signal transduction can be divided into myeloid 
differentiation primary response gene (MyD)88-dependent and MyD88-
independent pathways.  The MyD88-dependent pathway is responsible for the 
expression of pro-inflammatory cytokines and the MyD88-independent pathway for 
the induction of type I interferon genes.  NF-κB and MAPK activation can occur 
through both pathways [340]. 
 
Although other stimulants could have been used such as TNF-α or IL-1, we felt that 
LPS was a suitable choice in this case.  With relevance to intestinal inflammatory 
signalling, there is a high presence of Gram negative bacteria in the gut, many 
species of which are potentially pathogenic, and toll-like receptor signalling plays a 
pivotal role in the generation of appropriate and inappropriate inflammation in the 
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intestine [42].  This is addressed in more detail in chapter 1.2.1.  Our dose-response 
experiments allowed us to select an optimal LPS concentration of 1μg/ml for 
further experiments.  At this concentration IL-10 production by PBMC’s doubled; a 
clear upregulation potentially amenable to inhibition by a test agent such as 
curcumin. 
 
 
5.3 Curcumin and Anacardic Acid Induce a Bell-
Shaped Response in Interleukin-10 Production by 
Peripheral Blood Mononuclear Cells 
 
With our human PBMC culture model established, we proceeded to investigate the 
responses of these cells to curcumin.  At low concentrations, there was an initial 
rise in IL-10 production by normal PBMC’s stimulated with LPS.  With increasing 
doses of curcumin, IL-10 production diminished, creating a bell-shaped dose-
response curve (Figure 5.3).  This response was mirrored when experiments were 
repeated with anacardic acid, another known inhibitor of acetylation.  Cell viability 
was confirmed at the end of all experiments by trypan blue exclusion, and remained 
above 80%.  There was as expected a wide variability in both spontaneous and 
post-stimulation IL-10 production between donors, as noted by other investigators 
[308].  This can be appreciated by comparing Figures 5.3A and 5.3B; showing 
quite different levels of IL-10 production in PBMC’s donated by two healthy 
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donors. Although basal IL-10 production varied, the finding of a bell-shaped 
pattern of response to curcumin and anacardic acid was consistent in all samples 
tested.  These experiments were repeated at least in triplicate. 
 
Choice of curcumin and anacardic acid concentrations was based upon 
concentrations studied by previous investigators, on cytokine responses as 
measured here and on cell viability assays in our laboratory.  By trypan blue 
exclusion testing we found that PBMC’s remained above 80% viable in curcumin 
concentrations of up to 50μM, and in anacardic acid concentrations of up to 20μM, 
after 24 hours of incubation.  As discussed earlier (Chapter 3.2) in the case of 
curcumin this probably corresponds to concentrations considerably higher than 
those achievable by standard oral dosing in humans.  In the case of anacardic acid 
such factors are unknown as it has never been studied as a therapeutic agent in vivo. 
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Figure 5.3 Curcumin and anacardic acid induce a bell-shaped interleukin (IL)-10 
response in peripheral blood mononuclear cells (PBMC’s).  (A) IL-10 production by 
lipopolysaccharide (LPS)-stimulated PBMC’s with increasing curcumin dose.  (B) IL-10 
production by PBMC’s stimulated with 1μg/ml LPS with increasing anacardic acid dose. 
 
The interleukins are cytokines which are secreted by leukocytes and communicate 
messages between them.  As discussed in Chapter 1.2.6, IL-10 is an important anti-
inflammatory cytokine in the gut.  Curcumin has previously been shown to 
decrease expression of pro-inflammatory cytokines in a number of different cell 
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types including normal human PBMC’s [341].  Some published data also exist 
showing upregulation of IL-10 by curcumin, including in experimentally 
transformed human T cell blasts [318].  To our knowledge there is no published 
work on the effect of anacardic acid on mammalian cytokine profiles.   
 
In the current study, normal human PBMC’s exhibited a bell-shaped IL-10 
response to increasing doses of curcumin (Figure 5.3A).  Anacardic acid, like 
curcumin, is an inhibitor of acetylation (Chapter 1.5).  This is the only known 
biological property of anacardic acid, and the only known shared property of the 
two agents [303].  The finding of a similar bell-shaped IL-10 response by PBMC’s 
to anacardic acid (Figure 5.3B), whilst not conclusive for mechanism, suggests that 
both agents are acting via an acetylation-dependent mechanism.  These data are 
compatible with our hypothesis that curcumin acts to decrease the acetylation of 
Sp3, reducing its binding to the IL-10 gene promoter and releasing its suppression 
of IL-10 transcription (presented in detail in Chapter 1.2.10).  Why IL-10 
production is only enhanced at low concentrations of curcumin is unknown, and the 
current hypothesis does not explain the bell-shaped nature of the response.  
Intriguingly, this finding is in accordance with a number of reports of curcumin 
having paradoxically opposing biological actions at differing doses [342], and this 
lends weight to the notion that curcumin exerts its effects through more than one 
molecular mechanism.  It may be that at higher concentrations, the anti-acetylating 
effect of curcumin upon histones predominates, blocking access of positive 
transcription factors and thus reducing IL-10 expression.   
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Whilst our PBMC data demonstrate that curcumin has a biological impact on IL-10 
expression in human mononuclear cells, this bell-shaped pattern was not 
reproduced in LPMC’s for IL-1β or IFN-γ, nor in intestinal biopsies for IL-10, and 
we did not consider the extrapolation of data from circulating mononuclear cells a 
valid strategy in relation to the behaviour of intestinal mononuclear cells.  
However, by employing these techniques and studying the responses we were able 
to ascertain optimal culture conditions, including cell isolation techniques, handling 
procedures, culture time periods and dosing ranges, and apply these to experiments 
on LPMC’s.  These data also support the need for trialling of a wide range of doses 
in clinical studies, including low dose. 
  
 
5.4 Interleukin-10 Production by Peripheral Blood 
Mononuclear Cells Occurs Largely During Hours 12 
to 24 of Culture 
 
Time course experiments revealed that the greatest rate of IL-10 production by 
PBMC’s occurs during the second half of the 24 hour incubation period (Figure 
5.4).   
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Figure 5.4 Interleukin (IL)-10 is produced by peripheral blood mononuclear cells 
(PBMC’s) largely during hours 12-24 of culture.  (A) IL-10 production by lipopolysaccharide 
(LPS)-stimulated PBMC’s with different doses of curcumin.  (B) IL-10 production by LPS-
stimulated PBMC’s with different doses of anacardic acid. 
 
In vivo, IL-10 is released later than the pro-inflammatory cytokines after a stimulus 
such as LPS, and this has been shown in both animal and human models [343, 344].  
Thus IL-10 plays an important biological role in limiting unchecked inflammation 
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(Chapter 1.2.6).  It is likely that, had we measured the time courses for release of 
inflammatory cytokines such as TNF-α, IL-1, IFN-γ or IL-8, these would have 
peaked earlier.  However, such experiments have previously been published.  Our 
time course experiments allowed us to ascertain the ideal culture time period of 24 
hours; a balance between maximal cellular activity versus risk of infection or cell 
death – a risk which is higher in mononuclear cells isolated from (particularly 
diseased) intestinal specimens than from peripheral blood. 
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6.0 p38 Mitogen-Activated Protein Kinase and 
Nuclear Factor-κB Signalling in ex vivo 
Intestinal Mucosal Tissue  
 
6.1 p38 Mitogen-Activated Protein Kinase is 
Spontaneously Activated in Inflammatory Bowel 
Disease and this is Completely Abrogated by the 
Inhibitor SB203580 
 
p38 MAPK activation (phosphorylation) is characteristically greatly increased in 
mucosal biopsies from patients with active CD and UC, compared with normal 
mucosal biopsies taken from subjects without disease (Figure 6.1A).  The addition 
of specific p38 MAPK inhibitor SB203580 in 24 hour culture with biopsies from 
patients with active IBD, almost completely abrogates this spontaneous p38 MAPK 
activation (Figure 6.1B).   
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Figure 6.1 p38 mitogen-activated protein kinase (MAPK) is activated in inflammatory 
bowel disease.  (A) Phospho p38 MAPK and p38 MAPK loading control in normal, ulcerative 
colitis (UC) and Crohn’s disease (CD) biopsies.   3 individuals in each group.  (B) UC biopsies 
cultured with p38 MAPK inhibitor SB203580.  The experiments in figure 6.1 were performed 
by Dr Guillermo Docena who kindly shared his results with us. 
 
p38 MAPK becomes activated when it is phosphorylated (Figure 1.2 and Chapter 
1.2.2). Total p38 MAPK serves as a loading control for its phosphorylated form.  
This is a more specific and appropriate standardiser for phospho-p38 MAPK than 
the more generic cytosolic housekeeping gene β-actin, since it controls not only for 
equal protein loading but also for the proportion of p38 MAPK which is activated 
out of the total potential p38 MAPK in that particular tissue.  This is especially 
useful for biopsy work as opposed to work on a single cell type, because it helps to 
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correct for the variable proportions of cell types within the tissue, only some of 
which may be MAPK-producing cells. 
 
We confirm here as expected the greatly increased p38 MAPK activation in both 
CD and UC, as well as the minimal detectable activation in normal healthy gut.  
This illustrates the reason we have chosen to use only tissue from patients with 
active disease, upon which to study the effects of curcumin as a potential 
therapeutic agent in IBD.  In actively diseased tissue inflammatory mediators are 
activated and this provides a good ex vivo model to examine for suppression by 
curcumin.  As can be seen in Figure 6.1A these experiments would not be relevant 
or possible in healthy gut tissue.   
 
The specific p38 MAPK inhibitor SB203580 is a member of the pyridinyl 
imidazole compounds, and is known to block the pathway by competing for 
adenosine triphosphate (ATP) in the active pocket of the enzyme [345].  This 
compound was being tested as part of work funded by Glaxo Smith Kline, and is 
included here to illustrate the near total inhibition which occurs with directed 
inhibition of this kind.  We will compare with this the effects of curcumin as a 
potential p38 MAPK inhibitor. 
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6.2 Curcumin Decreases p38 Mitogen-Activated Protein 
Kinase Activation in Inflamed Intestinal Mucosal 
Tissue 
 
We hypothesised that curcumin would have direct anti-inflammatory effects in the 
gut mucosa in IBD.  In Chapters 4.0 and 5.0 we studied mucosal tissue biopsies and 
mononuclear cells from children and adults with active IBD and treated them in 
vitro with curcumin.  We showed favourable modulation of the cytokine profile 
with enhanced IL-10 production and reduced IL-1β.  We wished to seek a 
mechanistic explanation for the reduced expression of IL-1β observed with 
curcumin in intestinal mucosal tissue and LPMC’s.  In pursuit of this we first 
assessed the p38 MAPK signalling pathway in the inflamed intestinal mucosa in 
IBD. 
 
Overall, curcumin caused a median reduction of 42% in phosphorylated (activated) 
p38 MAPK in ex vivo tissue cultures from patients with active IBD, and this 
reduction was significant (p=0.023).  Once again data from all curcumin 
concentrations (Figure 6.2B) were combined for the purpose of statistical analysis 
(Figure 6.2C and Table 6.1).  Total p38 MAPK was used as a loading control for 
phosphorylated p38 (Figure 6.2A) and all p38 MAPK data is expressed as a 
densitometry ratio of phosphorylated p38/total p38 MAPK.  The slight difference in 
band morphology seen in Figure 6.2 compared to Figure 6.1 is due to the fact that 
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those in Figure 6.1 were run on pre-cast gels whereas those in Figure 6.2 were run 
on prepared gels.  All patient details and individual results can be found in the 
Appendix. 
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Figure 6.2 Curcumin reduces p38 mitogen-activated protein kinase (MAPK) 
activation in inflamed intestinal mucosal tissue.  (A) Western blot from single representative 
experiment showing phosphorylated p38 MAPK and p38 loading control in CD biopsies with 
varying concentrations of curcumin.  (B) Phospho-p38/total p38 densitometry as percentage 
change from baseline (vehicle control) with varying concentrations of curcumin.  Each point 
represents a single experiment.  Data from 8 individuals [5CD + 3UC].  (C) Phospho-p38/p38 
as average response by each patient to all curcumin concentrations 5-20µM. 
B 
C 
p = 0.0078 
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 Median phospho-p38/p38 
densitometry 
Inter-quartile 
range 
p 
value 
Vehicle 
control 
2.55 1.7-5.7 0.0078 
Curcumin 1.50 1.0-4.9 
 
Table 6.1 Statistics describing figure 6.1C.  Wilcoxon matched pairs test shows significant 
difference between the two groups. 
 
p38 MAPK plays a central role in inflammatory signalling, and is known to be 
inhibited by curcumin in various cell types [346] [347] [348].  It was therefore a 
candidate mechanism for the IL-1β suppression we observed in intestinal mucosal 
tissue and mononuclear cells (Chapters 4.0 and 5.0).  We hypothesised that 
curcumin may suppress inflammatory cytokine release by inhibition of p38 MAPK.  
To our knowledge this is the first work to examine the effect of curcumin on p38 
MAPK in ex vivo intestinal mucosal tissue in IBD. 
 
Because of the high spontaneous activation of p38 MAPK in active IBD, and since 
we are investigating curcumin as a potential therapy for IBD, we chose to study 
material from patients with active disease, placing a similarly inflamed specimen in 
vehicle control conditions alongside every experiment as an internal negative 
control.  We found a marked and significant reduction in activation 
(phosphorylation) of p38 MAPK with curcumin, of 42% overall in intestinal tissue 
from patients with active IBD.  This is a potential mechanism by which curcumin 
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reduces the expression of downstream pro-inflammatory cytokines such as IL-1β in 
the inflamed gut mucosa.   
 
The specific p38 MAPK inhibitor SB203580 blocks the pathway by competing for 
adenosine triphosphate (ATP) in the active pocket of the enzyme [345].  The 
inhibition of p38 MAPK phosphorylation seen with curcumin in intestinal mucosal 
biopsies occurs by a mechanism remaining as yet obscure, and may involve 
upstream elements in the p38 MAPK signalling pathway.  In contrast to the near 
total inhibition seen with SB203580 in figure 6.0B, the inhibition of p38 MAPK 
which we observed with curcumin was incomplete, and we therefore conclude that 
the effects of curcumin in the human intestinal mucosa in IBD are in part p38 
MAPK-dependent.  Curcumin is a biologically complex molecule, and it is likely 
that its anti-inflammatory effects occur through multiple mechanisms. 
 
 
6.3 Effect of Curcumin on Nuclear Factor-κB 
Activation in ex vivo Intestinal Mucosal Tissue 
 
In Chapters 4.0 and 5.0 we studied mucosal tissue biopsies and mononuclear cells 
from children and adults with active IBD and treated them in vitro with curcumin.  
We showed favourable modulation of the cytokine profile with enhanced IL-10 
production and reduced IL-1β.  Seeking a mechanistic explanation for the reduced 
expression of IL-1β observed with curcumin in intestinal mucosal tissue and 
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LPMC’s we first assessed the p38 MAPK signalling pathway in the inflamed 
intestinal mucosa in IBD (Chapters 6.1 and 6.2).  We showed that curcumin 
inhibited p38 MAPK activation and concluded that the IL-1β suppression is in part 
p38-MAPK dependent.   
 
As curcumin has been shown in some cell types to suppress the NF-κB signalling 
pathway [167] [168], we next proceeded to examine whether NF-κB suppression 
also played a role in the downstream anti-inflammatory effects of curcumin upon 
cytokines which we observed in the inflamed human gut mucosa.  We hypothesised 
that both the enhanced IL-10 and the reduced IL-1β observed with curcumin may 
be mediated via a NF-κB-dependent mechanism.  We found no evidence to suggest 
a change in either the nuclear p65 subunit or cytosolic IκB in ex vivo tissue cultures 
from paediatric patients with active IBD (Figure 6.3).  All patient details and 
individual results can be found in the Appendix. 
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Figure 6.3 There is no evidence of reduced NF-κB activation with curcumin in 
intestinal mucosal biopsies from children with active inflammatory bowel disease.  (A) 
Western blot from a single representative experiment showing nuclear p65 subunit and 
histone H1 loading control with corresponding cytosolic IκB and β-actin loading control in a 
Crohn’s disease (CD) biopsy.  (B) Data from all nuclear p65 experiments [n=4 (3CD + 
1UC)].  Error bars represent standard errors of the mean.  
 
The NF-κB signalling pathways and their importance in inflammation and IBD are 
described in detail in Chapter 1.2.3, and illustrated in Figure 1.3.  As explored in 
Chapter 1.4.4, curcumin inhibits NF-κB activation in a number of different models.  
This is the first study to our knowledge in ex vivo human intestinal mucosal tissue 
culture.  We show no clear difference in NF-κB activation in response to curcumin.  
It may be that in inflamed human gut, NF-κB signalling is not a relevant 
mechanism by which curcumin exerts its anti-inflammatory effects.   
 
Alternatively we consider the possibility that in our experimental model we were 
unable to show effectively the NF-κB inhibition which would occur with curcumin 
in the in vivo state.  Immunoblotting may be a technique of insufficient quantitative 
sensitivity to demonstrate partial changes in elements within the NF-κB pathway.  
p = NS 
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Or it is possible that, in a disease model which relies on complex tissue samples 
such as an intestinal mucosal biopsy, and in the presence of multiple potential 
bacterial and other inflammatory mediators in culture, we were unable to isolate or 
observe a true effect of curcumin upon NF-κB signalling.  This was one of the 
reasons for which, in the absence of a steady clinical supply of LPMC’s, we 
decided to proceed to a different reductionist experimental model to further 
examine the effects of curcumin in IBD. 
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7.0 Effects of Curcumin on Colonic 
Myofibroblasts from Patients with Active 
Inflammatory Bowel Disease 
 
We hypothesised that curcumin would decrease MMP-3 production; a key 
contributor to tissue destruction in IBD; and that this effect may be acetylation-
dependent.  We first measured in vitro MMP-3 production by colonic 
myofibroblasts (CMF) from patients with active IBD, cultured with curcumin.   
 
 
7.1 Curcumin reduces Matrix Metalloproteinase-3 
Production by Colonic Myofibroblasts in a Dose-
Dependent Manner 
 
Whilst an intestinal biopsy is a good model of true disease, it consists of many 
different cell types, in variable and different proportions in each biopsy.  We 
wished to study the effect of curcumin on a single key component, whilst still 
retaining the active IBD phenotype and not reverting to more distant cell lines.  
Following the issues with clinical supply of LPMC’s as described in chapter 5.0, 
we sought another alternative relevant cell type in IBD for in vitro study.  We 
therefore next chose to examine colonic myofibroblasts (CMF).  These are key 
 175 
stromal effector cells in IBD, and are amenable to in vitro culture directly from a 
patient with active disease.  Furthermore, because this cell type divides in vitro it is 
possible to culture primary CMF from much smaller pieces of surgically resected 
intestinal tissue than the minimum size required to obtain LPMC’s.  This solved the 
supply problem associated with running LPMC experiments.  Myofibroblasts do 
not express IL-1β or IL-10, but play an active role in IBD, expressing MMP-3 on 
stimulation with TNF-α. 
 
We found that curcumin suppressed MMP-3 production in TNF-α-stimulated CMF 
from patients with active IBD and the response was clearly dose-dependent (Figure 
7.1).  All patient details and individual results can be found in the Appendix. 
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Figure 7.1 Curcumin decreases matrix metalloproteinase (MMP)-3 production in 
colonic myofibroblasts (CMF) from patients with active inflammatory bowel disease.  (A) 
Western blot from a single representative experiment in Crohn’s disease (CD) CMF.  (B) Data 
from all experiments [n=7 (5CD + 2UC)].  Error bars represent standard errors of the mean.  
Because MMP-3 is measured in CMF supernatants, equal loading is controlled through the 
seeding of equal cell numbers in each culture well (3x105) and equal volume supernatant (15μl) 
in each electrophoresis well. 
 
This work shows for the first time in human intestinal stromal cells a dose-
dependent suppression of MMP-3 with curcumin (Figure 7.1).  This finding holds 
p = 0.016 
 177 
clear clinical relevance for the therapeutic potential of curcumin in limiting tissue 
damage and disease progression in IBD. 
 
CMF are intestinal stromal cells which, in health, produce low levels of matrix 
metalloproteinases (MMP) that remain largely in latent form.  They effect 
physiological cell turnover and promote wound healing.  In IBD, CMF over-
express MMP’s, which become activated in cascades causing unchecked tissue 
destruction and fibrosis.  In addition to this well documented role, it is increasingly 
recognised that CMF are also immunologically active cells.  They respond directly 
to bacterial products by up-regulating expression of TLR and CARD15 [349], they 
over-express TNF-α in CD [350] and the MMP’s produced by CMF increase 
immune cell activation and homing to the gut [214, 351].  MMP-3 enhances 
chemotaxis by intestinal epithelial cells to neutrophils in the gut via the chemokine 
CXCL7 (neutrophil activating peptide 2) [352].  CXCL7 is a potent neutrophil 
chemokine and is released by intestinal epithelial cells when MMP-3 
proteolytically cleaves platelet basic protein.  Furthermore myofibroblasts are 
required to maximise this intestinal epithelial chemokine signalling pathway, as 
demonstrated by activated CCD-18 (fibroblast) and CaCo2 (epithelial cell) co-
culture experiments [352]. 
 
There are over 20 different types of MMP, which are sub-classified according to 
the primary stromal substrate upon which they act (eg collagenases: MMP-1, -8, -
13, 18; elastases: MMP-12; and stromelysins: MMP-3, -7, -10, -11).  They are zinc-
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dependent endopeptidases which as a family are capable of degrading all types of 
extracellular matrix proteins [353].  In addition to this function, as mentioned above 
they also activate or degrade a number of other non-mesenchymal substrates 
including immunologically active proteins such as chemokines and cytokines [352] 
[351].  Their activity is closely regulated at multiple levels, including by 1:1 
inactive complex formation with endogenous tissue inhibitors of MMP (TIMP’s).  
Many MMP’s are over-expressed both in animal models of colitis and in human 
IBD, in seeming proportion to disease activity [354].  MMP-3 and -9 are the most 
consistently raised in different models of IBD, and are perhaps the most extensively 
studied to date. 
 
Thus CMF are an important cell type in IBD, involved in multiple aspects of 
disease evolution.  Furthermore unlike LPMC’s, CMF may be grown in primary 
culture in from patients with IBD, making them an ideal model for further study.   
 
CMF, although responsive to cytokines [355], do not themselves produce IL-1β or 
IL-10, as indicated by an absence of reports in the literature and confirmed in our 
laboratory.  We measured IL-1β and IL-10 in CMF supernatants, both TNF-α-
stimulated and unstimulated, and found minimal or no cytokine production.  Instead 
we examined MMP-3 (stromelysin-1) as a measure of CMF activation.  Curcumin 
has been shown to down-regulate MMP production in various cell types [192] 
[193], including recently MMP-9 in CaCo2 cells [356].  This latter work shows a 
dose-dependent response similar to our present results.  The effects of curcumin on 
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MMP’s are explored in greater detail in chapter 1.3.10.  Here we have concentrated 
on MMP-3 (stromelysin-1), whose importance in IBD has been clearly 
demonstrated.  MMP-3 is over-expressed in LPMC’s [354] and biopsies [357] from 
patients with CD, and a polymorphism in the MMP-3 gene promoter (causing 
increased MMP-3 production) is associated with increased susceptibility to CD 
[358].   
 
The effect of curcumin to decrease MMP production in the gut, as well as limiting 
tissue destruction, could reduce influx of activated leukocytes into inflamed gut 
tissue.  Theoretical evidence for this comes from cell line studies as described 
above, showing that MMP’s cause production of chemotactic factors and tissue-
specific homing of activated leukocytes into various tissues [214, 351, 352].  
Specific evidence that curcumin can indeed reduce the homing of leukocytes into 
inflamed gut comes from a recent study in which curcumin suppressed TNF-α- and 
LPS-induced vascular cell adhesion molecule (VCAM)-1 expression in human 
intestinal microvascular endothelial cells (HIMEC), and attenuated leukocyte 
adhesion to stimulated HIMEC’s [359].  These data support that the present finding 
of reduced MMP-3 production by CMF represents an important therapeutic role for 
curcumin in IBD; one which can result both in limitation of tissue damage and 
dampening of the excessive inflammatory and chemotactic response in vivo. 
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7.2 p38 Mitogen-Activated Protein Kinase is Not 
Significantly Affected by Curcumin in Colonic 
Myofibroblasts 
 
To seek a mechanistic explanation for the MMP-3 suppression observed with 
curcumin (Figure 7.1), we examined early (30 minute) and late (24 hour) p38 
MAPK activation in the CMF.  There was no difference between early and late 
samples.  Although we did observe a tendency towards decreased p38 MAPK 
activation with curcumin, the pattern was not clear or consistent (Figure 7.2).  We 
therefore conclude that curcumin does not significantly reduce p38 MAPK 
activation in TNF-α-stimulated ex vivo CMF from patients with active IBD.  This 
suggests that, in contrast to our mucosal tissue biopsy model (Chapter 6.2), p38 
MAPK signalling pathways are not of primary importance in the action of 
curcumin on stromal cells in IBD.  All patient details and individual results can be 
found in the Appendix. 
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Figure 7.2 p38 mitogen-activated protein kinase is not significantly affected by 
curcumin in colonic myofibroblasts (CMF) from patients with active inflammatory bowel 
disease.  (A) Western blot from a single representative experiment in ulcerative colitis (UC) 
CMF.  (B) Data from all experiments [n=5 (4CD + 1UC)].  Error bars represent standard 
errors of the mean. 
 
Unlike in our mucosal whole tissue system, in CMF curcumin had no clear effect 
on p38 MAPK activation.  Therefore the suppression of MMP-3 production by 
curcumin occurs largely through a p38 MAPK-independent mechanism.  To 
explain this discrepancy between biopsies and CMF, we postulate that the 
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inhibition of p38 MAPK signalling by curcumin in IBD occurs largely in cells of 
the immune system such as lymphocytes, macrophages, monocytes and dendritic 
cells, rather than in fibroblasts.  These cell types (which cannot without 
transformation be grown in successive passages in vitro) are richly found in 
intestinal mucosal biopsies.   
 
Indeed the contradictory effects of curcumin, on MAPK and other targets, are well 
documented in the literature and are addressed in detail in chapter 1.3.5.  Under 
some circumstances curcumin inhibits MAPK activation, as in a recent study using 
a primary human intestinal microvascular endothelial cell line, where curcumin is 
shown to inhibit p38 MAPK activation [172]; similarly curcumin is shown to 
inhibit JNK in Jurkat T cells (a human T cell line) [189].  Paradoxically other 
investigators show activation of MAPK by curcumin, for example of JNK in 
HCT116 cells, a human colon cancer cell line [190] and of p38 MAPK in primary 
human neutrophils [200].  Whilst curcumin has manifestly opposing effects on 
MAPK signaling pathways, in both cases the ultimate biologic outcomes are anti-
neoplastic and anti-inflammatory, and it appears that mechanisms vary according to 
cell and disease system, and even dose.  Thus curcumin is shown in some 
environments to activate MAPK signalling, with the biologic consequence of 
apoptosis; and elsewhere to inhibit MAPK signalling, where the consequences are 
anti-inflammatory and anti-angiogenic. 
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We also note that the p38 MAPK response by CMF to TNF-α stimulation (Figure 
7.2) was less pronounced than the MMP-3 response after the same stimulus (Figure 
7.1).  This further suggests that p38 MAPK pathways are not of primary relevance 
in gut mucosal fibroblasts as they are in cells of the mucosal immune system such 
as LPMC’s, and may explain why p38 MAPK signalling was affected by curcumin 
in these classic inflammatory cells and tissues but not in CMF. 
 
 
7.3   Nuclear Factor-κB Signalling is Not Significantly 
Inhibited by Curcumin in Colonic Myofibroblasts 
 
In light of previous reports on the mechanism of action of curcumin in other cell 
types [167] [168], we next proceeded to investigate whether the response of CMF 
to curcumin was NF-κB-dependent.  To this end we employed two separate 
methods; immunofluorescent staining and Western blotting.  By immunostaining 
we confirm successful ex vivo activation of CMF using TNF-α, with translocation 
of NF-κB p65 from the cytoplasm into the nuclei (Figure 7.3A).  Similarly to our 
earlier data on NF-κB in biopsies (Figure 6.3), we found no clear difference in NF-
κB nuclear translocation with curcumin in CMF (Figure 7.3A).  By Western blot 
we show only a small decrease in nuclear p65 with curcumin (Figures 7.3B and C).  
We conclude that while NF-κB signalling may be marginally inhibited by 
curcumin, this is not the primary mechanism through which it inhibits MMP-3 
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expression in CMF.  All patient details and individual results can be found in the 
Appendix. 
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Figure 7.3 NF-κB signalling is not significantly affected by curcumin in colonic 
myofibroblasts (CMF) from patients with active inflammatory bowel disease.  (A) 
Immunofluorescent staining of Crohn’s disease (CD) CMF for DAPI (nuclei) and NF-κB p65 
subunit; single representative experiment shown.  (B) Western blot from a single 
representative experiment showing nuclear p65 and histone H1 loading control.  (C) Western 
blot data from all experiments [n=3 (2CD + 1UC)].  Error bars represent standard errors of 
the mean.  
 186 
Curcumin did not significantly affect NF-κB signalling either in colonic mucosal 
biopsies (Figure 6.3) or CMF (Figure 7.3) from patients with active IBD.  
Therefore in the inflamed gut mucosa the actions of curcumin do not appear to be 
primarily NF-κB-dependent.  This finding is consistent and reproducible in both 
biopsy and CMF disease models.  Whilst it could be a reflection of the limitations 
of ex vivo models of disease, it is verified by two different experimental methods, 
Western blot and immunofluorescence.  It does suggest that neither the cytokine 
modulation nor the suppression of MMP-3 production in the inflamed gut mucosa 
by curcumin depend on NF-κB inhibition, and therefore a separate mechanism is in 
operation.   
 
 
7.4 The Suppression of Matrix Metalloproteinase-3 
Production in Colonic Myofibroblasts by Curcumin 
May Be Acetylation-Dependent 
 
7.4.0 Immunoblotting for p300 Acetyl Transferase 
 
In further pursuit of a mechanistic explanation for the MMP-3 suppression 
observed with curcumin (Figure 7.1), we next considered curcumin’s known 
potency as an inhibitor of acetylation.  We wished to demonstrate changes in the 
acetylation status of p300 acetyl transferase, a ubiquitous catalyst of acetylation, an 
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enzyme known to be involved in MMP production and an established target of 
curcumin (explored in more detail in Chapters 1.2.9 and 1.4.11).  Due to the large 
molecular weight of the protein (300kDa) and technical aspects concerning the 
sensitivity of the primary antibody, during optimisation of the Western blot it 
became apparent that in our experimental system the technique would be unfeasible 
(Chapter 2.3.3).  In order to obtain sufficient protein to yield a usable signal for 
p300, we were obliged to use several million CMF in each culture condition, a 
factor of ten higher than in all other experiments.  To grow this quantity of cells, 
multiple passages were required, producing unreliable yields of CMF which were 
further removed from the active IBD phenotype.  As well as the technical problems 
associated with attempts to obtain such numbers of cells, it has been shown by 
other investigators in our lab, and published by other groups, that CMF display 
significantly altered features of senescence at high passages, and this impacts 
greatly on their behaviour and function [360].  For this reason we decided that other 
avenues of investigation would be more fruitful. 
 
 
7.4.1 The Acetylation Inhibitor Anacardic Acid Suppresses 
Matrix Metalloproteinase-3 in a Dose-Dependent Fashion 
which Mirrors that Seen with Curcumin  
 
We then employed another method to address the possibility that curcumin’s effect 
on MMP-3 was due to its properties as an acetylation inhibitor.  We treated TNF-α-
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stimulated CMF with a different inhibitor of acetylation, anacardic acid.  Anacardic 
acid is, like curcumin, a naturally occurring plant-based substance, in this case 
found in cashew nut shell liquid.  Like curcumin, it is a non-competitive inhibitor 
of p300 acetyl transferase, a ubiquitous catalyst of acetylation [303] with no other 
reported regulatory effects such as MAPK or NF-κB modulation.  Anacardic acid 
suppressed MMP-3 production in TNF-α-stimulated CMF from patients with active 
IBD, in a dose-dependent manner (figures 7.4A and B) which closely mirrored that 
seen with curcumin.  This suggests that in CMF both compounds are acting via a 
mechanism dependent on their ability to inhibit acetylation.  All patient details and 
individual results can be found in the Appendix. 
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Figure 7.4 Anacardic acid (AA) suppresses MMP-3 production in colonic 
myofibroblasts (CMF) from patients with active inflammatory bowel disease.  (A) Western 
blot from a single representative experiment with AA in Crohn’s disease (CD) CMF.  (B) AA 
data from all experiments [n=7 (5CD + 2UC)].  Error bars represent standard errors of the 
mean.  
 
There is some published evidence that MMP production is p300 acetyl transferase-
dependent.  This is shown (for MMP-9) in a rat astrocyte model [361] and in mouse 
macrophages [362].  The substrate for acetylation remains obscure but in this latter 
model the authors show evidence of chromatin modification (acetylation of 
histones).  Further evidence for TNF-dependent MMP-9 production requiring 
histone acetylation comes from a human tracheal smooth muscle cell model [363], 
a process which interestingly in this work is indeed blocked by curcumin.  
p = 0.031 
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Furthermore, our group has previously shown upregulation of MMP-3 in human 
fetal intestinal mesenchymal cells by butyrate, a histone deacetylase (HDAC) 
inhibitor [108].  
 
To examine this possibility we tested another known inhibitor of acetylation 
anacardic acid in the same experimental system.  Anacardic acid has a very similar 
mode of action to curcumin, in that both compounds are reversible non-competitive 
inhibitors of p300 acetyl transferase, acting at a site remote from the active site of 
the enzyme [303]; this is the only known biological property of anacardic acid and 
the only known shared property of the two substances.  There is no previously 
published work on anacardic acid in the human gut.  The finding of a dose-
dependent pattern of MMP-3 suppression with anacardic acid in CMF, which 
parallels that seen with curcumin, supports the hypothesis that the effect is 
acetylation-dependent.   
 
 
7.4.2 The Pro-acetylating Agent Trichostatin A Enhances Matrix 
Metalloproteinase-3 Production and this is Abrogated by 
Both Curcumin and Anacardic Acid 
 
To examine the role of acetylation further, we used the well-established inhibitor of 
histone deacetylase (HDAC) trichostatin A (TSA), which is therefore a pro-
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acetylating agent [364].  In agreement with our earlier data (figure 7.1), we 
confirmed the upregulation of MMP-3 with TNF-α, and the suppression of this 
effect by curcumin; we also demonstrated that TSA up-regulated MMP-3 (figure 
7.5).  This upregulation was almost totally abrogated by both inhibitors of 
acetylation curcumin and anacardic acid (figure 7.5).   
 
 
Figure 7.5 Responses of Crohn’s disease (CD) colonic myofibroblasts (CMF) to 
tumour necrosis factor (TNF)-α, trichostatin (TS) A, curcumin and anacardic acid.  TSA 
enhances matrix metalloprotein (MMP)-3 production in CMF from patients with active CD 
and this is abrogated by both curcumin and anacardic acid.   
 
The HDAC’s are a family of enzymes which, in balance with the histone acetyl 
transferases, regulate the acetylation status of histone proteins within chromatin, 
playing an important epigenetic role in gene transcription, and thus have a 
ubiquitous role in cellular processes in health and disease.  Just as other non-histone 
proteins within the cell are now known to be subject to (reversible) acetylation, it is 
also becoming clear that the substrates of HDAC enzymes are not limited to 
histones either, but include a number of transcription factors, signal transducers and 
other proteins [365].  TSA was originally discovered as a product of 
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microorganisms.  It is antifungal and inhibits the eukaryotic cell cycle, and it is a 
potent and selective inhibitor of HDAC’s.  TSA is not stable in vivo and therefore 
its use has been primarily as an important tool in the understanding of epigenetic 
regulation and protein acetylation.   
 
Taken together, the findings displayed in figures 7.4 and 7.5 suggest that MMP-3 
production in CMF occurs at least in part through an acetylation-dependent 
mechanism, and that its suppression by curcumin relates to curcumin’s known 
potency as an inhibitor of p300 acetyl transferase [178] [179]. 
 
 
7.4.3 Butyrate Enhances Matrix Metalloproteinase 3 Production 
and this is Abrogated by Anacardic Acid but not Curcumin 
 
TSA is a strong HDAC inhibitor, and as a pro-acetylating agent it a useful 
experimental tool.  Butyrate is a naturally occurring HDAC inhibitor, present in 
significant concentrations in the human gut lumen.  Butyrate, acetate and 
propionate are the main short chain fatty acids (SCFA) produced by bacteria in the 
colon.  In light of the results obtained with TSA (Chapter 7.4.2) we wished finally 
to examine the response of fibroblasts to butyrate.  Because of the clinical 
relevance of butyrate and its relationship to TSA, this was a logical final step within 
this work.   
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We again confirmed successful upregulation of MMP-3 production by TNF-α, and 
we showed that butyrate, like TSA, also enhanced MMP-3 expression (Figure 7.6).  
There was no difference observed between the two butyrate doses applied, 5 and 
20mM.  The butyrate concentrations were chosen on the basis of in vitro work 
previously published in the field and also upon the evidence that usual clinical 
butyrate concentrations in the faecal stream range from 0 to approximately 20mM 
[366, 367].  The upregulation of MMP-3 by butyrate was partially abrogated by the 
acetylation inhibitor anacardic acid, in a similar (yet less complete) fashion to its 
abrogation of TSA-mediated MMP-3 production (Figure 7.5).  Conversely the 
addition of curcumin alongside butyrate caused MMP-3 production to increase yet 
further (Figure 7.6). 
 
 
Figure 7.6 Responses of Crohn’s disease (CD) colonic myofibroblasts (CMF) to 
tumour necrosis factor (TNF)-α, butyrate, curcumin and anacardic acid.  Butyrate enhances 
matrix metalloprotein (MMP)-3 production in CMF from patients with active CD and this is 
patially abrogated by anacardic acid but not by curcumin.   
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In agreement with previously published work showing increased histone acetylation 
and upregulation of MMP-3 production in human foetal small intestinal mucosal 
mesenchymal cells by both butyrate and TSA [108], we showed that TSA enhanced 
MMP-3 production by CMF (Figure 7.5), and butyrate reproduced this effect 
(Figure 7.6).  Butyrate and TSA are pro-acetylating agents.  They both increased 
MMP-3 production and this effect directly opposed that of the two inhibitors of 
acetylation curcumin and anacardic acid, which decreased MMP-3 production 
(Figures 7.1 and 7.4).  This is therefore suggestive of, but not conclusive for, an 
acetylation-dependent mechanism of action upon MMP-3 production by CMF.  
Furthermore the acetylation potency of TSA is approximately 1000 fold greater 
than that of butyrate [108], a fact consistent with the observation that TSA at 
micromolar concentration appeared to enhance MMP-3 production more strongly 
than butyrate at milimolar concentration, even allowing for the semi-quantitative 
nature of Western blot protein estimation. 
 
Why anacardic acid abrogated the butyrate-mediated increase in MMP-3 and 
curcumin did not, remains unexplained.  Whilst the only known biochemical 
properties of TSA and anacardic acid are pro- and anti-acetylation respectively, 
both butyrate and curcumin are known to be much more complex molecules with 
many and varied biological actions.  The complexity of curcumin has already 
largely been discussed.  It may be that where curcumin and butyrate interact, some 
of these wider mechanisms come into play and the situation no longer depends upon 
straightforward acetylation alone, or perhaps depends on acetylation of different 
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nuclear or cellular targets in changing relative contribution.  This could explain why 
simple abrogation is not seen, but the mechanism(s) behind the interaction remain at 
present a matter for surmise. 
 
Butyrate is a short chain fatty acid (SCFA) and a major fermentation product of the 
metabolism of dietary (largely soluble) fibre by colonic bacteria.  It is therefore an 
important component of the luminal environment, and is the direct product of a key 
interaction between nutrition and the host bacterial flora.  As well as being the most 
potent HDAC inhibitor of all the colonic SCFA’s [111], it is a nutrient in its own 
right and has varied biological effects.  Its interactions with the host are complex 
and its mechanisms not fully elucidated, but there is evidence that it modulates 
inflammation in the human gut and reprograms colonic epithelial cells, inducing 
differentiation, cell cycle arrest and apoptosis [368].  Whether some or all of these 
actions are a result of its HDAC inhibiting activity is not clear.  Butyrate levels 
vary considerably throughout life and alter in response to bacterial flora and 
substrate composition.  Levels are very low at birth and rise to adult levels by the 
age of two years [369].  Bottle fed babies have much higher butyrate levels in the 
gut than breast fed babies, for unknown reasons [369].   
 
Butyrate increases IL-8 secretion and decreases mast cell protein (MCP)-1 in 
intestinal epithelial cells, and these effects are much more pronounced in LPS- or 
IL-1β-stimulated cells [370].  Butyrate therapy shows anti-inflammatory effects in 
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preclinical models [371] and when administered topically in some clinical trials in 
UC [372, 373]; but not in CD, where luminal butyrate concentrations are raised 
[374].  In UC its beneficial effects appear to be limited to the initial six months of 
disease duration, during the early phase of epithelial cell disruption when it seems 
to improve mucosal barrier function [373].  In other clinical trials in UC, including 
well conducted controlled trials on patients with more established disease, butyrate 
therapy did not show benefit [375, 376]. 
 
The mechanisms behind the actions of butyrate are incompletely understood.  One 
group has studied its effects on cytokine production in PBMC’s.  In Staphylococcus 
aureus- or anti-CD3-stimulated human PBMC’s it enhanced IL-4 and IL-10 
production and decreased IL-12 and IFN-γ [377].  The effects on IL-12 were 
unchanged by the addition of anti-IL-10 antibodies, suggesting that its inhibition of 
IL-12 is independent of IL-10 suppression.  It is difficult to explain these differing 
effects on cytokine expression through acetylation alone, unless it is acting on 
promoters or repressors as well as upon histones.  In porcine concanavalin A-
stimulated PBMC’s butyrate increased IL-2 and IFN-γ secretion and mRNA levels 
[378].  Interestingly in this work, low dose butyrate enhanced IL-10 production 
whilst high dose butyrate paradoxically decreased it.  The investigators also show 
that butyrate increased production of suppressor of cytokine signalling (SOCS)3, a 
negative regulator of cytokine signalling, induced by, among other factors, IL-10.  
Addition of an adenyl cyclase inhibitor abolished some of the effects of butyrate, 
suggesting that these may be cyclic adenosine monophosphate (cAMP)-dependent.   
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As well as these mixed effects on cytokines there is evidence that butyrate inhibits 
carcinogenesis, reduces oxidative stress and strengthens the colonic mucosal 
defence barrier, possibly by improving the mucous layer [379].  The mechanisms 
underlying these effects remain unclear.  Most of this work comes from animal and 
cell culture work.  Human interventional trials of butyrate have to date centred on 
its use in various types of intestinal inflammation, some of which have been 
described above.   
 
Using microarray technology one group has compared the genetic reprogramming 
which takes place in an in vitro model of the colonic epithelium in response to 
butyrate, TSA and curcumin [368].  They showed that responses to butyrate were 
highly complex, involving recruitment of multiple different sequences of genes 
which show transient or more sustained increases or decreases over different time 
periods.  The responsive genes included those involved in signal transduction, cell 
cycling, cell maturation and apoptotic pathways.  The large number of genes 
recruited, their wide variation in function and their altered responsiveness over time 
imply that colonic epithelial reprogramming in response to butyrate is a complex 
and highly orchestrated sequence of events.  In contrast the changes induced by 
TSA were more limited and transient with no expansion or decrease with time.  
There were small clusters of genes which exhibited similarity of response to all 
three compounds; with greater overlap between butyrate and TSA, implying that 
these genes were regulated by their shared mechanism of HDAC inhibition.  
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However the more striking finding was how different the responses were; even 
between butyrate and TSA.   
 
Thus to view curcumin and butyrate as simple opposites, or butyrate and TSA as 
wholly analogous, is clearly an over-simplification, as acetylation is not their only 
property, and the multiple biological actions of both compounds are not yet fully 
understood.  This may explain the discrepancy within the results in Figure 7.6 and 
the differing actions of curcumin and anacardic acid observed with butyrate. 
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8.0 Discussion 
 
We have shown in the in vitro setting that curcumin favourably modulates the 
intestinal mucosal cytokine profile, with enhanced IL-10 production and reduced 
IL-1β.  These data were derived predominantly from colonic mucosal tissue biopsy 
work, using exclusively tissue taken from children with active IBD.  As such a 
major strength is the proximity of the experimental model to the true clinical 
disease situation.  Equally similar to the in vivo reality, this approach yielded a 
model with natural intrinsic complexity.  The inflammatory pathways at play in 
IBD are multiple and interconnected, and our tissue explant disease model provided 
a true echo of this.  Therefore we experienced wide inter-individual variability in 
cytokine production and in response to curcumin as a potential therapeutic agent.  
Once again these outcomes mirror the clinical experience of variability of response 
to treatments between individuals.  To overcome these factors we tested samples 
from a relatively large number of children and demonstrated a statistically 
significant increase in IL-10, a significant decrease in IL-1β and no significant 
change in IFN-γ. 
 
These findings are in keeping with our original hypothesis that curcumin, as an 
inhibitor of acetylation, enhances binding of the transcription factor Sp3 to the IL-
10 gene promoter, decreasing IL-10 transcription.  We demonstrated that the rise in 
IL-10 with curcumin was an effect particular to that cytokine, and not shared by its 
effects upon IL-1β or IFN-γ.  This neither proves nor disproves our hypothesis in 
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mechanistic terms; however as well as being consistent with our hypothesis it 
provides strong evidence that curcumin exerts beneficial effects in the intestinal 
mucosa in IBD.   
 
Also in ex vivo intestinal mucosal tissue from children with active IBD we have 
shown that curcumin reduces p38 MAPK activation.  Thus we have shown that 
curcumin inhibits p38 MAPK signalling and we have shown that curcumin 
decreases IL-1β expression.  This suggests that its downstream suppression of IL-
1β expression is at least in part p38 MAPK dependent.  The ability of curcumin to 
inhibit p38 MAPK is additionally relevant to the study of a potential therapeutic 
agent in IBD, since p38 MAPK is a key orchestrator of the inflammatory response, 
is consistently elevated in IBD and is of central importance to the pathogenesis of 
the disease. 
 
The experiments which we performed on LPMC’s from patients with active IBD 
yielded data in accordance with that derived from our work on intestinal mucosal 
biopsies; we showed a trend towards decreased production of both inflammatory 
cytokines IL-1β and IFN-γ.  If we had had access to a greater clinical supply of 
LPMC’s we would have hoped to be able to demonstrate statistically significant 
results in parallel with our tissue culture findings, and perhaps with greater 
consistency and less inter-individual variability.  In the absence of LPMC 
availability we examined the IL-10 responses of PBMC’s to curcumin.  We showed 
a consistent and reproducible bell-shaped response to curcumin, with enhanced IL-
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10 production at low curcumin concentrations and decreased production at high 
concentrations.  The paradoxical effects of curcumin at low versus high dose have 
been described by other groups [342] [222] and remain unexplained.  We propose 
the hypothesis that at low dose, inhibition of acetylation of Sp3 predominates, with 
consequent release of the IL-10 promoter to specific gene transcription; whilst at 
high dose, generalised inhibition of histone acetylation predominates, with 
widespread reduction in access to DNA for generalised gene transcription.   
 
The applicability of PBMC data to intestinal inflammation is uncertain and we did 
not attempt to extrapolate our PBMC findings in this way.  Without further access 
to supplies of LMPC’s we refined the isolation of colonic mucosal myofibroblasts 
(CMF) from surgically resected specimens of actively inflamed gut from patients 
with IBD.  In this way we obtained a dependable supply of activated primary 
intestinal cells which play an important role in the pathogenesis of IBD, and are 
amenable to in vitro growth.  In CMF we have demonstrated inhibition of matrix 
metalloproteinase (MMP)-3, an important contributor to tissue destruction, immune 
activation and leukocyte recruitment in IBD, by curcumin.  Perhaps because this 
disease model employed a single cell type only, we obtained results of much 
smaller variability, greater reproducibility and clear dose-responsiveness.   
 
We demonstrated that the inhibition of MMP-3 production by curcumin in CMF 
occurs via NF-κB- and p38 MAPK-independent pathways.  Thus our data show that 
curcumin inhibits p38 MAPK in intestinal mucosal tissue, but not in intestinal 
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mucosal fibroblasts.  In explanation we propose that MAPK signalling is a critical 
mechanism in mediating IL-1β production and other cytokine cascades, occurring 
largely in classic immunologically active cells such as lymphoctyes, which are 
richly found in mucosal biopsies.  On the other hand, regulation of MMP 
production in myofibroblasts is not yet well understood, and we suggest that 
MAPK signalling as an intermediary mechanism is relevant to a much lesser extent 
in stromal cells.  In support of this hypothesis, we show a less complete activation 
of p38 MAPK upon TNF-α stimulation of CMF (Figure 7.2), compared with the 
strong MMP-3 response seen upon TNF-α stimulation of CMF (Figure 7.1).  
Furthermore, p38 MAPK activation is very clearly relevant as an inflammatory 
signal in intestinal mucosal biopsies, where we show a strong degree of activation 
in IBD samples compared with healthy controls (Figure 6.1A). 
 
We have shown evidence that these effects of curcumin are at least partially 
dependent on its power to inhibit protein acetylation (p300 acetyl transferase) in the 
intestinal mucosa.  The inhibitor of acetylation anacardic acid produced a dose-
dependent MMP-3 response in CMF which closely mirrored that seen with 
curcumin.  Anacardic acid and curcumin are both plant-based non-competitive 
inhibitors of p300 acetyl transferase.  This is the only known biological property of 
anacardic acid and the only known shared property of the two compounds.  The 
pro-acetylating agents trichostatin A (TSA) and butyrate produced the opposite 
effect, increasing MMP-3 production by CMF.  TSA is a more potent acetylator 
than butyrate by approximately 1000 fold, and TSA enhanced MMP-3 more 
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strongly than butyrate, at a 1000 fold lower concentration.  The TSA-mediated 
increase in MMP-3 was almost entirely abrogated by both curcumin and anacardic 
acid.  These findings do not constitute conclusive proof, but provide evidence 
strongly in support of the hypothesis that the action of curcumin upon CMF in the 
inflamed intestine is acetylation dependent. 
 
Our hypothesis that curcumin inhibits the acetylation of Smad 7 was rejected, since 
we showed no consistent alteration in Smad 7 levels (known to be controlled by its 
acetylation status) in intestinal mucosal tissue or LPMC’s with curcumin.  
Therefore we conclude that curcumin does not exert its effects in IBD through a 
Smad 7 dependent mechanism.  However this does not preclude the possibility that 
curcumin’s potency as an inhibitor of acetylation is relevant to its other actions in 
IBD.  Above we describe the evidence for its effects upon CMF being acetylation 
dependent.  Furthermore its effect to enhance IL-10 production in inflamed gut, and 
its effects upon IL-1β and IFN-γ which oppose this, are consistent with our original 
hypothesis that curcumin enhances IL-10 expression through a specific acetylation-
sensitive element in the IL-10 gene promoter.  Finally in PBMC’s we show once 
again a close mirroring of the actions of curcumin upon IL-10 by anacardic acid, 
suggesting that these occur through the only shared property of these two 
compounds, inhibition of acetylation. 
 
All tissues and cells used in this work were primary, human, and almost exclusively 
derived from children and adults with active IBD.  Thus our findings hold good 
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translational relevance and provide a strong basis for the development of clinical 
trials of curcumin in IBD.   
 
The curcumin concentrations used in this and other published work correspond to 
doses many fold higher than those found in the diet, even in Asian populations.  
Therefore whilst the potential benefit of curcumin at therapeutic dose is clear, this 
may not extend to dietary or population relevance.  The safety, tolerability and non-
toxicity of curcumin at doses many fold higher than dietary have been well 
established, and it is classified ‘Generally Recognized as Safe’ by the United States 
Food and Drug Administration.  Oral doses up to 12g per day have been well 
tolerated in humans [152].  There is also good evidence at a population level of the 
safety of lifelong curcumin ingestion up to about 100mg/day from India, where 
there is a very high natural dietary curcumin content [166].  The question of dose is 
especially relevant to the study of curcumin, which appears to be capable of 
paradoxical efficacy at low dose under some circumstances  [342] [165] [222]. 
 
In vitro concentrations such as those used in this work are probably considerably 
higher than serum or tissue concentrations that can be achieved in vivo through oral 
dosing in humans, due to the drug delivery and bioavailability issues previously 
described.  We have already highlighted some of the issues which must be 
considered when assessing the translational relevance of in vitro work to the in vivo 
situation.  The question of curcumin concentration in cell culture in relation to that 
achievable clinically is central to this and other preclinical studies of curcumin.  In 
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one human trial 3.6g of oral curcumin achieved plasma levels of 11.1nmol/L in 
humans [157]; a concentration a factor of 1000 lower than those we have used in 
vitro.  Other investigators however found peak human plasma levels of 0.41-
1.75μM after oral dosing of 4-8g of curcumin [153]; these are only a factor of ten 
lower than the concentrations we have used.  Due to the wide variability in 
pharmacokinetic data from different studies it is difficult to ascertain for certain the 
relationship between in vitro and in vivo curcumin dosing.  In retrospect we would 
have liked to study some much lower curcumin concentrations in our in vitro work.  
These would hold relevance to the human clinical situation and would also be 
interesting because of the evidence to which we have already alluded from in vitro 
and animal work that curcumin can have paradoxical high efficacy at low doses.   
 
There is no study to date of the use of curcumin in topical rectal formulation.  It 
may be that a rectal delivery would surpass many of the drug delivery, tissue 
concentration and hydrophobicity challenges described, and could certainly achieve 
curcumin concentrations in the colonic lumen equivalent to those studied in 
supernatants in our in vitro work. 
 
We conclude that curcumin holds promise as a novel therapy for children, 
adolescents and adults with IBD.  Curcumin is a complex molecule whose precise 
modes of action remain obscure, and it seems likely that its molecular targets differ 
according to cell and disease system.  However we conclude that its actions in the 
inflamed human gut in IBD are at least in part acetylation dependent. 
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9.0 Future Directions 
 
We have demonstrated that curcumin beneficially modulates the cytokine profile 
and reduces MMP-3 production in the inflamed human gut mucosa in IBD.  
Curcumin is a known inhibitor of acetylation and we have shown evidence to 
suggest that its effects in the human gut are at least partially acetylation-dependent.  
We would like to elucidate clear mechanism(s) for the effects of curcumin in IBD.   
 
Our attempts to measure p300 acetyl transferase (Chapter 7.4.0) have not so far 
been productive.  As a next step in this direction we would like to examine p300 
acetyl transferase expression in gut mucosal biopsies, from which a higher yield of 
tissue can be obtained.  This may require the use of a large electrophoresis system 
allowing much higher protein loading.  If this technique is successful, we would 
aim to demonstrate changes in p300 with curcumin.  This could be done alongside 
TSA as a positive (pro-acetylating) control.   
 
Such lines of study would seek to prove that curcumin is acting through its potency 
as an inhibitor of acetylation.  The substrate(s) for acetylation remain unknown.  A 
natural question would be whether histones are the substrate.  To answer this, 
nuclear histones could be extracted and separated electrophoretically on a Triton X 
acetic acid-urea gel.  After Coomassie blue staining, the histones could be 
visualised with a marker, and relative quantities of acetylated forms assessed.  This 
is similar to a method previously used by our group [108]. 
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As in our original hypothesis, non-histone proteins are also known to be subject to 
acetylation, and are involved in signalling processes relevant to inflammation 
(Chapter 1.2.7).  Since our results clearly indicate that curcumin increases 
production of IL-10, we would like to turn our attention to the mechanism behind 
this.  We have shown that curcumin’s effect on IL-10 is opposite to its effects on 
pro-inflammatory cytokines IL-1β and IFN-γ.  This result is consistent with our 
hypothesis that curcumin acetylates the transcription factor Sp3, which in turn 
binds to a specific site in the promoter region of the IL-10 gene, causing down-
regulation of IL-10 transcription (Chapter 1.2.10).  We would like to undertake 
further work to prove this hypothesis.  
 
Firstly we would examine whether this is due to a true increase in gene 
transcription, by measuring IL-10 mRNA by reverse transcriptase polymerase chain 
reaction (RT-PCR).  If the mRNA increases in parallel to the IL-10 protein it would 
confirm that the increase in IL-10 expression we observed is not due to post-
translational events.  We would then wish to construct luciferase reporter plasmids 
containing the IL-10 promoter and transfect them into an appropriate cell line such 
as a macrophage cell line (eg RAW 264), similarly to a previously published 
technique [129].  Using electrophoretic mobility shift assay (EMSA) we would aim 
to determine the binding of transcription factors to the IL-10 promoter.  Specifically 
we would seek to demonstrate the binding of Sp3 to the IL-10 promoter using an 
anti-Sp3 antibody, and to detect changes in this binding in the presence of 
curcumin.  A comparison using short interfering (si) RNA against p300 acetyl 
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transferase would be a valid strategy in such experiments, to prove that any effect 
of curcumin on Sp3 binding to DNA is due to its inhibition of p300.  Unfortunately 
such work is outside the capacities of the present fellowship, but would be an 
interesting direction in which to proceed given available time and resources. 
 
Finally it would be useful to build on our in vitro work with in vivo studies.  
Considerable evidence already exists in support of the efficacy of curcumin in 
preclinical animal models of IBD.  The clinical data however are much less 
complete at present.  Future clinical trials should include wide curcumin dosing 
ranges, including low dose, as there is evidence from several sources (including our 
work) that the efficacy of curcumin in relation to dosage may be paradoxical.  
Other clinical issues such as drug delivery should also be addressed in future 
patient trials.  Curcumin achieves particularly good local penetrance and tissue 
concentrations in the gut, and due to its hydrophobicity and rapid elimination, oral 
administration is associated with problems.  Therefore alternative formulations or 
routes of administration can be considered, such as rectal.  To date, fewer than 100 
patients with IBD have been involved in published trials of curcumin therapy.  
None of these are children.  In light of strong early evidence of benefit and good 
data on human safety, further clinical trials of curcumin in IBD are certainly 
warranted.   
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Appendix 1 
 
In Appendix 1 we include for reference some key demographic and clinical data on 
the patients who kindly donated clinical material to our study.  The (anonymised) 
origins of all of the biopsies and cells used in this work can be found below.  
Appendix 2 includes tables relating which patients’ materials were used in which 
experiments.  Our patient base reflects our clinical and epidemiological knowledge 
about IBD in childhood and adulthood.  We selected our patients based on (a) 
known or suspected, and subsequently histologically confirmed, active IBD; (b) 
ability and willingness to give informed consent; and (c) undergoing colonoscopy at 
the Royal London Hospital or bowel surgery at the Royal London or Homerton 
Hospitals.  Other than these criteria we were unselective, and approached all 
children and their families or adults presenting consecutively to our clinical unit, 
during the time periods that particular samples were required in the laboratory.   
 
We used in this work clinical specimens from 30 individuals.  21 of our patients 
were children (16 years of age or under; average age 12.6 years).  We used biopsies 
only from children since numbers of children undergoing colonoscopy were 
sufficient to achieve this (15/15).  However only six of the 15 surgical samples 
came from children, since the throughput of patients having bowel resections for 
IBD was relatively small and we were obliged to use samples from patients of all 
ages in order to obtain sufficient numbers.  The average age of the patients who 
donated surgical specimens of bowel was 26.4 years.  Overall ten patients had UC 
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and 20 CD.  This is consistent with known differences in the two disease 
incidences, and with the currently rising incidence of CD, especially in childhood 
and adolescence [2].  13 of the 30 patients were female (8 CD and 5 UC).  Of the 14 
children with CD, 5 of them were female.  This once again is consistent with the 
knowledge that whilst overall CD is commoner amongst women, in childhood it 
affects more boys than girls [1, 5].   
 
Nine of the 10 patients with UC had pancolitis, reflecting both the more severe 
phenotype seen in childhood [1], as well as our obligate selection of adult patients 
whose disease necessitated surgery.  The commonest affected sites in CD were as 
expected the terminal ileum and caecum.  The overall average age of our UC 
patients was 16 years; average age of CD patients was 20.9 years.  Of our paediatric 
patients, the average age of those with CD was 14.1 years, and the average age of 
those with UC was 9.6 years.  This in consistent with the epidemiological 
observation that UC can occur in younger children than CD.  Average C reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) were 18.3mg/l and 
23.8mm/hr respectively in patients with UC and 53.9mg/l and 34.3mm/hr in CD.  
This coincides with the expected higher systemic inflammatory state in CD 
compared with the relatively more localised inflammation limited to the colon in 
UC. 
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Patient Characteristics 
Patient 
Number 
Disease 
type 
Disease site Age  Sex Blood 
results 
Drugs Notes 
6315 UC Pancolitis 14 M CRP <5 
Hb 7.2 
Plt 253 
ESR 25 
- New 
diagnosis 
6316 CD Terminal 
ileum, 
caecum 
15 M CRP 10 
Hb 12.4 
Plt 454 
ESR 18 
- New 
diagnosis 
6317 CD Terminal 
ileum, 
caecum 
15 F CRP 19 
Hb 12.4 
Plt 415 
ESR 15 
Pentasa 
Azathioprine 
 
6319 CD Terminal 
ileum, 
colon 
15 M Hb 9.2 
Plt 242 
Mesalazine 
Azathioprine 
 
6322 UC Pancolitis 4 F CRP <5 
Hb 10.3 
Plt 521 
- New 
diagnosis 
6323 UC Rectum to 
proximal 
transverse 
colon 
13 M CRP 11 
Hb 6.9 
Plt 366 
ESR 54 
- New 
diagnosis 
6327 UC Pancolitis 8 F CRP <5 
Hb 14 
Plt 311 
ESR 4 
Asacol 
Prednisolone 
 
6328 CD Terminal 12 M CRP 15 - New 
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ileum, 
caecum 
Hb 12.4 
Plt 448 
ESR 27 
diagnosis 
6329 CD Terminal 
ileum, 
colon, 
oesophagus, 
stomach 
14 M CRP 58 
Hb 11.8 
Plt 490 
ESR 55 
- New 
diagnosis 
6330 CD Terminal 
ileum, 
colon 
13 M CRP 71 
Hb 9.5 
Plt 664 
ESR 7 
- New 
diagnosis 
6331 UC Pancolitis 6 F CRP <5 
Hb 13.6 
Plt 387 
- New 
diagnosis 
6332 CD Terminal 
ileum, 
caecum 
15 M CRP 111 
Hb 9.8 
Plt 742 
ESR 54 
- New 
diagnosis 
6336 CD Terminal 
ileum, 
colon 
15 F CRP 55 
Hb 9.4 
Plt 633 
ESR 53 
- New 
diagnosis 
6338 CD Terminal 
ileum, 
caecum 
16 M CRP 32 
Hb 9.3 
Plt 613 
ESR 34 
Sulfasalazine 
Azathioprine 
 
6341 UC Pancolitis 6 F CRP <5 
Hb 11.1 
Plt 513 
ESR 12 
- New 
diagnosis 
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JE29 CD Ileum, 
colon, 
stomach 
15 M CRP 108 
Hb 12 
Plt 482 
ESR 52 
Mesalazine 
Azathioprine 
Prednisolone 
Infliximab 
Metronidazole 
Fistula 
Abscess 
JE31 CD Terminal 
ileum, 
caecum 
35 F CRP 233 
Hb 9 
Plt 194 
- Stricture 
Right hemi-
colectomy 
JE32 CD Left colon 15 F CRP 13 
Hb 12.6 
Plt 337 
ESR 22 
Mesalazine 
Azathioprine 
 
JE38 UC Pancolitis 34 M Unavailable Azathioprine 
CyclosporinA 
Subtotal 
colectomy 
JE43 CD Terminal 
ileum, 
colon, 
perianal 
29 F CRP 178 
Hb 11.3 
Plt 705 
 
Asacol 
Methotrexate 
Budesonide 
Ciprofloxacin 
Subtotal 
colectomy 
Completion 
proctectomy 
JE45 UC Pancolitis 25 F CRP 117 
Hb 10.6 
Plt 788 
Asacol Subtotal 
colectomy 
JE47 CD Terminal 
ileum, 
caecum 
63 M CRP <5 
Hb 12.1 
Plt 482 
Sulfasalazine 
Prednisolone 
Right hemi-
colectomy 
JE49 CD Colon 35 M CRP 13 
Hb 11.4 
Plt 427 
ESR 59 
Asacol Subtotal 
colectomy 
JE51 CD Terminal 
ileum, 
colon 
8 F CRP <5 
Hb 11.4 
Plt 588 
Asacol 
Prednisolone 
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1f CD Colon 26 F CRP 47 
Hb 9.1 
Plt 159 
Azathioprine Right hemi-
colectomy 
Small 
bowel 
resection 
200 UC Pancolitis 34 M Unavailable Azathioprine 
Prednisolone 
CyclosporinA 
Subtotal 
colectomy 
226 UC Pancolitis 16 M Unavailable Mesalazine 
Azathioprine 
Subtotal 
colectomy 
227 CD Colon 32 M Unavailable - Colonic 
stricture 
249 CD Left colon 14 M CRP <5 
Hb 13.4 
Plt 282 
- Colonic 
stricture 
PB1 CD Ileum, 
colon 
15 F CRP 8 
Hb 13.4 
Plt 344 
ESR 16 
Asacol Subtotal 
colectomy 
Abscess 
Fistulae 
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Appendix 2 
 
Every patient who donated material used in this thesis is anonymously identified 
above by number in Appendix 1.  Appendix 2 describes which of these individual 
patients, and where relevant which types of cells or tissues, contributed to each 
group of experiments.  Each table in Appendix 2 is referenced to its corresponding 
Figure in the text of the thesis. 
 
Figure 3.1: Patient Identification 
Disease type Tissue or cell type Patient number 
CD LPMC’s JE29 
 
 
Figure 3.2A: Smad 7/β-actin Densitometry (percentage change from baseline) 
Disease 
type 
Tissue 
or cell 
type 
Patient 
number 
Negative 
control 
Curcumin 
5μM  
(Δ%) 
Curcumin 
10μM  
(Δ%) 
Curcumin 
20μM 
(Δ%) 
CD Biopsies 6317 0 -4 -29 -5 
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Figure 3.2B: Smad 7/β-actin Densitometry (percentage change from baseline) 
Disease 
type 
Tissue 
or cell 
type 
Patient 
number 
Negative 
control 
Curcumin 
5μM  
(Δ%) 
Curcumin 
10μM  
(Δ%) 
Curcumin 
20μM 
(Δ%) 
CD Biopsies 6316 0 +3 - -26 
CD Biopsies 6317 0 -4 -29 -5 
CD Biopsies 6330 0 +31 +33 +42 
CD LPMC’s JE31 0 -21 -62 - 
CD Biopsies JE32 0 +12 +2 - 
UC Biopsies 6315 0 +5.8 -5 +4.1 
UC Biopsies 6323 0 - -7.5 -7.5 
UC LPMC’s JE38 0 - -21 -16 
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Figures 4.1 and 4.2: Interleukin-10 (pg/ml) 
Disease 
type 
Patient 
number 
Negative 
control 
Curcumin 
5μM 
Curcumin 
10μM 
Curcumin 
20μM 
CD 6316 596 114 1229 959 
CD 6319 35 152 161 - 
CD 6328 1408 2859 2432 2130 
CD 6329 520 665 208 1041 
CD 6336 57 246 248 801 
CD 6330 332 746 188 532 
CD 6332 213 1015 1202 305 
CD JE47 1227 1618 1930 1863 
UC 6315 35 306 193 746 
UC 6322 47 56 68 48 
UC 6323 638 411 683 685 
UC 6331 2.6 48 120 130 
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Figures 4.3 and 4.4: Interleukin-1β (pg/ml) 
Disease 
type 
Patient 
number 
Negative 
control 
Curcumin 
5μM 
Curcumin 
10μM 
Curcumin 
20μM 
CD 6316 1711 485 864 1700 
CD 6319 513 485 492 492 
CD 6329 138 98 135 57 
CD 6336 166 45 69 151 
CD 6330 1146 1008 1021 974 
CD JE47 421 429 398 150 
UC 6315 398 244 499 293 
UC 6322 460 551 433 411 
UC 6327 680 556 573 600 
UC 6331 253 286 270 360 
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Figures 4.5 and 4.6: Interferon-γ (pg/ml) 
Disease 
type 
Patient 
number 
Negative 
control 
Curcumin 
5μM 
Curcumin 
10μM 
Curcumin 
20μM 
CD JE32 7246 2226 1476 4688 
CD 6316 2307 209 1014 1099 
CD 6319 119 129 104 0 
CD 6329 2311 2311 1688 1888 
CD 6336 724 681 461 1524 
CD 6330 541 391 477 411 
CD 6332 179 1249 1479 725 
CD JE47 1882 2049 3004 2652 
UC 6315 213 248 124 484 
UC 6322 574 659 339 79 
UC 6323 2619 2005 - 2035 
UC 6331 389 245 29 39 
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Figure 5.1: Interleukin-1β and Interferon-γ (pg/ml) 
Disease 
type 
Patient 
number 
Cytokine Negative 
control 
Curcumin 
5μM 
Curcumin 
10μM 
Curcumin 
20μM 
CD JE43 IL-1β 139 122 95 97 
UC JE38 IL-1β 506 261 157 95 
CD JE31 IFN-γ 1988 788 576 - 
CD JE43 IFN-γ 1608 1524 1547 1411 
CD JE47 IFN-γ 444 657 357 357 
UC JE45 IFN-γ 459 257 52 - 
 
 
Figure 6.2A: Phosphorylated p38 MAPK/p38 MAPK Densitometry (arbitrary 
units) 
Disease 
type 
Patient 
number 
Negative 
control 
Curcumin 
5μM 
Curcumin 
10μM 
Curcumin 
20μM 
CD 6316 2.1 1.1 0.7 1.5 
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Figure 6.2B: Phosphorylated p38 MAPK/p38 MAPK Densitometry (arbitrary 
units) 
Disease 
type 
Patient 
number 
Negative 
control 
Curcumin 
5μM 
Curcumin 
10μM 
Curcumin 
20μM 
CD 6316 2.1 1.1 0.7 1.5 
CD 6317 1.3 0.8 0.5 0.5 
CD 6330 8.0 8.0 7.0 7.0 
CD JE31 3.0 4.0 2.0 2.0 
CD JE47 1.9 1.2 2.0 2.0 
UC 6322 3.3 0.9 0.6 - 
UC 6323 1.5 1.3 - 1.3 
UC 6331 8.4 8.0 2.0 9.0 
 
 
Figure 6.3: Nuclear Factor-κB p65 Subunit/Histone H1 Densitometry 
(arbitrary units) 
Disease type Patient number Negative control Curcumin 20μM 
CD 6338 1 1 
CD 6341 0.8 0.8 
CD JE49 0.9 1 
UC JE51 1 1.1 
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Figure 7.1: Matrix metalloproteinase-3 Densitometry (arbitrary units) 
Disease 
type 
Patient 
number 
Negative 
control 
TNF-
α 
Curcumin 
5μM 
Curcumin 
10μM 
Curcumin 
20μM 
Curcumin 
30μM 
CD 1f 44 163 88 139 71 - 
CD 227 51 228 211 201 212 170 
CD 249 121 233 235 235 181 - 
CD PB1 128 212 223 184 208 103 
CD JE43 96 186 198 176 - 163 
UC 200 53 199 194 149 122 86 
UC 226 137 217 218 206 187 157 
 
 
Figure 7.2: Phosphorylated p38 MAPK/p38 MAPK Densitometry (arbitrary 
units) 
Disease 
type 
Patient 
number 
Negative 
control 
TNF-
α 
Curcumin 
5μM 
Curcumin 
20μM 
Curcumin 
30μM 
CD 1f 1.1 1.1 - 1.1 1.2 
CD 227 1 1 1 0.9 0.9 
CD 249 1.4 2.8 - 1.7 1.5 
CD JE43 0.7 1.6 1.3 1 - 
UC 200 0.6 0.8 0.9 1 0.9 
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Figure 7.3: Nuclear Factor-κB p65 Subunit/Histone H1 Densitometry 
(arbitrary units) 
Disease 
type 
Patient 
number 
Negative 
control 
TNF-
α 
Curcumin 
10μM 
Curcumin 
20μM 
Curcumin 
30μM 
CD 1f 130 145 131 139 138 
CD 227 172 188 183 169 161 
UC 226 91 110 75 97 93 
 
 
Figure 7.4: Matrix metalloproteinase Densitometry (arbitrary units) 
Disease 
type 
Patient 
number 
Negative 
control 
TNF-
α 
Anacardic 
acid 2μM 
Anacardic 
acid 5μM 
Anacardic 
acid 10μM 
Anacardic 
acid 15μM 
Anacardic 
acid 20μM 
CD 1f 74 194 207 186 150 90 - 
CD 227 65 222 223 231 201 195 154 
CD 249 144 236 217 164 140 70 38 
CD PB1 58 154 139 - 54 - 41 
CD JE43 108 183 191 202 210 203 43 
UC 200 96 186 - 144 63 - 32 
UC 226 49 217 143 187 176 178 45 
 
 
Figure 7.5 and 7.6: Patient Identification 
Disease type Patient number 
CD 227  
 
 
